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Abstract 
$O]KHLPHU¶VGLVHDVHLVWKHPRVWFRPPRQIRUPa-80%) of dementia, currently 
affecting approximately half a million people in the UK and ~30 million people 
worldwide. The autosomal dominant form of AD represents a small proportion       
(~1-2%) of AD cases and is genetically well characterised. The vast majority of AD 
cases that show symptoms later in life (> 65 years of age) are genetically complex. 
This type of ADDOVRNQRZQDVODWHRQVHW$O]KHLPHU¶VGLVHDVH/2$'GLVHase, is 
still highly heritable with an estimated heritability of up to 76% (Gatz et al., 2006).  
Unfortunately, there is no cure for this devastating disease. Investigating genetic 
factors influencing the risk of LOAD is imperative for development of effective 
therapeutic treatments and more accurate diagnosis. 
A cross-platform comparison of four Genome-wide association studies (GWAS) was 
performed in an effort to identify novel genetic associations with LOAD (Chapter 3). 
A TRIM15 SNP rs929156 demonstrated significant evidence of association with 
LOAD with a p-value approaching genome-wide significance (p = 8.77 x 10-8) and an 
odds ratio that showed consistent effect on risk (OR = 1.1, p = 0.03). Within this 
chapter, a bio-informatic program to automate the process of GWAS meta-analysis 
taking into account linkage disequilibrium (LD) is also presented. Subsequently two 
fragments of the TRIM15 JHQHLQFOXGLQJERWK¶DQG¶HQGIODQNLQJUHJLRQVwere 
sequenced using the ABI SOLiDTM next generation sequencing technology. This was 
a pilot study using a pooled DNA strategy to determine whether this region harbours 
multiple rare variants which are associated with the disease (Chapter 4).  
Lastly, a candidate gene study combined with whole genome analysis was performed 
in an effort to search for genetic variants influencing human ageing using LOAD 
GWAS data (Chapter 5).  
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Chapter 1:    Introduction 
$O]KHLPHU¶VGLVHDVHLVWKHPRVWFRPPRQcause of dementia in the elderly and 
accounts for more than two-thirds of all dementia cases. Dementia affects ~820,000 
people in the UK, and costs the UK economy approximately £23 billion per year 
$O]KHLPHU¶V5HVHDUFK8.. There are ~35 million people worldwide who suffer from 
$O]KHLPHU¶VGLVHDVHDQGWKLVILJXUHhas been estimated to rise to 65.7 million in 2030 
and 115.4 million in 2050 (Ferri et al., 2009). The prevalence of AD ranges from 0.6% 
in persons aged 65 to 69 years to 22.2% at ages 90 and older (Lobo et al., 2000).  
1.1 Outline of the project 
The following studies have been explored in this thesis (with the general aspects 
covered by Chapters 1, 2 and 6): 
x Analysis of Genome Wide Association Study (GWAS) data looking for 
replicating signals in LOAD  Chapter 3 
x Next generation sequencing (NGS) of tripartite motif containing 15 (TRIM15) 
gene using pooled DNA samples  Chapter 4 
x Genetic variants influencing human ageing from LOAD Genome Wide 
Association Studies (GWAS)  Chapter 5 
Respective specific aims are described in each of the chapters as appropriate.  
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1.2 Symptoms, diagnosis and treatment RI$O]KHLPHU¶VGLVHDVH 
Symptoms 
AD is clinically identified by a progressive loss of cognitive abilities. The symptoms at 
early stages involve mild memory loss - finding difficulty in remembering recently 
learned facts such as people, places and meetings. As the disease progresses, 
various advanced symptoms can occur such as confusion, irritability and aggression, 
mood swings, language breakdown, long-term memory loss, and sensory decline. 
Ultimately, the disease causes loss of body functions, and finally death.   
AD is pathologically characterized by extracellular deposits of abnormally 
accumulated ȕ-DP\ORLG$ȕpeptide in the form of senile plaques in cerebral cortex, 
and intracellular neurofibrillary tangles (NFTs) of abnormally hyperphosphorylated 
tau (W) proteins. Both observations are likely to be caused by misfolding and gradual 
conversion of highly soluble proteins into insoluble filamentous polymers (Forman et 
al., 2004). Furthermore, through brain scanning, such as computed tomography (CT) 
or magnetic resonance imaging (MRI), AD brains demonstrate severe cortical 
shrinkage, enlarged ventricles and shrinkage of the hippocampus, a region of the 
brain thought to be responsible for storing and retaining memories.  
Diagnosis 
$O]KHLPHU¶VGLVHDVH$'FDQRQO\EHGHILQLWHO\GLDJQRVHGpost mortem when 
an autopsy of the brain is performed (Carrette et al., 2003). However, it has been 
demonstrated that using a combination of tools, it is possible to estimate and make a 
probable diagnosis of AlzheimeU¶VGLVHDVHLQDOLYLQJSDWLHQWDQGWhe accuracy can 
range from ~80% to 95% (Ballard et al., 2011; Mucke, 2009). 
A number of AD diagnosis criteria have been established to date. The most widely 
used methods are known as NINCDS_ADRAD, DSM-IV and CERAD. These criteria 
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involve a number of diagnostic procedures, such as taking history from patients and 
their families, assessment of their cognitive function by carrying out 
neuropsychological tests (e.g. mini-mental state examination MMSE (Folstein et al., 
1975)), and GLVWLQJXLVK$O]KHLPHU¶VGLVHDVHIURPRWKHUQHurodegenerative dementias. 
Other forms of dementia include frontotemporal dementia (FTD), dementia with 
Lewy-body (DLB) and Creutzfeldt-Jakob disease (CJD).  
According to these diagnostic criteria, AD patients are assigned into three different 
risk groups - definite, probable and possible. Definite AD is defined only if 
histopathological evidence is available (Table 1.1) (Dubois et al., 2007).  
The NINCDS-ADRDA criteria were established in 1984 by the NINCDS (National 
Institute of Neurological and Communicative Disorders and Stroke) and ADRDA 
$O]KHLPHU¶V'LVHDVHDQG5HODWHG'LVRUGHUV$VVRFLDWLRQMcKhann et al., 1984). A 
similar AD diagnosis criteria DSM-IV TR was published by the American Psychiatric 
Association in 2000. These criteria are under constant review and take into account 
technology advances in functional neuroimaging techniques such as PET (positron 
emission tomography) and SPECT (single photon emission computed tomography) 
scans. The latest amendment to the NINCDS-ADRDA criteria was carried out in 2007 
(Dubois et al., 2007). 
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Table 1.1 Summary of NINCDS-ADRDA criteria for diagnosis of AD. Table lists 
criteria for the different AD risk groups. Adapted from Yaari and Corey-Bloom, 2007.  
 
 
  
Possible 
x Atypical onset, presentation, or clinical course of 
dementia 
x Presence of another illness capable of producing 
dementia 
Probable AD 
x Deficits in two or more domains of cognition 
x Progressive decline of memory and other cognitive 
functions 
x Preserved consciousness 
x Onset between ages 40 and 90 
x Absence of systemic or other brain disease that could 
account for symptoms 
Definite AD 
x Clinical criteria for probable AD 
x Tissue diagnosis by autopsy or biopsy 
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The severity of AD can be assessed using the MMSE score (Folstein et al., 1975);  
x mild AD: MMSE score 21 to 26  
x moderate AD: MMSE score 10 to 20 
x moderate severe AD: MMSE score 10 to 14 
x severe AD:  MMSE score less than 10 
AE42, total tau and hyperphosphorylated tau are well established AD biomarkers. 
Abnormally low AE42 levels and high tau (either total tau or hyperphosphorylated tau) 
levels in CSF act as an important indicator of AD pathogenesis (Buchhave et al., 
2009; Tapiola et al., 2009).  
Over the last few years, a number of more distinctive biomarkers of AD have become 
available from studying cerebrospinal fluid (CSF). The level of biomarkers such as 
secreted protein acidic and rich in cysteine-like protein 1 (SPARCL1), contactin-1 
(CNTN1), contactin-2 (CNTN2), alpha-dystroglcan, neuronal pentraxin receptor 
(NPR), carnosine dipeptidase 1 (CNDP1) and a 120kDa isoform of the precursor of 
neural cell adhesion molecule 1 (NCAM-120) have been found to be significantly 
different in AD CSF compared with normal subjects (Yin et al., 2009).  
Treatment 
Currently, there is no FXUHIRU$O]KHLPHU¶VGLVHDVH. The damage to the brain is 
thought to have occurred as many as 10 to 20 years before any symptoms arise. 
Therefore, pre-symptomatic diagnosis is considered crucial for early and effective 
treatment of Al]KHLPHU¶VGLVHDVHWRKDOWGLVHDVHSURJUHVVLRQDQGUHGXFHV\PSWRPV 
Though the disease is generally believed to be irreversible, it is hoped that 
interventions preventing neuronal cell death, could activate the self-repair 
mechanism of the brain, leading to restoration of broken neural circuits, and a 
functional recovery may become possible (Mucke, 2009). Current therapeutic drugs 
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are effective in relieving the disease symptoms. However, the efficacy of these drugs 
in slowing down the disease progression and recovery of the brain is limited.  
Five drugs have been approved by EMEA (European Agency for the Evaluation of 
Medical Products) and FDA (USA Food and Drug Administration) for the treatment of 
AD. These drugs are Donepezil, ENA-713, Galantamine, Memantine and Tacrine. 
These medicines can be divided in two major categories according to their targets - 
cholinesterase inhibitors (Donepezil, ENA-713, Galantamine, Tacrine) and an 
antagonist for NMDA-type (N-methyl-D-aspartate) glutamate receptor (Memantine).  
Acetylcholine is an important neurotransmitter, which has been found to be depleted 
in AD brains. Antagonising its degrading enzyme acetylcholinesterase increases the 
acetylcholine level in the brain. Thus it improves neurotransmission and ultimately 
cognitive function. Cholinesterase inhibitors are prescribed to AD patients with mild to 
moderate symptoms (Winblad et al., 2001). However, these inhibitors may cause 
adverse effects such as diarrhea, vomiting, nausea, fatigue, insomnia and anorexia.  
Memantine is an uncompetitive antagonist of NMDA-type receptor for glutamate, a 
main excitatory neurotransmitter in the human central nervous system (CNS). 
Glutamate is known to play an important role in neural transmission, learning, 
memory processes and neuronal plasticity (Sucher et al., 1996). The level of 
glutamate in the brain has important implications in determining synaptic cell survival, 
where it has been found that excess levels of glutamate are toxic to neurons. This 
increase in the level of glutamate was found to be caused by over-stimulation of 
NMDA receptors (Robinson and Keating, 2006). Antagonising NMDA receptor thus 
formed the biological basis for this drug. A previous clinical trial has suggested a 
small beneficial effect of Memantine during six month placebo controlled trials in 
moderate to severe AD. However, it is not yet clear if it has any effect in AD patients 
with less severe symptoms (Areosa et al., 2005). Memantine has been found well 
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tolerated in clinical trials, with dizziness and mild headaches reported as the main 
adverse effects. Interestingly, combined treatment using both Memantine and 
Donepezil appear to improve cognitive performance over either therapy alone on 
multiple clinical measures, suggesting a synergistic effect between the two drugs 
(Ihalainen et al., 2011; Tariot et al., 2004). 
AE vaccination 
Current available drugs for treatment of AD are severely limited in that they are 
designed to relieve AD symptoms. In order to halt the disease progression, 
interference of pathogenic events leading to the clinical symptoms is essential.  
Since deposition of amyloid plaques is a major clinical feature of AD, removal of 
these plaques has been thought to be able to block the disease progression. A 
placebo-controlled clinical trial of AE42 immunisation showed that although patients 
exhibited clear reduction of AE plaques from the brain, there was no evidence of 
either slowing down of disease progression or improving survival (Holmes et al., 
2008). Furthermore, full length AE vaccination has been shown to elicit strong side 
effects which can cause over-activation of the innate immune system, which in turn 
accelerates disease progression rather than slowing it down (Holmes et al., 2008). 
AD patients treated with AN1792 (an active AE vaccine) exhibited a significant 
increase (p = 0.02) in the risk of aseptic meningoencephalitis compared with placebo 
controlled AD patients (Orgogozo et al., 2003). As a result, AE vaccination avoiding 
these pro-inflammatory responses (mainly anti-AE Th1 immune response) is under 
intensive development. Moreover, AE vaccination combined with immuno-
suppressive therapy has also been suggested (Cribbs, 2010).  
However, previous studies indicate a strong correlation between soluble oligomeric 
AE concentration and AD, whereas a poor correlation has been observed as 
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compared with AE plaques counts (Davis et al., 1999; Lue et al., 1999; 
Neuropathology Group of the Medical Research Council Cognitive Function and 
Ageing Study, 2001). This has led to speculations that the plaque form of AE is 
perhaps harmless or even protective.  Active removal of AE plaques could however 
elevate the concentration of soluble AE oligomers, resulting in acceleration of disease 
progression (Holmes et al., 2008).     
Alternative medications 
A number of over-the-counter medications (such as melatonin and Omega-3 fatty 
acids) are also available to AD patients. 
Melatonin is a natural hormone secreted by the pineal gland. It regulates sleeping 
cycles and has shown putative beneficial effects to people with sleeping disturbance 
(Brzezinski et al., 2005). Cardinali et al., 2002 suggested it might also be helpful in 
suppressing agitation and anxiety. However, such beneficial effects have not been 
consistently observed in other studies. For example, Gehrman et al., 2009 did not 
find any significant effect of melatonin (including sleep, circadian rhythms or agitation) 
on AD patients (when compared with randomized AD subjects who take placebos). 
There is also evidence that melatonin may disrupt, rather than improve sleep if 
inappropriately used (Arendt et al., 2008).  
Omega-3 fatty acid (which mainly consists of eicosapentaenoic acid [EPA] and 
docosahexaenoic acid [DHA]) is one of the most widely used alternative therapies for 
treating AD. The popularity of Omega-3 fish oil is probably due to its well recognized 
effects of protection of heart diseases with no obvious adverse effects. DHA, which is 
a major constituent of fish oils, is a long-chain polyunsaturated fatty acid (comprising 
~12-16% of the total fatty acids) in the brain (Quinn et al., 2010). The level of DHA 
has been found to be decreased (~30-50%) in AD patients compared with age-
matched controls.  
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A longitudinal study taking 815 individuals (who were unaffected by AD) aged 
between 65 to 94 years and followed by 3.9 years showed that subjects who 
consumed fish regularly (at least once a week) exhibited a reduced risk (~60%) of 
developing Alzheimer¶VGLVHDVH (relative risk, 0.4; 95% CI 0.2-0.9) (Morris et al., 
2003). This protective effect has led to extensive follow-up studies which aim to test 
whether Omega-3 fatty acids can also slow down the disease progression. Several 
studies have shown that the intake of Omega-3 fatty acids only appear to have a 
small beneficial effect on patients with very mild AD symptoms, and no effects for 
patients with moderate to severe symptoms (Freund-Levi et al., 2006; Quinn et al., 
2010). Interestingly, a recent study has found that the level of plasma DHA is not only 
proportional to intake of DHA by eating fish, seafood or DHA supplement, but is also 
associated with APOE İJHQRW\SH. It has been suggested that the absorption of 
DHA may be impaired in APOE İFDUULHUs, and therefore these people do not benefit 
from consumption of DHA (Cunnane et al., 2009).    
Other alternative treatments for AD include aromatherapy, music therapy, drinking 
wine (in moderation) and green tea, as well as taking Vitamin E as dietary 
supplements. However, these alternative treatments generally lack biological and 
scientific basis, and their effectiveness are questionable. It has been shown that an 
intake of high-dosage vitamin E increases the risk of mortality and thus should be 
avoided (Miller et al., 2005).   
It is hoped, with the additional knowledge gained through genetic studies of AD, that 
more effective therapeutic interventions could be developed in the future by targeting 
the root cause of AD rather than only its symptoms (Mucke, 2009).  
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1.3 Early onVHW$O]KHLPHU¶VGLVHDVH 
(DUO\RQVHW$O]KHLPHU¶VGLVHDVH (EOAD) refers to AD cases that develop symptoms 
early in life (before 65 years of age). This form of AD cases constitutes only a small 
proportion (~1% to 2%) of all AD patients, and is genetically well characterised 
(Campion et al., 1999). EOAD exhibits a Mendelian form of inheritance in an 
autosomal dominant manner.  
EOAD is largely caused by fully penetrant mutations in three genes  amyloid 
precursor protein (APP), chromosome 21q21.3; presenilin 1 (PSEN1), chromosome 
14q24.2 and presenilin 2 (PSEN2), chromosome 1q42.1. Mutations in the PSEN1 
gene have been found to account for the majority of familial AD cases with ~170 
mutations being identified, compared with only ~30 and ~10 mutations in APP and 
PSEN2, respectively (Shepherd et al., 2009).  
All of these mutations have been shown to affect APP proteolytic processing, 
resulting in generation of toxic AE peptides (the major component of senile plaques) 
in the brain. The alterations in APP processing in favour of AE production and its 
accumulation in the brain are key pathogenic events in EOAD (Marzolo and Bu, 
2009).  
Proteolytic processing of APP 
APP is proteolytically processed through one of the two mutually exclusive pathways 
(amyloidogenic pathway and non-amyloidogenic pathway) via three enzymes - D, E 
and J secretase (Haass and Selkoe, 2007).  
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In the amyloidogenic pathway (Figure 1.1)$33LVILUVWFOHDYHGE\ȕ-secretase (also 
known as E-site APP cleaving enzyme 1 - BACE1), releasing a soluble APPE 
fragment and a membrane-bound APP C-terminal fragment (APPCTFE). The C-
terminal fragment is subsequently cleaved by J-secretase within the membrane, 
UHOHDVLQJ$ȕSHSWLGHVDQGWKH$33LQWUDFHOOXODUGRPDLQ$,&'7KLVLQWUDFHOOXODU
domain acts as a transcription factor which regulates gene expression (Konietzko et 
al., 2008). AICD has been shown to induce transcriptional activation of neprilysin 
(NEP), which in turn plays an important role in degradation of AE (Pardossi-Piquard 
et al., 2005). AICD has a short half-life and is rapidly degraded in the cytosol (Cupers 
et al., 2001) by insulin-degrading enzyme (IDE) (Edbauer et al., 2002). In addition, 
APP-binding protein Fe65 stabilizes AICD and stimulates translocation of AICD to the 
nucleus and binding of histone acetyltransferase TIP60 (Goodger et al., 2009).  
A number of cleavage sites of intramembrane proteolysis by J-secretase have been 
identified (Figure 1.1), each result in production of different sizes of AE peptides 
ranging from 37 to 43 amino acids (e.g. AE38, AE40 and AE42) (Marzolo and Bu, 
2009). The precise site of J-secretase cleavage has important implications for AE 
aggregation, which in turn can affect the downstream disease pathology. The 
therapeutic modification of the J-secretase cleavage site to J38 has been shown to 
significantly reduce $ȕDJJUHJDWLRQSURSHQVLW\(Haass and Selkoe, 2007).  
The J-secretase complex is composed of four proteins including PSEN1 or PSEN2, 
nicastrin (NCSTN), anterior pharynx defective 1 (APH-1) and presenilin enhancer 
protein 2 (PEN2) (Haass, 2004). A previous study has shown that a fully active J-
secretase can be reconstituted in yeast when all four components are expressed 
(Edbauer et al., 2003).   
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Figure 1.1 Schematic representation of the amyloidogenic pathway. APP (grey 
cylinder) is first cleaved by E-secretase, releasing the soluble E-cleaved APP 
fragment (sAPPE). The C-terminal fragment (99 amino acids in length) is 
subsequently cleaved within the transmembrane domain by J-secretase, which 
liberates the AE peptide and an APP intracellular domain (AICD). J-secretase can 
cleave the APP transmembrane domain at multiple sites  JȗDQGİ$GDSWHGIURP
Haass and Selkoe, 2007).  
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PSEN1 or PSEN2 protein constitute the catalytic core of the J-secretase complex. 
Mutations in PSEN1 and PSEN2 are thought to influence J-secretase cleavage 
events by shifting it two amino acids to the C-terminus, and thus increasing the 
SURGXFWLRQRI$ȕ(Haass, 2004)$ȕDQG$ȕDUHWKHPRVWFRPPRQLVRIRUPVRI
$ȕSHSWLGHV(Deane et al., 2009)7KHORQJHUIRUP$ȕLVPRUHILEULOORJHQLFDQG
neurotoxic, and has been shown to be more difficult to clear from the brain compared 
with AE40 (Shepherd et al., 2009).  
In the non-amyloidogenic pathway (Figure 1.2), $33LVILUVWFOHDYHGE\Į-secretase 
within the AE domain, and thus precludes AE production. The cleavage by D-
secretase generates a soluble APPD peptide and membrane-bound C-terminal APP 
fragment (APPCTFD). Subsequent intramembrane cleavage of the APPCTFD by the 
J-secretase complex produces a shortened fragment P3 and a cytoplasmic APP 
intracellular domain (AICD). It is unclear if P3 peptides play any functional role in 
pathogenesis of AD.  
It is noticeable that AICD is produced in both amyloidogenic and non-amyloidogenic 
pathways. Interestingly, functional active AICD is likely to be generated 
predominantly through amyloidogenic pathways, where translocation of AICD to the 
nucleus has been found to be significantly reduced when the endosomal E-cleavage 
pathway was blocked by pharmacological or genetic inhibitors (Goodger et al., 2009).  
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Figure 1.2 Schematic representation of the non-amyloidogenic pathway. 
Schematic structure of APP (grey cylinder) is shown together with AE (as shown). In 
the non-amyloidogenic pathway, APP is first cleaved by D-secretase within the AE 
domain, thus precluding production of AE. This cleavage by D-secretase results in 
release of a soluble APP fragment (sAPPD), and a shortened form of the membrane 
bound C-terminal fragment (83 amino acids in length). Subsequent cleavage of the 
C-terminal fragment by J-secretase within the membrane releases a P3 peptide and 
a cytoplasmic APP intracellular domain (Adapted from Haass and Selkoe, 2007). 
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1.4 Late oQVHW$O]KHLPHU¶VGLVHDVH 
Late onset AlzKHLPHU¶VGLVHDVH/2$', also known as sporadic AD (SAD) 
represents the majority (~98-99%) of AD cases. LOAD exhibits a complex aetiology 
with strong genetic and environmental determinants. Like many other complex 
common diseases, sporadic AD is likely to be governed by an array of common risk 
alleles across a number of different genes (Bertram et al., 2008).  
Mutations in APP, PSEN1 and PSEN2 responsible for causing EOAD have not been 
reliably detected in LOAD patients, suggesting a distinct pathogenesis of LOAD 
exists in comparison to EOAD. Although LOAD does not show Mendelian inheritance, 
it is still highly heritable with an estimated heritability of up to 76% as determined by 
studies of monozygotic and dizygotic twins (Gatz et al., 2006).  
Although EOAD and LOAD share common neuropathological phenotypes including 
both extracellular senile plaques and intracellular neurofibrillary tangles (NFTs), the 
DFFXPXODWLRQ RI $ȕ in LOAD is believed to be a UHVXOW RI $ȕ FOHDUDQFH deficits or 
increased AE aggregation rather than being causative as in EOAD pathology 
(Shepherd et al., 2009; Sleegers et al., 2010).  
Age is the one of the biggest non-genetic risk factors for LOAD, where the likelihood 
of developing AD approximately doubles every 5 years after the age of 65 (Feulner et 
al., 2009). It should be noted that as much as 24% of LOAD risk could be attributable 
to non-genetic factors, such as diet and lifestyle (Gatz et al., 2006).  
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1.5 The Amyloid Cascade 
$VWKHWZRPDLQIHDWXUHVRI$'DUHGHSRVLWVRIVHQLOHSODTXHVFRQWDLQLQJ$ȕSHSWLGHV
and intracellular deposits of neurofibrillary tangles containing hyperphosphorylated 
tau protein, and there is genetic evidence from studies of EOAD, pathways 
FRQFHUQLQJ$ȕDQGWDXhave been a major focus of AD research.  
All identified mutations associated with AD (both EOAD and LOAD) have been found 
either directly or indirectly linked with the formation, aggregation and removal 
processes of $ȕ. These findings eventually lead to the formation of the amyloid 
cascade hypothesis. AE are small peptides (~4 kDa) and the most common isoforms 
are AE40 and AE42 (Deane et al., 2009). 
The Amyloid Cascade Hypothesis proposes that progressive cerebral accumulation 
of beta-DP\ORLG$ȕLVWKHFHQWUDOWULJJHURIWKHSDWKRORJLFDOFKDQJHs found in the 
brain of AD patients. These changes include synapse loss, activation of inflammatory 
processes, induction of neurofibrillary changes and ultimately neuronal death (Hardy 
and Higgins, 1992; Selkoe, 1991). 
AE conformation and toxicity 
It has been suggested that different conformations of AE could induce neurotoxicity in 
distinct biological pathways. AE40 and AE42 exist in different aggregation states from 
monomers to dodecamers, where oligomer refers to any aggregation state with the 
exception of a monomer. Insoluble fibrils formed as oligomers grow in size, and 
accumulation of these ultimately forms AE plaques found in the brain of AD patients. 
In addition, AE42 peptide has been found to be more fibrillogenic than AE40 (Tanzi 
and Bertram, 2005).  
,WKDVEHHQVKRZQWKDWDFFXPXODWLRQRI$ȕFDQFDXVHQHXURWR[LFHIIHFWVUHVXOWLQJLQ
the release of reactive oxygen species, loss of calcium homeostasis and activation of 
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the several kinases including GSK3 - a kinase responsible for phosphorylation of tau 
protein (Lee et al., 2005).  
There is emerging evidence that small soluble AE oligomers are more toxic than 
mature fibrils. This has been supported by numerous studies in biochemistry and 
histopathology, where biochemically measured levels of soluble AE (monomers and 
oligomers) correlate much better with the extent of synaptic loss and severity of 
cognitive dysfunction in AD than do simple plaque counts (Holmes et al., 2008; Lue 
et al., 1999). 
AE homeostasis 
7KHOHYHORIVROXEOH$ȕLVKRPHRVWDWLFDOO\FRQWUROOHGE\LWVSURGXFWLRQLQQHXURQVDQG
its subsequent clearance. Such homeostasis is thought to be deficient in the brain of 
an AD patient. Levels of neurotoxic AE in the brain have been found elevated in AD 
contributing to the disease progression and neuropathology (Deane et al., 2008). 
Furthermore, an LQFUHDVHG$ȕWR$ȕUDGLRLVDUREXVWLQGLFDWRURI$'
(Kuperstein et al., 2010).  
Given that the DFFXPXODWLRQRI$ȕLQthe brain is determined by the rate of generation 
versus clearance, both pathways are considered targets for therapeutic interventions. 
The clearDQFHRI$ȕIURPWKHEUDLQFDQ be achieved through two biological pathways 
  proteolytic degradation or receptor mediated transport (Tanzi et al., 2004). 
AE clearance by receptor mediated transport 
The clearance RI$ȕIURPWKHEUDLQ through the blood brain barrier (BBB) is facilitated 
by lipoprotein receptor-related protein 1 (LRP1) and p-glycoprotein on brain 
capillaries by binding to chaperones (such as apolipoprotein E (APOE)) DQGĮ-
PDFURJOREXOLQĮ0 (Cirrito et al., 2005). LRP1 antagonists have shown to reduce 
WKHHIIOX[RI$ȕIURPEUDLQE\XSWRLQPLFHLQMHFWHGZLWKUDGLRODEHOHG$ȕ
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(Shibata et al., 2000). However, it is still unclear if LRP1 also mediates AE influx from 
the bloodstream. Like AE and APOE protein, LRP1 and its ligands are also detected 
in amyloid plaques in AD brains (Marzolo and Bu, 2009).  
It has also been found that LRP1 IDYRXUVFOHDUDQFHRI$ȕRYHUWKH$ȕ (more 
amyloidogenic species of the peptide) and this might impede $ȕWUDQVSRUWDWLRQRXW
of the brain through the BBB (Deane et al., 2004). Thus the predominant path of 
$ȕFOHDUDQFHIURPWKHEUDLQLVWKRXJKWWR be via the proteolytic degradation, as this 
peptide is not efficiently exported. 
AE clearance by proteolytic degradation 
In the brain, sROXEOH$ȕis degraded by activated microglia. The activation of 
microglia is likely to be promoted by toll-like receptors (TLR). Frank et al., 2009 found 
that mRNA which encodes a membrane surface TLR is significantly up-regulated in 
plaque-associated brain tissues in aged APP23 transgenic mice.  
$ȕSHSWLGHVDUHproteolytically degraded within the brain principally by neprilysin 
(NEP) intracellularly and insulin degrading enzyme (IDE) extracellularly (Jiang et al., 
2008). Genetic inactivation of these genes or administration of inhibitors of these 
proteinases in the brain (of non-transgenic mice) leads to VXEVWDQWLDOHOHYDWLRQRI$ȕ
levels in the brain and induction of plaque deposition (Dolev and Michaelson, 2004). 
Conversely, overexpression of IDE or neprilysin results LQORZHUHGEUDLQ$ȕOHYHOs 
and reduced plaque formation (Hemming et al., 2007).  
The APOE protein plays a critical role in efficient intracellular degradation of soluble 
$ȕE\PLFURglia. The APOE activity has been shown (using transgenic mice) to be 
influenced by ATP-binding cassette 1 (ABCA1), which lipidates APOE. Loss of 
function of ABCA1 impairs AE degradation in microglia. ABCA1 null microglia 
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demonstrates a significantly higher OHYHORILQWUDFHOOXODU$ȕ compared with wild type 
(microglia in presence of ABCA1) (Jiang et al., 2008). 
IDE is secreted by both microglia and astrocytes. It plays an important role in 
extracellular degradation of soluble AE with minor contributions by other secreted 
proteinases (Qiu and Folstein, 2006; Qiu et al., 1998). In an experiment carried out 
by Jiang et al. 2008, soluble AE was found to be efficiently degraded after addition to 
an astrocyte-conditioned medium. Addition of insulin (a competitive inhibitor of IDE) 
prevents this degradation. Interestingly, $ȕFOHDUDQFHE\,'(LV also influenced by 
APOE lipidation by ABCA1, where conditioned medium from ABCA1 deficient 
astrocytes exhibited significantly higher levels of AE compared with medium from wild 
type astrocytes. In addition, extracellulDU$ȕFOHDUance has been found more efficient 
in the presence of both APOE and IDE (Jiang et al., 2008).  
AE and metals 
$ȕDJJUHJDWLRQKDVEHHQIRXQG to be facilitated by interaction with metal ions, such 
as zinc, copper, and other heavy metals. Aberrant metal homeostasis has been 
observed in AD patients, and it is thought that these ions contribute to AD 
pathogenesis through enhancing the formation of reactive oxygen species and toxic 
AE oligomers. These metals have been shown to be able to facilitate and stabilizH$ȕ
deposits (Maynard et al., 2005). 
Intervention of such interaction using metal-complexing drugs (e.g. clioquinol) has 
been on clinical trial for treatment of AD (ongoing). A pilot phase II clinical trial using 
a small number of subjects (n = 36) suggests that clioquinol improves cognition and 
lowers plasma levels of AE42 (Ritchie et al., 2003). However, clioquinol appears to 
be neurotoxic which induces subacute myelo-optic neuropathy (SMON) syndrome (a 
syndrome that involves sensory and motor disturbance in the lower limbs and visual 
changes) (Bareggi and Cornelli, 2011).  
 Introduction 
20 
 
1.6 Pathways concerning tau protein 
Tau protein, also known as microtubule-associated protein tau/saitohin (MAPT/STH), 
LVFRQVLGHUHGDFHQWUDOPHGLDWRURI$O]KHLPHU¶VGLVHDVHSDWKRJHQHVLVVLQFHRQHRI
the clinically observed characteristic of AD is the formation of intracellular 
neurofibrillary tangles (NFT) mainly composed of abnormally hyperphosphorylated 
tau proteins.  
Mutations in the MAPT (which encodes tau protein), although found to result in tau 
hyperphosphorylation, do not specifically lead to AD symptoms. These mutations 
have been shown to be a major cause of a different type of dementia - frontotemporal 
dementia (FTD) (Haberland, 2010). FTD is histologically distinct from AD as the brain 
is normally free of AE plaques (Small and Duff, 2008).  
Tau is a phosphoprotein which normally contains one to three moles of phosphate 
per mole of tau protein in the healthy brain, and the level of which is dramatically 
increased (three to four folds higher) in the brain tissues of AD patient of similar age 
(Zhang et al., 2009).  
The main recognized function of tau is to promote assembly and stabilization of 
microtubules in the brain. The binding capacity of tau is highly regulated by protein 
phosphorylation. The hyperphosphorylated tau has lower binding capacity to 
microtubules compared with unphosphorylated tau protein, resulting in destabilization 
of microtubules in the brain (Sato-Harada et al., 1996). Tau protein phosphorylation 
is achieved by protein kinases: glycogen synthase kinase 3 (GSK3), cyclin-
dependent kinase 5 (CDK5), possibly cyclic AMP-dependent protein kinase A (PKA) 
and protein kinase C (PKC) (Churcher, 2006).  
6LPLODUWR$ȕWDXFDQpolymerize and form paired helical filaments (PHFs), and 
accumulation of these leads to formation of neurofibrillary tangles (NFTs). NFTs are 
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not exclusive to AD however and have been found in many other neurodegenerative 
diseases: 'RZQ¶VV\QGURPHSURJUHVVLYHVXSUDQXFOHDUSDOV\363FRUWLFREDsal 
degeneration (CBD), frontotemporal dementia and Parkinsonism linked to 
chromosome 17 (FTDP-17)3LFN¶VGLVHDse, and Niemann-Pick type C disease (Avila 
et al., 2004).  
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1.7 'LVFXVVLRQRYHUFXUUHQWEHOLHIRQ$O]KHLPHU¶VGLVHDVHFHQWUDO
pathogenesis 
In EOAD, it is clear that alteration of APP processing in favour of AE production 
(particularly AE42) is sufficient to cause the disease. Given EOAD and LOAD share 
common pathological features (extracellular AE plaques and intracellular 
hyperphosphorylated tau tangles), biological pathways concerning AE and tau are 
undoubtedly critical pathological events in AD.  
There is an increasing volume of evidence that suggests that AE and tau may not be 
the root cause of LOAD pathology (Hardy and Selkoe, 2002) as partial and complete 
UHPRYDORI$ȕSODTXHVE\LPPXQLVDtion does not show significant effects on cognitive 
function. Clear end stage dementia has been observed in individuals with almost the 
complete elimination of plaques (Holmes et al., 2008).  
Regarding tau proteins, although it has been found that the number and total length 
of microtubules were significantly reduced in pyramidal neurons from AD in 
comparison to controls (p = 4 x 10-6), no significant correlation between the loss of 
microtubules and PHFs has been observed (p = 0.8). Individuals without PHF have 
often been found with clear microtubule deficits (Cash et al., 2003). In addition, it has 
been suggested that tau hyperphosphorylation may be neuroprotective in the early 
stages of disease process, which possibly enables neurons to self-repair. Cells 
overexpressing hyperphosphorylated tau protein has been shown to be more 
resistant to apoptosis (Zhang et al., 2009). There is however, a general consensus 
that a prolonged existence of NFTs is toxic and harmful to neurons.  
These studies provide evidence that other biological pathways exist that are crucial 
to the pathogenesis of LOAD. The recently identified LOAD genes (Harold et al., 
2009; Hollingworth et al., 2011; Lambert et al., 2009; Naj et al., 2011; Seshadri et al., 
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2010) promise a new era of AD research, and are likely to reveal biological pathways 
underlying the root cause of the disease.  
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1.8 Genetic risk factors in LOAD 
Apolipoprotein E 
APOE encodes for a 299 amino acid glycoprotein (~34 kDa) in humans. This gene is 
expressed in several organs, with the highest expression found in the liver and the 
brain (Bu, 2009).  
The APOE protein exists in three isoforms, E2, E3, E4 translated from three specific 
DOOHOHVİİDQGİUHVSHFWLYHO\Mahley, 1988). The three allelic forms of APOE 
are determined by two missense single nucleotide polymorphisms (SNPs)  
rs429358 (T/C) and rs7412 (C/T) (Table 1.2). These two SNPs cause coding change 
at amino acid positions 112 and 158, respectively (C112R and R158C).  
APOE is a major risk factor for LOAD explaining ~25% of the population attributable 
risk (Lambert et al., 2009). The association of APOE İZLWK/2$'ZDVILUVWUHSRUWHG
in 1993 through linkage analysis using family pedigrees (Corder et al., 1993; 
Saunders et al., 1993; Sleegers et al., 2010). This association has been confirmed by 
numerous genetic association studies (http://www.alzgene.org/).  
The presence of APOE H4 greatly increases the risk of AD and reduces the average 
age at onset (Feulner et al., 2009). Individuals carrying a single copy of H4 have a ~4-
IROGKLJKHUULVNRIGHYHORSLQJ$'LQFRPSDULVRQWRFDUULHURIWKHİDOOHOHa-16-fold 
LQFUHDVHGULVNRI$'LIZLWKWZRFRSLHVRIİAPOE H2 is known to engender a 
reduced risk of AD (Bertram et al., 2010).  
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Table 1.2 Summary of APOE İİDQGİDOOHOLFVWDWXVThe APOE İİDQGİ 
status are determined by two SNPs: rs429358 and rs7412. Individual heterozygous 
at both SNP loci is an indication of APOE Hİ4 status (Kim et al., 2009).  
  
Allelic status rs429358 rs7412 Description 
İ T T 
İDOOHOHKDVDIUHTXHQF\RIaLQWKH
general population, and is known to elicit a 
protective effect against AD 
İ T C İLVWKHPRVWFRPPRQDOOHOHRIAPOE with a frequency of ~77% in the general population 
İ C C 
the İDOOHOHKDVDIUHTXHQF\RIaLQWKH
general population, whereas ~40% in patients 
with AD. 
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Neither of these SNPs that generate the APOE alleles has been genotyped in 
HapMap project. As existing GWAS chips are designed using SNPs derived from the 
International HapMap Project, both APOE SNPs are therefore not genotyped by 
current LOAD GWAS (The International HapMap Consortium, 2003). SNP rs2075650, 
ZKLFKGRHVSUHVHQWRQWKHFKLSLVNQRZQWREHLQWLJKW/'ZLWKWKH$32(İDOOHOH
(Yu et al., 2007). SNP rs2075650 has been reported to be associated with risk of AD 
with p-value 1.8 x 10-157 (Harold et al., 2009).  
The principal biological function of APOE is lipid and cholesterol metabolism. In 
plasma, high density lipoprotein (HDL) contains APOA-1 as its major apolipoprotein, 
whereas APOE is the most predominant apolipoprotein of HDL in the CNS (Kim et al., 
2009). 
It has been shown that APOE is involved in both AE aggregation and clearance 
(Figure 1.3) (Bu, 2009).   
APOE can interact with AE either directly or indirectly and promotes AE clearance 
through both receptor mediated transport and proteolytic degradation as described 
(See Introduction 1.5). The E4 isoform of APOE is associated with not only the least 
efficient transport, but also reduced capability of promoting degradation of soluble AE 
in comparison with E2 and E3 isoforms (Deane et al., 2008; Jiang et al., 2008).  
Furthermore, AE in the blood stream is transported by cholesterol-rich HDL particles, 
where APOE is also one of the structural components, prior to elimination by the liver 
(Koudinov et al., 1998).  
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Figure 1.3 Pathogenic mechanism of APOE in LOAD. It has been postulated that 
APOE isoforms influence risk of AD via regulating aggregation and clearance of AE. 
In addition, the different isoforms, levels and lipidataion status of APOE have been 
proposed as central mediators of LOAD pathology through modulating synaptic 
functions, AE neurotoxicity, tau hyperphosphorylation, and neuroinflammation 
(Adapted from Kim et al., 2009).  
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APOE has also been suggested to play a crucial role in AE aggregation (Kim et al., 
2009). A positive correlation of the APOE İDOOHOHGRVDJHDQGLQFUHDVHGQHXULWLF
plaques in AD has been observed in humans through post-mortem microscopic 
examination (Tiraboschi et al., 2004). A follow-up imaging study using PET scans 
also confirmed this association (APOE İallele dosage vs. fibrillar AE burden) 
(Reiman et al., 2009). Moreover, a previous study has revealed that APOE İallele 
dosage is associated with a decreased $ȕ$ȕUDWLR in CSF (p = 0.0001), a 
robust indicator of AE levels in the brain (Kauwe et al., 2009).  
APOE may also influence AD pathology through pathways not directly linked to AE. 
As a major apolipoprotein in the brain, APOE is known to play a pivotal rule in 
cholesterol homeostasis by serving as a ligand in receptor-mediated endocytosis of 
cholesterol-containing lipoprotein particles (Sleegers et al., 2010). Abnormal 
cholesterol metabolism has been implicated as a key event leading to the 
pathogenesis of AD (Martins et al., 2006).   
 
LOAD susceptibility genes apart from APOE 
In 2009 and 2011, a total of nine genes, CLU, PICALM, CR1, BIN1, ABCA7, 
MS4A6A, CD33, CD2AP and EPHA1, have been unequivocally identified and 
confirmed by several large GWAS (each consisting of over 10,000 samples) 
influencing the risk of LOAD (Harold et al., 2009; Hollingworth et al., 2011; Lambert 
et al., 2009; Naj et al., 2011; Seshadri et al., 2010).  
These genes can be assigned into three biological pathways, with a number of genes 
involved in multiple pathways. CLU, CR1, ABCA7, MS4A6A, CD33 and EPHA1 have 
putative functions in the immune system; PICALM, BIN1, CD33 and CD2AP are 
proteins that play a critical role in synaptic cell membrane processes and endocytosis. 
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CLU and ABCA7 (together with APOE) are crucial in lipid and cholesterol metabolism 
(Hollingworth et al., 2011; Morgan, 2011).  
CLU (clusterin)  
Two independent GWAS (Harold et al., 2009; Lambert et al., 2009) both identified 
and replicated a SNP rs11136000 located in an intron of the CLU gene, giving strong 
evidence of association with risk of LOAD with genome-wide level of significance (p = 
1.4 x 10-9 and p = 7.5 x 10-9, respectively).  
CLU (also known as APOJ) encodes another abundantly expressed apolipoprotein in 
the human brain. CLU exhibits similar biological functions as APOE, involved in both 
cholesterol and lipid metabolism and has been shown to promote export of AE across 
the BBB (Guerreiro and Hardy, 2011). CLU was also found in amyloid plaques in the 
brain (Calero et al., 2000; May et al., 1990). It has been shown that AE deposition are 
cooperatively regulated by APOE and CLU in vivo, where APOE and CLU double 
gene knockout PDAPP mice exhibit significantly higher AE load in comparison to 
either of the single gene knockout transgenic mice (DeMattos et al., 2004).  
CLU is a multifactorial glycoprotein, and one of the described functions is related to 
inflammation and immunity through regulating activity in the complement pathway 
(Falgarone and Chiocchia, 2009; Jenne and Tschopp, 1989; Jones and Jomary, 
2002).  
Furthermore, expression of CLU has been found to be elevated in response to injury 
and chronic inflammation of the brain, suggesting that CLU may have an important 
role in preventing possible damage to neurons (Calero et al., 2000).  
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PICALM (phosphatidylinositol-binding clathrin assembly protein) 
$613UVORFDWHGDW¶WRWKHPICALM gene was first discovered and 
reported to be associated with risk of LOAD (OR = 0.85, p = 1.9 x 10-8) by Harold and 
colleagues (Harold et al., 2009). The effect has been replicated in an independent 
sample cohort with ~4,000 samples (p = 0.014, OR = 0.90). On meta-analysis, the 
combined datasets showed a strong evidence of association with a p-value that 
exceeded genome-wide significance (p = 1.3 x 10-9, OR = 0.86).  
The association with PICALM was further supported by a large GWAS conducted by 
Lambert and colleagues using samples from a French population; a SNP proxy 
rs541458 in LD with rs3851179 (r2 = 0.622) has shown a significant evidence of 
association with LOAD (p = 0.0028, OR = 0.88), although it did not reached genome-
wide significance.  
PICALM encodes a protein which plays a critical role in clathrin-mediated 
endocytosis, a key process involved in regulation of receptors, synaptic transmission 
and clearance of apoptotic cells (Baig et al., 2010). PICALM may alter the risk of 
LOAD through regulating synaptic transmission and/or AE production by modulating 
the rate of endocytosis of APP, an essential step preceding APP cleavage by E-
secretase (Figure 1.1) (Goodger et al., 2009; Tebar et al., 1999).  
A recent study using immunolabelling has shown that PICALM is predominately 
present in endothelial cells, mainly expressed in the endothelium of the blood vessel 
walls and weakly labelled in neurons. This has led to speculation that PICALM may 
also be involved in AE clearance via the BBB into the blood stream (Baig et al., 2010).  
Furthermore, a significant epistatic interaction (p = 0.0068; logistic regression using 
an additive model) was reported between the APOE İDOOHOHDQGPICALM SNP 
rs3851179 using 3,055 AD cases and 8,169 age-matched controls. The effect of 
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PICALM was only observed in samples carrying at least one copy of APOE İJun 
et al., 2010); p = 3.4 x 10-3 in presences of APOE İDQGp = 0.73 in absence of 
APOE İ.  
CR1 (complement receptor 1) 
SNP rs6656401, present in an intron of CR1, has been shown to be associated with 
an increased risk of LOAD by the Lambert et al., 2009 GWAS. This association was 
confirmed by Harold et al., 2009 GWAS, with a p-value of 10-6 (OR = 1.17). Together 
these two GWAS comprise over 25,000 samples (Harold et al., 2009; Lambert et al., 
2009).  
In addition to the association with risk of LOAD, the CR1 SNP rs6656401 was also 
found to be associated with a faster rate of cognitive decline (p = 0.011) and an 
increased deposition of neuritic amyloid plaques (p = 0.009), where the significance 
was not affected by including the APOE İVWDWXV as a covariate (Chibnik et al., 
2011).  
CR1 encodes a major receptor of C3b, a key inflammatory protein involved in AD 
pathogenesis (Khera and Das, 2009). It has been postulated that CR1 may be 
involved in the process of AE clearance through mediating complement-driven 
phagocytosis, which may in turn prevent brain damage through reducing AE-induced 
neurotoxicity (Carrasquillo et al., 2010). Using hAPP transgenic mice, it has been 
shown that mice expressing sCrry (soluble complement receptor-related protein y), 
an inhibitor of C3 activation, exhibited ~2-3 folds elevated AE deposition in the brains 
compared with mice without such inhibition (Wyss-Coray et al., 2002).  
Furthermore, a significant epistatic interaction between the APOE H4 and CR1 SNP 
rs6656401 has been reported (p = 9.6 x 10-3), with stronger association observed in 
carriers of the APOE İLambert et al., 2009).  
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BIN1 (bridging integrator 1) 
A three stage meta-analysis consisting of over 35,000 samples (8,371 cases) 
identified an association of a SNP rs744373 (within ~30kb of the BIN1 gene) with an 
increased risk of LOAD (p = 1.59 x 10-11, OR = 1.13) (Seshadri et al., 2010). The 
effect of this SNP was replicated in an independent Spanish sample cohort (1,140 
AD cases and 1,209 controls) with a p-value 0.02 and an odds ratio in the same 
direction.  
BIN1 (also known as amphiphysin-2) is expressed most abundantly in the CNS and 
muscles, and appears to be involved in the endocytosis of synaptic vesicles (Cousin 
and Robinson, 2001). A study using transgenic mice found that the amphiphysin 1 
knockout mice, which cause reduction of amphiphysin 2 selectively in the brain, 
exhibited major learning deficits and increased rate of mortality (Di Paolo et al., 2002).  
ABCA7 (ATP-binding cassette transporter protein) 
The ABCA7 SNP rs3764650 was found to be significantly associated with an 
increased risk of LOAD in a combined sample cohort, consisting of over 60,000 
samples (25,900 LOAD cases and 41,584 controls) (p = 5 x 10-21, OR = 1.23) 
(Hollingworth et al., 2011).  
ABCA7 encodes an ATP-binding cassette (ABC) transporter and is abundantly 
expressed in the brain (Kim et al., 2006). ABCA7 is involved in the transfer of lipids 
and cholesterol to lipoprotein particles such as APOE and CLU.  
Although no evidence of epistatic interactions between these loci were observed, it 
does not preclude possibility of biological interactions (Hollingworth et al., 2011).  
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MS4A6A (membrane-spanning 4 domains, subfamily A, member 6A) 
A SNP (rs610932) in proximity to gene MS4A6A exhibited a significant evidence of 
association with a reduced risk of LOAD (p = 1.2 x 10-16, OR = 0.91) (Hollingworth et 
al., 2011). The marker was found within an LD block ~290kb in size. This region 
comprises six genes of MS4A gene family, which includes MS4A2, MS4A3, MS4A4A, 
MS4A4E, MS4A6A and MS4A6E.  
These genes encode for proteins which share structural similarities  all members 
comprise a transmembrane domain, suggesting that these proteins may be involved 
in synaptic cell membrane processes (Liang et al., 2001). The exact biological 
function of MS4A6A has yet to be characterised.    
CD2AP (CD2 associated protein), CD33 (sialic acid binding immunoglobin-like lecting) 
and EPHA1 (ephrin receptor A1) 
Three other genes CD2AP, CD33 and EPHA1 have also been implicated in LOAD 
pathogenesis (Hollingworth et al., 2011). Markers of these genes (rs9349407, 
rs3865444 and rs11767557) demonstrated strong evidence of association with LOAD 
which reached genome-wide level of significance (p < 1 x 10-8), albeit at a lower 
statistical significance than genes mentioned earlier (CLU, PICALM, CR1, BIN1, 
ABCA7, MS4A6A).  
Both CD33 and CD2AP encode for proteins important in communication between 
cells and transduction of molecules across the membrane (Crocker et al., 2007; 
Lynch et al., 2003). EPHA1 encodes for an ephrin receptor which has been 
previously reported to play a role in synaptic development and plasticity (Lai and Ip, 
2009).  
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Summary of genes and pathways in $O]KHLPHU¶VGLVHDVH 
Identification of these genetic risk factors provides better understanding of underlying 
biological pathways and mechanisms of LOAD. Future drugs that target pathways 
highlighted by these genes enable potential development of effective treatments and 
more accurate diagnosis of AD.  
Figure 1.4 summarises the JHQHVDQGSDWKZD\VLQ$O]KHLPHU¶VGLVHDVHLPSOLFDWHG
from recent large GWAS (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 
2009; Naj et al., 2011; Seshadri et al., 2010). These pathways include immune 
system function, lipid and cholesterol metabolism and synaptic cell membrane 
processes and endocytosis.  
Apart from pathways elucidated from recent large GWAS, several other biological 
pathways have also been implicated in AD, including oxidative stress (Lovell and 
Markesbery, 2007), mitochondria function (Swerdlow, 2011), the insulin signalling 
pathway (Liolitsa et al., 2002; Stewart and Liolitsa, 1999) and metal homeostasis 
(Maynard et al., 2005).  
One of the main advantages of GWAS is that the genes selected are not dependent 
on pre-conceived knowledge about their function, and therefore may be able to 
highlight a more general picture of AD genetics (Lambert and Amouyel, 2011).  
In view of the genes identified by current GWAS results and the amyloid cascade 
hypothesis proposed by Hardy and Selkoe, 2002, a number of common mechanisms 
can be implicated (Figure 1.5): 
x Familial early-onset forms of AD caused by rapid accumulation of AE peptides 
due to overproduction, which is associated with mutations in APP, PSEN1 
and PSEN2   
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x Late onset AD caused by subtle and insidious impaired clearance of the AE 
peptides, associated with APOE, CLU, CR1, PICALM, BIN1, ABCA7 and 
potentially as yet unidentified others.  
If the hypothesis is true, there is likely an overlap of the two gene categories at 
intermediate age at onset (Lambert and Amouyel, 2011). This hypothesis requires 
further investigation.   
 
  
 Introduction 
36 
 
 
 
 
 
Figure 1.4 Genetic risk factor and pathways in $O]KHLPHU¶VGLVHDVHGenes 
involved in each pathway are shown in red. There is a significant overlap with a 
number of genes being involved in multiple pathways. AE metabolism and 
homeostasis may have a direct effect on pathways implicated in LOAD (as indicated 
by blue arrows). The familial form of AD, which occurs before age 65, is 
predominantly caused by mutations in three genes  APP, PSEN1 and PSEN2. 
(Adapted from  Morgan, 2011)  
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Figure 1.5 Summary of pathogenic events leading to EOAD and LOAD 
proposed by Hardy and Selkoe, 2002 considering new AD genes identified by 
recent large GWAS (Adapted from Lambert and Amouyel, 2011).  
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1.9 The missing heritability of LOAD 
Genome-wide association studies have been successful in identifying hundreds of 
replicable common genetic variants associated with a variety of complex diseases 
(Hindorff et al., 2009). These genetic risk factors found by GWAS greatly improve our 
understanding of the genetic basis of many complex disorders including LOAD.  
The Population-attributable fraction (PAF) is defined as the proportion of disease 
cases in a population that would be prevented if an exposure were eliminated 
(Bertram et al., 2007). Population-attributable fraction (PAF) is also known as 
population-attributable fraction of risk or population-attributable risk (Ertekin-Taner, 
2010; Lambert and Amouyel, 2011; Lambert et al., 2009).  
The Population Attributable fraction (PAF) can be calculated using the formula shown 
below (Bertram et al., 2007):  
۾ۯ۴ ൌ ۴ ൈ ሺ۽܀ െ ૚ሻ۴ ൈ ሺ۽܀ െ ૚ሻ ൅ ૚ 
F is the frequency of the risk allele in the general population and OR is the odds ratio 
of the risk allele (Yang et al., 2003).  
The newly found LOAD genes (CLU, PICALM, CR1, BIN1, ABCA7, MS4A6A, CD33, 
CD2AP and EPHA1) were estimated to have a PAF range from 2.72% to 5.97% (Naj 
et al., 2011). The estimation of PAF must be interpreted with caution, as it is based 
on a number of assumptions, and may vary substantially between studies (Bertram et 
al., 2007).  
It has become increasingly evident that despite expanded GWAS that are capable of 
capturing most common variants with both moderate and small effects, a substantial 
fraction of the heritability of LOAD remains unaccounted for (µPLVVLQJKHULWDELOLW\¶).  
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The remaining unexplained heritability is believed to be due to a combination of 
factors:  
x additional common variants of smaller effect size (which current GWAS are 
still underpowered for detection), 
x additional common variants missed by GWAS due to incomplete coverage, 
x genetic risk caused by low frequency and rare variants, which are not 
detectable by GWAS, 
x synthetic associations attributable to rare variants and 
x epistasis (known as gene-gene interaction). 
Other factors such as copy number variations (CNVs) and gene-environmental 
interactions could also play a role in AD pathogenesis and contribute to the missing 
heritability (Morgan, 2011).   
Additional common variants 
It is plausible that additional common variants are associated with risk of LOAD, but 
have not yet been discovered due to insufficient power. The sample size of a GWAS 
determines the effect size of a common variant that can be detected. Identification of 
associations with common variants of smaller effect sizes may continue to provide 
insights into the complex biological pathways involved in AD. However, identification 
of these variants is unlikely to have any immediate consequences in terms of disease 
prediction and diagnosis (Seshadri et al., 2010).  
Rare variants   
Another explanation of missing heritability is due to low frequency and rare variants, 
which occur with a frequency < 5%. The existing commercial genotyping chips for 
GWAS are not designed for capturing SNPs with a MAF less than 5%. There is 
increasing evidence that these low frequency rare variants can make a significant 
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contribution to the heritability of complex traits and diseases (Rivas et al., 2011). 
These less frequent variants are often found to have larger effect sizes than common 
variants (Bodmer and Bonilla, 2008).  
Synthetic associations 
It has been suggested that a proportion of GWAS signals could be attributable to 
casual rare variants of larger effect size due to incomplete LD with these rare 
variants (Dickson et al., 2010).  
Detection of a GWAS signal may therefore underestimate the actual effect size of the 
rare variants (Wang et al., 2010), although the actual number of common variants 
attributable to these variants is still unclear. It has also been argued that synthetic 
associations attributable to rare variants do not explain most of GWAS results (Wray 
et al., 2011).   
Genetic architecture of complex traits 
Figure 1.6 illustrates the predicted genetic architecture of complex disorders. 
According to their allele frequency and effect size, SNPs can be separated into five 
different categories:  
x common variants of large effect size,  
x common variants of small effect size,  
x low frequency variants with intermediate effect, 
x rare variants causing Mendelian diseases and  
x rare variants of small effect size.  
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Figure 1.6 Genetic architecture of complex traits. Figure summarizing the role of 
genetic variants in complex disorders by allele frequencies and their genetic risk. 
Allele frequency is shown on the x-axis versus odds ratios on the y-axis. Common 
variants (MAF > 0.05) can be detected through genome-wide association studies, 
whereas low frequency and rare variants may only be ascertained through direct 
genotyping and sequencing projects. (Adapted from Manolio et al., 2009)  
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Linkage analysis (using family pedigrees) is a powerful tool to map the location of 
disease-causing loci in reference to the human genome. It was one of the most 
widely used technologies preceding the GWAS era. However, linkage analysis is not 
capable of identifying SNPs with small effect size. APOE H2 and H4 are examples of 
common variants with large effect size OR = ~4 (Bertram, 2011).  In very few cases 
however do common genetic variants exist that have a high risk (i.e. OR > 4) 
associated with complex disorders.  
The vast majority of common variants have shown to exert only a small effect size 
with OR ranges 1.1-1.5. These odds ratio have been consistently observed through 
studies of many complex disorders (Bodmer and Bonilla, 2008). These genetic loci 
are difficult to detect using pedigree information. The advent of GWAS enabled 
systematic detection of the associations between common variants and disease 
given that a large enough sample size is utilized to provide adequate power of 
detection (Figure 1.6).  
There is emerging evidence that less frequent and rare variants may contribute to a 
significant proportion of the missing heritability of LOAD. Although these variants are 
only present in a small proportion of the population, the effect sizes (of these variants) 
are often found to be higher than the association with common variants (Figure 1.6).  
Rare variants of small effect size may also exist (Figure 1.6). This type of variant is 
difficult to detect by any genetic means. Methods to detect these rare variants require 
further exploration.  
Epistasis 
One of the possible explanations of the missing heritability is epistasis. It is a 
measure of the interaction between two or more genetic loci (synergistic or 
antagonistic) contributing to the risk of disease. PLINK µ--HSLVWDVLV¶RUµ--fast-
HSLVWDVLV¶ (Purcell et al., 2007) and synergy factor analysis (Combarros et al., 2009) 
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are among the methods being widely used for assessing epistatic interactions 
between genes. Epistatic interactions between SNPs in the regulatory regions of IL6 
and IL10 have been reported, and have been shown to be associated with a reduced 
risk of AD (Infante et al., 2004). This interaction was replicated in a follow-up study 
(Combarros et al., 2009).  
 
1.10 Summary 
$O]KHLPHU¶VGLVHDVHLVWKHPRVWFRPPRQIRUPRIGHPHQWLDLQWKHHOGHUO\DFFRXQWLQJ
for approximately two thirds of all dementia cases (Blennow et al., 2006). With the 
average life expectancy continuing to rise (i.e. the population ageing), the number of 
AD cases is likely to increase in the near future. The number of individuals suffering 
from AD is expected to rise to ~115.4 million worldwide by 2050 (Ferri et al., 2009).  
Genetic research in a small proportion (~1% to 2%) of AD patients with an autosomal 
dominant pattern of inheritance has contributed greatly to our understanding of AD 
pathogenesis by identifying causal mutations in three genes - APP, PSEN1 and 
PSEN2 (See Amyloid Cascade; Introduction 1.5 for details). These AD cases are 
known as FAD, as they show AD symptoms early in life (before the age of 65) 
(Bertram and Tanzi, 2008).  
LOAD represents the vast majority of AD cases, and their development is likely to be 
affected by both genetic and environmental factors. This non-Mendelian form of AD 
is still highly heritable, with an estimated heritability ranging from 60% to 80% (Gatz 
et al., 2006). Mutations in genes causing the early onset form of $O]KHLPHU¶VGLVHDVH
including APP, PSEN1 and PSEN2, do not appear to be strongly associated with the 
risk of late onset form of $O]KHLPHU¶V disease (Bertram, 2011).  
Apart from APOE gene, nine additional genes (CLU, PICALM, CR1, BIN1, ABCA7, 
MS4A6A, CD33, CD2AP and EPHA1) have been identified by GWAS and confirmed 
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by several replication studies as influencing the risk for LOAD (Harold et al., 2009; 
Hollingworth et al., 2011; Lambert et al., 2009; Naj et al., 2011; Seshadri et al., 2010) 
(Genetic risk factors in LOAD; Introduction 1.8). Despite these successes, there 
is increasing evidence to suggest that a large proportion of the genetic variation 
contributing to AD risk remains unidentified (Sherva and Farrer, 2011) (See The 
missing heritability of LOAD; Introduction 1.9 for details).  
Early GWAS conducted during 2007 and 2009 generally failed to produce any 
convincing results due to the lack of power (Sherva and Farrer, 2011). It is believed 
that by combining each individually underpowered GWAS power could increase thus 
allowing identification of genuine associations and previous spurious associations will 
likely diminish. This formed the basis of the study as described in Chapter 3 - 
Analysis of Genome Wide Association Study (GWAS) data looking for 
replicating signals in LOAD.  
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Chapter 2:    Materials and methods 
2.1 Study samples 
Next generation sequencing 
150 DNA samples (75 AD cases and controls) were used for next generation 
sequencing (Chapter 4). These samples came from three research centres: 
Nottingham, Manchester and Leeds (Appendix 8.1).  
Samples used for studying human ageing  
SNP rs4110518 was genotyped in 462 samples (335 AD cases and 127 controls) 
with age-at-death (AAD) information (Chapter 5). Sample IDs of these samples are 
not shown.  
All DNA sampleVXVHGDUHSDUWRI$O]KHLPHU¶V5HVHDUFK8.$58.FROOHFWLRQ. 
Approval was obtained from the ethics committee or institutional review board of 
each institution responsible for the ascertainment and collection of samples. Written 
informed consent was obtained for all individuals that participated in this study.  
Except the autopsy sample cohort, which were examined post-mortem, all other AD 
cases were diagnosed according to NINCDS-ADRDA (National Institute of 
Neurological and Communicative Disorders and Stroke and the $O]KHLPHU¶V'LVHDVH
and Related Disorders Association), DSM-IV (Diagnostic and Statistical Manual of 
0HQWDO'LVRUGHUV,9RU&(5$'&RQVRUWLXPWR(VWDEOLVKD5HJLVWU\IRU$O]KHLPHU¶V
Disease) criteria (McKhann et al., 1984; Mirra et al., 1991).  
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2.2 Laboratory methods 
A number of laboratory methods were utilized to generate biological data for analysis 
in Chapters 4 and 5. Specifically, DNA extraction and quantitation, LR-PCR, 
agarose gel electrophoresis, BigDye® sequencing and gel extraction were utilized to 
produce DNA pools for next generation sequencing (Chapter 4). TaqMan® 
genotyping assays were used to validate and replicate SNP results as described in 
Chapter 4 and Chapter 5.   
2.2.1 DNA extraction from post-mortem brain tissues 
DNA was extracted from brain tissues (~50mg) using QIAGEN® DNeasy Blood & 
7LVVXH.LWDFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFROProteins and RNA were 
degraded by addition of 20µl protease K (20mg/ml; QIAGEN®) and 4µl RNase A 
(provided in the kit). DNeasy® mini spin columns (provided) were used to purify DNA 
by selective binding of DNA to the membrane as contaminants pass through. The 
DNA was eluted using 150µl elution buffer (supplied in the kit) and stored at 20°C 
prior to use in PCR.  
2.2.2 DNA quantitation using NanoDrop® 
DNA was quantified using NanoDrop® spectrophotometer using a standard 
laboratory protocol.   
The inability of distinguishing UV absorption of free nucleic acid from double stranded 
DNA meant that this technology is not sufficiently accurate to be used for 
experiments that require a precise DNA concentration, e.g. next generation 
sequencing library preparation, real-time PCR and DNA cloning. Alternative methods 
such as Qubit®, Quanti-iT PicoGreen® should be used instead.  
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2.2.3 Long-range polymerase chain reaction (LR-PCR) 
Primers (sense and antisense) for LR-PCR were designed using primer-BLAST 
program (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The quality of the primers 
were measured using Primer3 (v 0.4.0) (http://frodo.wi.mit.edu/primer3/) (Rozen and 
Skaletsky, 2000) and SNPcheck (v 2.0) (https://ngrl.manchester.ac.uk/SNPCheckV2) 
using default settings.  
The following primers were used for TRIM15 µ$¶DQGµ%¶DPSOLFRQV: 
TRIM15 µ$¶ 
x Sense: ATGGGTGAAGGACCGTGGCT 
x Anti-sense: AGGAAAGTGCCCCAAGGCCA 
TRIM15 µ%¶ 
x Sense: AGGGGAAGGCGCCACAGTTT 
x Anti-sense: ACAGGAGAATGGGCCCCACA 
PCR amplification 
TRIM15 µ$¶DQGµ%¶DPSOLFRQV were LR-PCR amplified using FINNZYMES PhusionTM 
High-Fidelity DNA Polymerase on an Applied Biosystem Veriti® 96-well thermal 
cycler.  
The PhusionTM DNA polymerase, according to the manufacturer, has the following 
advantages:  
x Allows amplification of large size DNA amplicons (up to 15kb using genomic 
DNA) 
x High Fidelity  ~50-fold more accurate than Taq DNA polymerase 
x High speed  15-30 seconds per 1 kb 
Cycling conditions used for TRIM15 µ$¶DQGµ%¶DPSOLFRQVDUHVKRZQLQTable 2.1. 
PCR products were stored at 20°C.  
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Table 2.1 Amplification of TRIM15 gene by LR-PCR. Table showing A) cycling 
programs for TRIM15 µ$¶DQGµ%¶ amplicons and B) reagents used for each of the 50µl 
reactions. The optimal annealing temperature for each amplicon (indicated by µ¶was 
determined by performing a temperature gradient optimisation.   
 
 
  
A) 
TRIM15 µ$¶DPSOLFRQ (1,984 bp) 
Temperature Time Cycles 
98°C 30 seconds 1 
98°C 10 seconds 
35 70.3°C* 30 seconds 
72°C 1 minute 
72°C 7 minutes 1 
10°C  Hold 
TRIM15 µ%¶DPSOLFRQ (4,935 bp) 
Temperature Time Cycles 
98°C 30 seconds 1 
98°C 10 seconds 
35 71.2°C* 30 seconds 
72°C 2 minutes and 30 seconds 
72°C 7 minutes 1 
10°C  Hold 
B) 
Reagent Concentration Volume 
Phusion HF or GC buffer 5x 10µl 
dNTPs 10mM 1µl 
forward primer 100µM 0.25µl 
reverse primer 100µM 0.25µl 
Phusion® DNA Polymerase  2U/µl 0.5µl 
DNA 50ng/µl 1µl 
Nuclease free H2O NA 37µl 
Total: 
 50µl 
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Optimisation of conditions for LR-PCR 
For each primer pair, the reaction was optimised using the strategy:  
x Annealing temperature was optimised by performing temperature gradients, 
57-72°C initially followed by a smaller temperature gradient according to the 
band intensity (e.g. 62-67°C). 
x Mg2+ concentration was optimised by performing a Magnesium gradient  
1.5mM, 2mM, 2.5mM, 3mM and 3.5mM.  
x Addition of dimethyl sulfoxide (DMSO) was attempted to test if it improves the 
performance of the LR-PCR; DMSO may improve the LR-PCR performance 
by inhibiting formation of any secondary structures in the DNA template and 
facilitating complete DNA denaturation.   
 
2.2.4 Agarose gel electrophoresis 
PCR products were visualised by agarose gel electrophoresis. Small 0.7% agarose 
gels (gel volume 25ml) were prepared as follows: 
x 0.17g of agarose powder (Fisher Scientific®)  
x 25ml 1xTAE (40mM Tris acetate, 1mM EDTA) 
x 3µl of ethidium bromide (EtBr) (10 mg/ml, Pharmacia Biotech)  
Medium (50ml 1xTAE buffer, 0.35g agarose and 5µl of EtBr) and large agarose gels 
(80ml 1xTAE buffer, 0.56g agarose and 8ul EtBr) were also used when necessary.  
PCR products mixed with DNA loading buffer (Fermentas®) were subjected to 
electrophoresis together with the GeneRulerTM 1kb ladder at ~80V. The DNA was 
visualised using a UV transilluminator.  
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2.2.5 BigDye® sequencing 
Sanger sequencing was used to examine if the LR-PCR products were of the correct 
fragment (by comparing with reference human genome sequence, hg19) prior to 
DNA pooling for next generation sequencing (Chapter 4).  
LR-PCR products were purified using ExoSAP-IT® (composed of Exonuclease I and 
Shrimp Alkaline Phosphatase) and sequenced using the BigDye Terminator v3.1 
VHTXHQFLQJNLWDFFRUGLQJWRPDQXIDFWXUHU¶Vrecommendations. Addition of ExoSAP-
IT® facilitates removal of unincorporated dNTPs and residual primers.   
BigDye® terminator reaction premix contains essential reagents including AmpliTaq® 
DNA polymerase, deoxynucletides (dNTPs) and fluorescently labelled 
dideoxynucleotides (ddNTPs). Cycling programs and reagents used in each of the 
reactions are shown in Table 2.2.  
After the sequencing reaction, the mixture was filtered by running through Edge 
Biosystem Performa® DTR Gel Filtration cartridges to remove excess ddNTPs. The 
reaction was dried on a thermal block at 90°C. The dried DNA pellets were stored at 
20°C prior to capillary electrophoresis using an ABI® 3130 Genetic Analyser. 
Capillary electrophoresis was performed by the Molecular Diagnostic Lab at the 
University of Nottingham.   
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Table 2.2 Sequencing using BigDye® (v 3.1). Table showing A) cycling conditions 
and B) reagents used for the ExoSAP-IT® treatment and BigDye® sequencing 
reactions.  
 
 
  
A) ExoSAP-IT® treatment 
Temperature Time Cycles 
37°C 15 minutes 1 
80°C 15 minutes 1 
10°C  Hold 
Sequencing reaction using BigDye® 
Temperature Time Cycles 
96°C 1 minute 1 
96°C 30 seconds 
25 cycles 50°C 15 seconds 
60°C 4 minutes 
10°C  Hold 
B) ExoSAP-IT® treatment 
Reagent Concentration Volume 
LR-PCR product ~200ng/µl 5µl 
ExoSAP-IT premix 100% 2µl 
Total: 
 7µl 
BigDye® sequencing 
Reagent Concentration Volume 
ExoSAP-IT purified PCR product  5µl 
Sequencing primer 5µM 1µl 
BigDye® terminator reaction premix 100% 3µl 
ABI® sequencing buffer 5x 1µl 
Total: 
 10µl 
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2.2.6 Gel extraction 
LR-PCR product was purified by gel extraction using QIAquick® gel extraction kit 
DFFRUGLQJWRPDQXIDFWXUHU¶VUHFRPPHQGDWLRQV 
SYBR® Green (Invitrogen SYBR SafeTM DNA gel stain) was used (instead of EtBr) 
for agarose gel electrophoresis to avoid introducing damage to the DNA. The 
agarose gel was visualised using a Dark Reader® transilluminator, where the desired 
DNA band was excised from the agarose gel using a clean, sharp scalpel blade 
before being transferred into a 1.5ml Eppendorf tube. The agarose gel was 
subsequently dissolved and filtered out using the kit. The DNA was collected using 
30µl nuclease free water. The elution process was repeated, and the DNA was 
stored at 20°C.  
2.2.7 TaqMan® SNP Genotyping assay 
TaqMan® genotyping assay was supplied at 40x concentration. The assay was 
diluted to a 20x working concentration by adding one volume of 1xTE buffer (10mM 
Tris-HCL, 1mM EDTA at pH8.0).  
TaqMan® genotyping was performed using Agilent® Real-Time PCR optical 8-tube 
strips and optically clear 8-cap strips on the STRATAGENE Mx3000PTM Real-Time 
PCR System. DNA templates were diluted to 10ng/µl concentration using nuclease-
free water prior to genotyping.  
Cycling conditions and reagents used for the assay are summarised in Table 2.3. 
The data was analysed using MxPro QPCR (v 4.01) and results were exported into 
Microsoft Excel format for further analysis. TaqMan® genotyping assays are claimed 
to be highly accurate, although false positive amplifications are possible due to the 
KLJKWKURXJKSXWDQGUHSHWLWLYHQDWXUHRIWKH¶QXFOHDVHDVVD\Special laboratory 
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Table 2.3 TaqMan® genotyping assay. Table showing A) cycling program and B) 
reagents used for the TaqMan® genotyping assay on STRATAGENE Mx3000PTM 
Real-Time PCR System.  
 
  
A) 
TaqMan® genotyping assay 
Temperature Time Cycles 
50°C 2 minutes 1 
95°C 10 minutes 1 
95°C 15 seconds 
55 
60°C 1 minute 
10°C  Hold 
B) 
Reagent Concentration Volume 
TaqMan® genotyping assay 20x 1µl 
TaqMan® Universal PCR 
MasterMix 2x 9µl 
Nuclease-free water NA 8µl 
DNA template 10ng/µl 2µl 
Total: 
 20µl 
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2.3 Bioinformatics tools and data analysis 
Open source bioinformatic tools have been utilized to enable a wide range of data 
analysis presented in this thesis. :KHUHLQGLFDWHGµ,QKRXVH¶3HUOVFULSWV were written 
and have been implemented to facilitate various data analysis (See Methods 2.3.2).  
A range of bioinformatics tools are described in this section, facilitating data analysis 
as described in Chapters 3, 4 and 5. Specifically, PLINK software (v1.06) was 
utilized in Chapter 3 and Chapter 5 to analyse GWAS data and produce association 
results. The Haploview program was used in Chapter 3 to produce LD plots, and in 
Chapter 5 to create the Manhattan plot. VISTA and ECR browser were utilized to 
analyse conservation and facilitating selection of conserved regions for next 
generation sequencing (Chapter 4). EIGENSTRAT was utilized in Chapter 5 to 
analyse population stratification using LOAD GWAS data. QUANTO (v1.2.4) was 
utilized to perform power calculations for the association studies in Chapter 3, 4 and 
5.  
2.3.1 PLINK 
PLINK is a powerful whole-genome association and linkage analysis toolset 
developed by Purcell et al., 2007. It has become one of the most reputable 
bioinformatic toolsets for GWAS data analysis to date. By September 2011, the 
corresponding manuscript (Purcell et al., 2007) has been cited by over 2,400 peer-
reviewed scientific papers.  
One of the advantages of using PLINK is it provides a comprehensive range of tools, 
including GWAS data manipulation, quality control, association studies (single SNP 
analysis and haplotype analysis), transmission disequilibrium testing (TDT), GWAS 
meta-analysis, epistasis, imputation and permutation. The results generated by 
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PLINK can be used directed by other bioinformatic software (e.g. Haploview) for 
further in-depth analysis.  
PLINK is operated through the command line interface as currently there is no viable 
GUI available for handling large datasets.  
PLINK file format 
A summary of PLINK input file format is shown in Table 2.4. It should be noticed that 
data stored in PED and MAP files are interlinked, genotype data stored in the PED 
file correlates to the corresponding MAP file. Therefore, any manual changes on 
these files should be avoided, as it could render the data unusable by introducing 
error.  
Missing data in PLINK is by default represented as either -9 or 0, with an exception of 
missing genotype data which is presented as 0 (zero).  
  
 Materials and methods 
 
56 
 
Table 2.4 Summary of PLINK input file format. Table showing the PLINK input file 
format together with a brief description.  
File types Description 
PED and MAP 
x Standard (generic) PLINK input file format 
x PED file is comprised of six compulsory columns (Family ID, 
Individual ID, Paternal ID, Maternal ID, Sex and Phenotype) and 
variable number of genotype columns (column 7 and onwards). 
x MAP file consists of exactly four columns (Chromosome 
number, SNP identifier, Genetic distance and Base-pair 
position) 
x no headers 
BED, FAM and 
BIM 
x PLINK binary file format 
x BED files store genotype information in a compressed binary 
format, which is unreadable using a text editor. 
x The FAM file consists of exactly six columns as in the PED file. 
The BIM file includes the first four columns of the MAP file plus 
two additional columns showing the corresponding SNP 
genotypes. 
x no headers 
PHENO 
x PHENO file is able to store multiple alternative phenotypes for 
analysis without modification of the PED file or FAM file.  
x The PHENO file consists of two compulsory columns (family ID 
and individual ID) and variable number of phenotype columns.  
x 7KH3+(12ILOHLVLQFOXGHGLQWKHDQDO\VLVE\VSHFLI\LQJµ--
SKHQR¶LQ3/,1. 
x Requires headers, two compulsory columns headers, FID and 
IID, representing family ID and individual ID 
COVAR 
x Stores covariate information to be included in PLINK analysis.  
x The covariate (COVAR) file consists of two compulsory columns 
which are identical to the first two columns of the PHENO file, 
and variable number of covariate columns.  
x 7KH&29$5ILOHLVLQFOXGHGLQWKHDQDO\VLVE\VSHFLI\LQJµ--
FRYDU¶LQ3/,1. 
x Requires headers, two compulsory columns headers, FID and 
IID, representing family ID and individual ID 
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It is recommended to convert the standard PLINK format (PED and MAP) to the 
binary format when handling large datasets. Binary files are much smaller in file size, 
PLINK analysis performs much quicker using the binary input format.  
3/,1.DQDO\VLVLQFOXGLQJDOWHUQDWLYHSKHQRW\SHDQGFRYDULDWHVLVVSHFLILHGE\µ--
SKHQR¶DQGµ--FRYDU¶IROORZHGE\WKH3+(12DQG&29$5ILOHQDPHV, respectively.  
One of the utilities of using PHENO file is to perform expression quantitative trait loci 
(eQTL) analysis, where hundreds of thousands of gene expression data could be 
analysed all at once. 
Adjusting for covariates is crucial in GWAS analysis, as it ensures that the 
association signal identified is not due to underlying biases such as age, gender, 
centre of study and other sample heterogeneity.  
By default, PLINK represents data using number codings as listed: 
x Phenotypes  1 and 2 represents controls and cases 
x Gender  1 and 2 represents males and females 
x Genotypes  1 and 2 represents minor and major allele (also coded as A, T, 
C or G) 
Case/Control association analysis 
PLINK provides a number of methods for case/controls association studies. The most 
FRPPRQO\XVHGPHWKRGµ--DVVRF¶SHUIRUPVallelic dosage analysis (Wald test) on 
query SNPs. For example: 
plink --file mydata --assoc 
The command generates an output file µSOLQNDVVRF¶ZKLFh contains the following 
fields: 
x CHR - chromosome number,  
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x SNP - SNP ID,  
x BP - base-pair position,  
x A1- the minor allele based on whole sample,  
x F_A - frequency of this allele in cases,  
x F_U - frequency of this allele in controls,  
x A2 - the major allele,  
x CHISQ - chi-squared statistics on 1 degree of freedom,  
x P - asymptotic p-value and  
x OR - estimated odds ratio.  
Optional aGGLWLRQRIµ--FL¶ within the command line calculates 95% confidence 
interval for ORs (odds ratios).  
µ--DVVRF¶ examines potential association much faster than logistic regression analysis; 
however it does not allow inclusion of covariates.  
Logistic regression analysis 
Logistic regression analyses are more sophisticated and allow inclusion of covariates. 
The logistic regression model is more robust than linear regression as it can handle 
non-linear effects and it does not make assumptions on distribution of the 
explanatory variables (e.g. a normal distribution) (Bewick et al., 2005).  
Logistic regression analysis still has a number of inbuilt assumptions, and requires 
much larger sample sizes than a standard linear regression analysis. In addition, the 
logistic regression analysis in PLINK assumes the phenotype (e.g. disease trait) is 
binary. Therefore, the analysis is quantitative rather than qualitative. This is 
considered a limitation of logistic regression analysis, as taking into account the 
severity of AD and disease related endophenotypes is likely to further increase power 
enabling identification of genuine disease associated variants (Plomin et al., 2009) 
that could be missed using the current approach.  
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The analysis can be implemented with the following command line: 
plink --file mydata --logistic --covar myfile.covar --covar-name 
age,sex,APOEstatus 
µ--ILOH¶VSHFLILHVWhe data files to be analysed as µP\GDWDSHG¶DQGµP\GDWDPDS¶µ--
ORJLVWLF¶LQGLFDWHV the logistic regression analysis is utilized in the analysis. µ--FRYDU¶ 
DQGµ--covar-QDPH¶VSHFLILHVWKH covariate terms. 
Association analysis using different genetic models 
Different genetic models can be specified and analysed using logistic regression as 
shown: 
x $GGLWLYHLQKHULWDQFHPRGHOµ--ORJLVWLF¶RQLWVRZQ 
x Dominant LQKHULWDQFHPRGHOµ--logistic --GRPLQDQW¶ 
x 5HFHVVLYHLQKHULWDQFHPRGHOµ--logistic --UHFHVVLYH¶ 
An alternative way to include different genetic models in the analysis LVWRXVHµ--
PRGHO¶FRPPDQGWKRXgh this does not allow adjusting for covariates. The following 
tests are provided in PLINK µ--PRGHO¶FRPPDQG 
x Cochran-Armitage trend test 
x Genotypic (2 df) test 
x Dominant gene action (1 df) test 
x Recessive gene action (1 df) test 
GWAS Quality controls (QC) 
SNPs and individuals can be filtered out from an analysis by addition of QC filters in 
the command line. µ--JHQR¶DQGµ--PLQG¶exclude SNPs and individuals according to 
JHQRW\SLQJUDWHµ--PDI¶H[FOXGHV613VEHORZDXVHU-defined minor allele frequency. 
µ--KZH¶UHPRYHV SNPs from the analysis according to Hardy-Weinberg Disequilibrium 
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p-values. Furthermore, in studies including families pedigrees, Mendelian errors can 
EHGHWHFWHGE\µ--PH¶FRPPDQG 
Combinations of these methods provide flexibility and control in response to various 
GWAS data analysis types.  
Quantitative Trait analysis 
Two main methods are provided in PLINK to perform quantitative trait analysis, µ--
DVVRF¶DQGµ--OLQHDU¶The PLINK program automatically engages a quantitative trait 
analysis when it encounters integers other than 0, 1, 2 or -9 in the sixth column of the 
PED file.  
The µ--DVVRF¶ command does not take into account covariates in a quantitative trait 
analysis, conversely µ--OLQHDU¶does allow covariates µ--FRYDU¶DQGµFRYDU-QDPH¶WREH
included in the analysis. 
The versatility of PLINK also allows for different genetic models to be explored in 
quantitative trait analysis, as previously described.   
PLINK gene report function 
The PLINK gene report function can annotate SNPs according to their base pair 
coordinates relative to genes. Two files are required in this analysis, a PLINK results 
ILOHHJµDVVRF¶DQGa file containing coordinate information of known human genes.  
The gene list (glist-hg18), which consists of ~20,000 human genes was downloaded 
from the PLINK website at http://pngu.mgh.harvard.edu/~purcell/plink/res.shtml. This 
list consists of four columns - Chromosome, Start base pair position, Stop base pair 
position and Gene name. This facility can be implemented using a similar command 
to the below example: 
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plink --gene-report results.assoc.linear --gene-list glist-hg18.txt --pfilter 0.05 
--gene-list-border 20 --out outputfile 
 µ--pILOWHU¶VSHFLILHV that the association p-value threshold is equal to 0.05, 
indicating that the output would only present SNPs with p-value less than 0.05. µ--
gene-list-ERUGHU¶LQGLFDWHV the maximum distance between the SNP and the 
reported gene is equal to 20kb.  
A PERL program was written (Appendix 8.4.4) as a plug-in to complement the 
PLINK gene report function. The program tabulates the PLINK output into a format 
enabling further manipulation and analysis (Figure 2.1).  
This PERL program FRQVLVWVRIWZRILOHVµJHQHBUHSRUWBSOXJLQSO¶ DQGµPRGXOHVSP¶
The program can be executed via the command line interface µSHUO
JHQHBUHSRUWBSOXJLQSO¶or the appropriate file icon. Input file name can be specified by 
editing µJHQHBUHSRUWBSOXJLQSO¶ file using a standard text file editor, such as WordPad 
in Windows. Results are provided in a tab-delimited text file format, which can be 
accessed via conventional statistical tools (Figure 2.2).  
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Figure 2.1 PLINK gene-report function output. Only SNPs that pass the user input filters are listed LHµ--SILOWHU¶DQGµ--gene-list-
ERUGHU¶*HQHGHWDLOV are shown together with corresponding SNPs (DIST - distance between the SNP and start of the gene, CHR - 
chromosome number, SNP - rs identifier, BP - base pair position, A1 - minor allele code, TEST - model of test, NMISS - number of non-
missing individuals, OR - odds ratio, SE - standard error, L95 and U95 - lower and upper 95% confidence interval, STAT - association 
test statistics, P - p-value of the association). The corresponding genes (shown in bold) are automatically sorted in alphabetical order.  
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Figure 2.2 Output of the PERL program IRU3/,1.µJHQH-UHSRUW¶IXQFWLRQThe 
results from PLINK output. Figure 2.1 are converted into a simplified tabulated 
format. SNP - SNP Identifier, CHR - chromosome number, BP - base pair position 
are shown together with P - p-value of the association, OR - odds ratios, GENE - 
gene name, LENGTH - size of the gene and DIST - distance between the SNP and 
the start position of the corresponding gene (negative values indicate that SNP is 
located before the start position of the gene).   
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2.3.2 PERL programming language 
PERL is a programming language that has been widely utilized for the development 
of novel bioinformatic applications. Analysis of large-scale genomic data is often 
challenged by the lack of suitable bioinformatic programV:ULWLQJµLQKRXVH¶
bioinformatic tools not only permits exploiting new ideas, but also reduces time for 
tasks which would otherwise be laborious.  
In this thesis, four Perl programVZHUHGHYHORSHGµLQKRXVH¶IRUWKHIROORZLQJ
calculations: 
x Determination of common SNPs between different genotyping chip platforms 
(e.g. Illumina HumanHap300 versus Illumina HumanHap610, which is a pre-
requisite step for principal component (PC) analysis (as described in 
Methods 2.3.9). The program was documented in Appendix 8.4.1.  
x Calculation of the number of independent tests in GWAS to enable an 
accurate multiple testing adjustment for GWAS analysis (as described in 
Methods 2.3.2). Appendix 8.4.2.  
x A GWAS meta-analysis tool taking into account LD, shown in Chapter 3. 
Appendix 8.4.3.  
x A plug-in for PLINK gene-report function (as described in Methods 2.3.1). 
Appendix 8.4.4.  
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2.3.3 Calculation of the number of independent tests 
GWAS has given insights into the aetiology of many complex diseases including 
LOAD. However, due to the large number of SNPs tested all at once, apparently 
µVLJQLILFDQW¶ILQGLQJV may arise simply due to chance. However, the majority of these 
findings are likely to be false positives. Thus a very stringent significance threshold is 
necessary to provide confidence in the findings. For instance, in a GWAS using 
500,000 independent markers, 25,000 would be expected to show a nominal p-value 
< 5 x 10-2 by chance alone and five out of this 25,000 could be significant with p-
values < 1 x 10-5. The most widely used methods for solving this multiple testing 
issue is to use Bonferroni correction, where it suggests that if µn¶ independent tests 
are carried out, the significance level for the entire series of tests is equal to the p-
value of a single test divided by µn¶. The significance threshold of p = 5 x 10-8 has 
been widely used to infer a genuine association in GWAS (Bertram et al., 2008).  
It is generally believed that Bonferroni correction is overly conservative in GWAS 
findings (Sherva and Farrer, 2011). A p-value of 5 x 10-8 is equivalent to a p-value of 
0.05 after a Bonferroni correction of 1,000,000 independent tests, whereas early 
GWAS only possessed ~500,000 SNPs (Affymetrix 500K chip) or ~610,000 SNPs 
(Illumina 610 chip). Second, due to the existence of LD between SNPs on these 
genotyping chips, a large number of SNPs are not independent. Taken together, it 
implies that a SNP with p-value > 5 x 10-8 may well harbour genuine associations.  
Linkage disequilibrium (LD) measures the probability that alleles at two loci are      
co-inherited, the LD value is affected by genetic recombination (Wray et al., 2011). 
A more accurate Bonferroni correction p-value threshold can be generated using the 
exact number of independent tests, where multiple SNPs are counted as a single 
independent test if they are in perfect LD (i.e. with r2 = 1). It is conceivable that using 
imperfect proxies (r2 < 1) is likely to further reduce the number of independent test. 
 Materials and methods 
 
66 
 
The results, however, must be interpreted with caution, as lowering the LD r2 value 
will likely introduce errors. The relationship between the LD r2 value and the amount 
of noise contributing to the calculation of genome wide significance threshold 
requires further investigation.   
In order to calculate the exact number of independent test, SNPs genotyped on 
GWAS chips ZHUHH[WUDFWHGIURPWKH+DS0DSGDWDVHWXVLQJµ--H[WUDFW¶DQGµ--make-
EHG¶FRPPDQGWithin this file, SNPs in perfect LD are ascertained using the 
following PLINK commands: 
plink --Ǯǯ--r2 --ld-window-kb 1000 --ld-window 99999 --ld-window-
r2 1 --out ǮǤǯ 
µ--U¶Ls the command for calculating r2 value of LD. µ--ld-window-NE¶LQGLFDWHV
the calculation is undertaken within 1Mb distance of index SNPs saved in the input 
file. µ--ld-ZLQGRZ¶VSHFLILHVWKHPD[LPXPQXPEHURISDLU-wise combinations to 
be calculated for each SNP is 99999. µ--ld-window-U¶LQGLFDWHVWKH/'U2 threshold 
is equal to 1.  
The LD r2 values calculated using PLINK are based on haplotype frequencies 
estimated via the Expectation Maximisation (EM) algorithm.   
Given that any two SNPs with their base-pair positions more than 1 Mb apart highly 
unlikely to be in perfect LD, the calculation is conducted within a window of 1Mb 
either side of the index SNP.   
A PERL script (Appendix 8.4.2) was written to calculate the number of LD clusters 
and the number of SNPs in perfect LD. The number of independent tests was then 
calculated using the formula: 
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ۼܝܕ܊܍ܚܗ܎ܑܖ܌܍ܘ܍ܖ܌܍ܖܜܜ܍ܛܜܛൌ ሾۼܝܕ܊܍ܚܗ܎܁ۼ۾ܛܗܖܜܐ܍܋ܐܑܘ െ ۼܝܕ܊܍ܚܗ܎܁ۼ۾ܛܑܖܘ܍ܚ܎܍܋ܜܔܑܖܓ܉܏܍ሿ൅ ۼܝܕ܊܍ܚܗ܎ۺ۲۱ܔܝܛܜ܍ܚܛ 
The PLINK output file (.ld) was used for this calculation using this PERL script. The 
genome-wide significant thresholds were calculated based on the number of actual 
independent tests. This approach has been used in studies described in Chapter 3 
and Chapter 5.  
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2.3.4 Linkage disequilibrium analysis 
LD patterns dramatically increase the coverage of SNPs chips used in GWAS. In 
cross-platform meta-analysis, LD further increases the number comparable SNPs 
between different studies.  
There are two ways of measuring the strength of LD - r2 DQG'¶U2 is more frequently 
used in comparison of SNPs with similar allele frequencies, ZKHUHDV'¶LV often used 
when assessing the relationship between common and rare variants (Wang et al., 
2010; Wray et al., 2011).  
The r2 value is considered PRUHVWULQJHQWWKDQ'¶$/'YDOXH of r2 equal to 1 
SURGXFHVD'¶YDOXHDOVRHTXDOWRZKHUHDVLI/'YDOXH'¶HTXDOWRU2 value can 
range from close to 0 to 1. 
The valuHRI'¶LVQRWDIIHFWHGE\WKHGLIIHUHQFHLQDOOHOH frequencies between two 
SNPs. Measures of the linkage between two SNPs can be assigned into four 
categories - Perfect LD, Complete LD, Moderate LD and no evidence of LD.  
CandiSNPer 
CandiSNPer is a web based bioinformatic application which allows efficient search of 
SNP LD patterns based on user-specified parameters (input SNP rs number, LD r2 
value, output window sizes and population sizes), and simultaneously annotates 
tagged SNPs, which are in LD with the index SNP (initial input SNP), based on its 
functions (Schmitt et al., 2010).  
CandiSNPer automatically categorize SNPs into different functional classes, and 
annotates them in different colours. The program can be accessed through the 
website http://www2.hu-berlin.de/wikizbnutztier/software /CandiSNPer. 
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Default functional classes in CandiSNPer are: 
Class 1: Stop lost, Stop gained, Frameshift 
Class 2: Nonsynonymous coding, Splice site, Essential splice site 
&ODVV6\QRQ\PRXVFRGLQJ¶875¶8758SVWUHDP'RZQVWUHDP 
Class 4: Intronic, Pseudogene 
Class 5: Intergenic 
Class 6: Start SNP: rs number 
CandiSNPer directly retrieves the latest version of SNP data (in real time) from the 
Ensembl database. It calculates both LD r2 DQG'¶values and provides the results in 
a graphical HTML format. Furthermore, CandiSNPer automatically predicts and 
highlights the LD block where the index SNP is located.  
 
SNAP (SNP Annotation and Proxy Search) 
SNAP is a web based bioinformatics tool for assessment of LD between SNPs 
(Johnson et al., 2008). The SNAP program is accessible at 
http://www.broadinstitute.org/mpg/snap/ldsearch.php. 
It provides an efficient method to retrieve proxies for SNPs under investigation. The 
LD values between SNPs are calculated using the HapMap and pilot 1000 genome 
data. Furthermore, SNAP provides a function to graphically represent a µUHJLRQDO/'
SORW¶ for use in publications.  
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2.3.5 Haploview 
Haploview is a bioinformatic program designed to compute linkage disequilibrium 
statistics and population haplotype patterns using a wide range of genotype data 
input formats (Barrett et al., 2005). The software is written and operated within the 
Java scripting language. 
Haploview has been widely used for genetic studies, including association studies, 
haplotype analysis, and calculation of SNP coverage in GWAS using the Haploview 
µWDJger¶ program.  
Generation of a Manhattan Plot 
A Manhattan plot is a useful method to visualise the results of a GWAS, facilitating 
the identification of associated SNPs with disease or traits of interest.  
Data in PLINK format was loaded into the Haploview program XVLQJWKHµ/RFXV
,QIRUPDWLRQ)LOH¶LQSXWER[Parameters can be adjusted using the pop-up window 
after clickLQJWKHµ3ORW¶EXWWRQ. The following parameters were adjusted: 
x µFKURPRVRPHV¶ZDVVHOHFWHGLQµ[-D[LV¶GURSGRZQOLVW 
x µS¶ZDVVHOHFWHGLQµ\-D[LV¶GURSGRZQOLVW 
x µ-ORJ¶ZDVVHOHFWHGLQµVFDOH¶GURSGRZQOLVW 
x µ!¶ZDVVHOHFWHGLQµVXJJHVWLYHEOXHOLQH¶GURSGown list and 4.3 was inputted 
x µ!¶ZDVVHOHFWHGLQµVLJQLILFDQWUHGOLQH¶GURSGRZQOLVWDQGZDVLQSXWWHG 
All other parameters were in default setting.  
The appearance of the Manhattan plot could be adjusted via the µSURSHUWLHV¶ option 
provided. An example Manhattan plot is shown in Figure 2.3 using the Mayo GWAS 
data (Carrasquillo et al., 2009). The x-axis and y-axis represents chromosomal 
position and -log10GWAS (p-value), respectively.  
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Figure 2.3 Manhattan plot depicting GWAS output using LOAD GWAS data. The 
data consists of 1,998 individuals (799 LOAD cases and 1,199 controls) and 313,330 
SNPs. Chromosomal position is shown on the x-axis versus -log10 GWAS p-value on 
the y-axis. Red and blue horizontal lines represent p-value threshold 5 x 10-8 and 5 x 
10-5, respectively. SNPs are represented by dots highlighted in different colours 
according to chromosomal locations. A series of green vertical dots represents SNPs 
in LD with APOE H4 genotypes. The plot is shown for illustrative purposes only, and 
has not been used for actual studies.  
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+DSORYLHZµWDJJHU¶SURJUDP 
The +DSORYLHZµWDJJHU¶SURJUDP is powerful tool to estimate the coverage of SNPs 
typed on a GWAS chip with respect to all known SNPs.  
The HapMap genotype data release #24 was used in this calculation. Data in 
HapMap format was loaded into the Haploview program XVLQJWKHµEURZVH¶EXWWRQ 
provided. TKHµWDJ¶DQGµQRQ-WDJ¶613Vwere selected using tick boxes - µIRUFHLQFOXGH¶
IRUµWDJ¶613VDQGµIRUFHH[FOXGH¶IRUµQRQ-WDJ¶613V 
The coverage was calculated based on the number of SNPs (within the specified 
genome region) which are captured by the µWDJ¶613VGenome regions were 
specified by selection of all SNPs within these regions. Selecting SNPs was 
XQGHUWDNHQXVLQJµFapture tKLVDOOHOH"¶WLFNER[HVSURYLGHG.  
A SNP was defined as being captured by tKHµWDJ¶613LIWKHWZR613Vshowed a 
pairwise LD r2  0.8. Other parameters were in default.  
An example of HaploviHZµWDJJHU¶SURJUDP output is demonstrated in Figure 2.4. In 
the example, two SNPs ZHUHVHOHFWHGDVµWDJ¶ SNPs, which captured 18% (13 out of 
69) SNPs with r2 56 SNPs have not been captured. 
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Figure 2.4 +DSORYLHZµ7DJJHU¶SURJUDP output. Two SNPs selected DVµ7HVWV¶ 
(rs12359570 and rs7079104) captured SNPs OLVWHGDVµ$OOHle captured¶7KHµtDJJHG¶
SNPs are listed in black fontDQGµXQWDJJHG¶SNPs are in red font. This figure is 
shown for illustrative purposes only.  
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Generation of a Haploview LD plot 
The Haploview LD plot has been widely used in genetic studies to interpret 
association study results, e.g. if two SNPs are in the same LD block, the association 
observed with one SNP could be in fact due to LD with the other functional SNP 
which is showing an effect.  
Data were loaded into Haploview using the same method as mentioned earlier. SNPs 
to be included in the LD plot were selected using the tick boxes provided. The LD plot 
is shown by simply VHOHFWLQJWKHµ/'SORW¶WDJ.  
Haploview provides three different algorithms for estimating LD blocks:   
x µFRQILGHQFHLQWHUYDOV¶ (the default setting)(Gabriel et al., 2002),  
x µ)RXU*DPHWH5XOH¶(Wang et al., 2002) and  
x µ6ROLG6SLQHRI/'¶ (Barrett et al., 2005).  
An example LD plot is shown in Figure 2.5. Colour of each rhombus represents 
strength of LD between SNPs: 
x Red - perfect LD, reflected by both r2 DQG'¶YDOXHV equal to 1. Genotypes in 
one SNP perfectly inform the genotype of the other. 
x Blue - complete LD, where '¶YDOXHHTXDOWRDQGU2 < 1. Complete LD refers 
to a scenario where two SNPs possess a significantly different MAF, and the 
alleles of the two SNPs are coupled as much as is possible given the different 
allele frequencies (Wray et al., 2011).  
x Light red (or pink) - moderate LD, where both r2 DQG'¶YDOXHDUe less than 1.  
x White - the two SNPs are independent. 
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Figure 2.5 Haploview LD plot. The strength of LD was represented by different 
colours (red - perfect LD, blue - complete LD, pink - moderate LD and white - no 
evidence of LD). The genomic region is represented by the horizontal bar shown at 
the top, and the physical distance between SNPs are as indicated by connecting 
solid lines. This LD plot is shown for illustrative purposes only and has not been used 
for actual studies.  
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2.3.6 Conservation analysis 
Both VISTA browser (Frazer et al., 2004) and Evolutionary Conserved Regions (ECR) 
browser (Ovcharenko et al., 2004) are designed to examine conservation between 
the human genome and the genomes of vertebrate animal species (such as mouse, 
rat, chimpanzee, rhesus monkey, dog, cow, opossum, chicken, frog, zebrafish).  
Animals such as mouse, rat and rhesus monkey or chimpanzee are the most widely 
used animal species for studying conservation, likely contributed by the fact that mice 
and rats are the standard laboratory animals, whereas monkey and chimpanzee 
share high degree of homology with human.  
The conservation scores are pre-computed for both VISTA and ECR browsers, 
allowing rapid retrieval of data from them both.  
SNPs that fall in a conserved region are considered more likely to be functional than 
anonymous polymorphisms (Carrasquillo et al., 2009). This is also supported by the 
fact that regions such as exons and untranslated regions (UTRs) are more likely to 
be conserved than introns and intergenic regions.  
Both VISTA and ECR browsers are implemented in Java programming language. 
They share a high degree of similarity such as both providing very similar graphical 
user interfaces (GUI). Sequences and annotation data utilized in the ECR browser 
are directly downloaded from the UCSC Genome Browser in real-time.  
VISTA browser 
The VISTA browser can be accessed via the website http://pipeline.lbl.gov/. For 
TRIM15 gene analysis (as described in Chapter 4), µ9HUWebrate -> Human -> Mar. 
¶ZDVselected in the drop-down list, and base pair coordinates µFKU-
¶ (NCBI36/HG18) was enterHGLQWKHµSRVLWLRQ¶LQSXWER[ The coordinates 
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were adjusted in order that that flanking regions of the gene are included in the 
analysis. The following parameters were adjusted:  
x $QLPDOVSHFLHVµ5KHVXV'RJ+RUVH0RXVH5DWDQG&KLFNHQ¶ZHUHVHOHFWHG
XVLQJWKHµVHOHFWDGG¶GURSGRZQOLVWThe actual sequence alignments 
between human genome and animal genome were retrieved via the 
µaOLJQPHQW¶LFRQ 
x The range of the conservation score was adjusted to between 50% and 100% 
XVLQJµPLQLPDO\¶DQGµPD[LPDO\¶LQSXWER[HV provided.   
x The significance threshold was adjusted to 70% using the µFRQLGHQWLW\¶ input 
box.  
All other parameters were in default. 
With the default setting, conservation scores exhibited by the software are based on 
alignments of 100 nucleotide bases at a time. At each new chromosomal position, 
the score is recomputed by shifting one nucleotide. The final conservation plot is 
represented in the form of a curve. Conserved genome regions are automatically 
highlighted by the software in different colours.   
ECR browser 
The ECR browser can be accessed via the website http://ecrbrowser.dcode.org/. 
Genomic coordinates were input using the dropdown list and input boxes provided. 
Parameters were adjusted using a similar method as for the VISTA browser.  
A unique feature of ECR browser is it highlights conserved regions with clickable 
rectangles (in pink colour). Clicking these rectangles provides access to detailed 
percentage identity, corresponding sequence alignment, and a hyperlink to predict 
transcription factor binding sites within this region.  
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2.3.7 Power Calculation for SNP discovery 
The power of a statistical test is defined as the probability that it will correctly lead to 
the rejection of a false null hypothesis. In SNP discovery, it refers to the probability of 
detecting a SNP with given minor allele frequencies (MAF).  
Power calculations were performed to calculate sample sizes required in order to 
detect a SNP. Sequencing of a single chromosome provides a probability of 0.01 to 
detect a SNP with MAF of 0.01. This is represented as P[detection] = 0.01. 
Consequently, P[non-detection] = 0.99.  
If two chromosomes are sequenced, P[detection] and P[non-detection] are shown as 
follows: ۾ሾ܌܍ܜ܍܋ܜܑܗܖሿ ൌ ૙Ǥ ૙૚ܠ૙Ǥ ૙૚ ൅ ૙Ǥ ૙૚ܠ૙Ǥ ૢૢ ൅ ૙Ǥ ૙૚ܠ૙Ǥ ૢૢ ൌ ૙Ǥ ૚ૢૢ ۾ሾܖܗܖ܌܍ܜ܍܋ܜܑܗܖሿ ൌ ૙Ǥ ૢૢ૛ ൌ ૙Ǥ ૢૡ૙૚ 
,IµQ¶chromosomes are sequenced, then ۾ሾ܌܍ܜ܍܋ܜܑܗܖሿ ൌ ૚ െ ૙Ǥ ૢૢܖ ۾ሾܖܗܖ܌܍ܜ܍܋ܜܑܗܖሿ ൌ ૙Ǥ ૢૢܖ 
If 95% power is required, then ۾ሾ܌܍ܜ܍܋ܜܑܗܖሿ ൌ ૚ െ ૙Ǥ ૢૢܖ ൌ ૙Ǥ ૢ૞ 
Therefore, ܖ ൌ ሾܔܗ܏૙Ǥ ૙૞ሿሾܔܗ܏૙Ǥ ૢૢሿ ൌ ૛ૢૡ 
Therefore, in order to detect SNPs with MAF 0.01 with 95% power, sequencing of 
298 chromosomes (i.e. 149 individuals) are necessary. The following formula has 
been used to calculate sample size (n) with any specified power and MAFs.  ܖ ൌ ሾܔܗ܏ሺ૚ െ ܘܗܟ܍ܚሻሿሾܔܗ܏ሺ૚ െ ۻۯ۴ሻሿ  
The 95% power shown here is for illustrative purpose only, rather than what has 
actually been used in the study.  
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2.3.8 Power calculation for detecting an association 
QUANTO (v1.2.4) is a bioinformatics application designed to calculate power (or 
sample size required to achieve certain power) for genetic based association studies. 
Three statistical models are provided in QUANTO, the main effects caused by genes, 
gene-environment interaction and gene-gene interaction. The program provides GUIs 
allowing modification of input parameters. 
The gene-environment interaction model was utilized, as LOAD is affected by both 
genetic and environmental factors (Avramopoulos, 2009). The model µJHQH-
environment interacWLRQ¶ZDVVHOHFWHG(YLDµParameters -> Outcome/Design -> 
Disease¶). 
QUANTO requires mandatory configuration of four groups of parameters: µ*HQH¶
µ(QYLURQPHQW¶µ2XWFRPH0RGHO¶DQGµ3RZHU¶Figure 2.6). These parameters must 
be adjusted in order.  
µ*HQH*¶*HQHWLFHIIHFWSDUDPHWHUVXVHGLQWKLVLQVWDQFHFigure 2.6a 
x Allele frequency: 0.01- 0.05; Increments: 0.01 
x Inheritance mode: Log additive 
x Susceptibility frequency: generated by the software from the allele frequency 
and inheritance model specified 
µ(QYLURQPHQW¶Figure 2.6b 
x Population prevalence: 0.24 (representing an environmental component of 
LOAD equal to 0.24) 
µ2XWFRPH0RGHO¶Figure 2.6c 
x Population risk: 0.12 (an average risk of LOAD estimated between 65 to 100 
years of age). 
x Genetic effect size: 2 (represented by ORs) 
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x Environmental effect size: 1.2  
x Gene-environmental interaction: no interaction was assumed 
x OR summary: computed based on the inputs.  
µ3RZHU¶Figure 2.6d 
x Sample size: represents the number of case-control pairs (75 was used as 
this represents the number of AD/Control samples analysed in Chapter 4) 
x Type I error rate: 0.05 (maximum tolerated type I error) 
x Perform 2 df test: yes (enables calculation of power taking into account 
effects from both genetic and environmental factors) 
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Figure 2.6 Input dialogues for performing power calculation using QUANTO (v 
1.2.4). Four input dialogues windows: µ*HQH*¶µ(QYLURQPHQW¶µ'LVHDVH5LVN
3DUDPHWHUV¶DQGµ3RZHU¶ are shown with example input.   
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2.3.9 Population stratification analysis 
EIGENSTRAT 
The association identified in a case/control or quantitative trait GWAS analysis could 
be due to underlying population substructure (i.e. population stratification) and 
therefore must be considered in downstream analysis.  
EIGENSTRAT is a bioinformatic program for calculation of heterogeneity between 
samples according to SNPs typed on GWAS chip platforms (Price et al., 2006). The 
software evaluates all possible systematic bias of allele frequencies between 
different GWAS datasets and presents these differences in the form of principal 
components (PCs). These PC values calculated can be adjusted and controlled in a 
standard logistic regression (or linear regression) analysis by including them as 
covariates. PC analysis reduces the genotype data to a number of dimensions, 
defined as the top eigenvectors of a covariance matrix between samples (Price et al., 
2006).  
EIGENSTRAT estimates genetic outliers, which are defined as any individual whose 
ancestry is at least 6 standard deviations (SD) from the mean on one of the top ten 
axes of variation. Genetic outliers are often an indication of individuals carrying 
suspicious genotypes possibly due to genotyping errors.  
Genomic control inflation factor (ɉ), a representation of overall inflation of association 
p-values, can be calculated using EIGENSTRAT. This inflation could be due to 
variety of QC issues, including population stratification, centre effects and genotyping 
errors.   
Reference datasets are required by EIGENSTRAT to provide a baseline for the 
analysis, HapMap data release 23 was used to fulfil this requirement. These datasets 
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are publicly available from HapMap (The International HapMap Consortium, 2003), 
three populations were downloaded are shown:  
x CEU founders (release 23, 60 individuals, filtered 2.3 million SNPs) - US Utah 
population with Northern and Western European ancestry (samples collected 
LQE\WKH&HQWUHG¶(WXGHGX3RO\PRUSKLVPH+XPDLQ&(3+ 
x JPT + CHB founders (release 23, 90 individuals, filtered 2.2 million SNPs) - 
45 unrelated Japanese in Tokyo, Japan, and 45 unrelated Han Chinese in 
Beijing, China.  
x YRI founders (release 23, 60 individuals, filtered 2.6 million SNPs) - Yoruba 
people in Ibadan, Nigeria.  
The filtered HapMap file included SNPs with MAF greater than 0.01 and genotyping 
rate greater than 0.95.  
Data preparation for PC analysis 
To ensure the PCs calculated (representing population stratification) were not 
affected by a large number of SNPs which are in LD, it is essential to create a LD 
pruned GWAS dataset (including both study samples and HapMap samples). It 
should be emphasized that it is not essential to use any specific set of SNPs since 
common SNPs are in LD with each other. An accurate estimation of PCs requires a 
minimum of 20,000 SNPs on the chip (Price et al., 2006).  
The common SNPs between different GWAS datasets and HapMap data #23 were 
determined using an µLQKRXVH¶PERL program as described in Methods 2.3.2. Prior 
to analysis using EIGENSTRAT, the HapMap CEU population dataset were pruned 
using the following commands in PLINK: 
plink --bfile hapmap_CEU_r23a_filtered --extract MayoSNPs.txt --make-bed --
out hapmapCEUr23aM 
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µ--EILOH¶LQGLFDWHs the input PLINK files are in binary formatµ--H[WUDFW0D\R613VW[W¶
extracts all common SNPs which were stored LQWKHµ0D\R613VW[W¶ILOHµ--make-EHG¶
specifies the output file (in PLINK binary format)DQGµ--RXW¶VSHFLILHVWKHRXWSXWILOH
name.  
A LD pruned dataset was generated using the following command: 
plink --bfile hapmapCEUr23aM --indep-pairwise 1500 150 0.2 --out 
hapmapMP 
µ--indep-pairwise 1¶LVWKHPDLQPHWKRG for pruning out SNPs with 
pairwise LD r2 value greater than 0.2 across sliding windows (window size of 1500 
SNPs and 150 SNPs to shift the window). This command generated two files 
µKDSPDS03SUXQHLQ¶FRQVLVWVRI LD pruned SNPs, whereas µKDSPDS03SUXQHRXW¶ 
file is comprised of all remaining SNPs (which have been pruned out).  
Each of the GWAS datasets and three HapMap datasets (as mentioned earlier) were 
subject to pruning using the LD pruned SNPs. Commands used to prune HapMap 
data CEU population are shown: 
plink --bfile hapmap_CEU_r23a_filtered --extract hapmapMP.prune.in --
recode12 --out CEU_PR 
plink --file CEU_PR --make-bed --out CEU_PRB 
µ--UHFRGH¶LQGLFDWHs WKDWDOO613VDUHFRQYHUWHGLQWRWKHVDPHFRGLQJIRUPDWµ¶
DQGµ¶FRGLQJLQ3/,1.Iormat (as described in Methods 2.3.1). µ--make-EHG¶
indicates that standard PLINK files (PED and MAP) are converted into the PLINK 
binary format (BED, BIM and FAM). This process was repeated for the other 
populations and the GWAS dataset.  
These four files were then merged into a single file XVLQJ3/,1.µ--EPHUJH¶FRPPDQG
XQGHUµCRQVHQVXVFDOO¶PRGH 
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plink --bfile AGE_PRB --merge-list Mergelist.txt --make-bed --out 
merge_ACCY 
µ--merge-OLVW¶LVWKHPDLQPHWKRG for merging binary PLINK datasets. The 
µ0HUJHOLVWW[W¶ file contains three rows as shown: 
CEU_PRB.bed CEU_PRB.bim CEU_PRB.fam 
CHBJPT_PRB.bed CHBJPT_PRB.bim CHBJPT_PRB.fam 
YRI_PRB.bed YRI_PRB.bim YRI_PRB.fam  
SNPs with a genotyping rate less than 0.95 (--geno 0.05) were excluded (Methods 
2.3.1). In order to calculate PC values, it is necessary that all samples are converted 
LQWRµFRQWUROV¶LQWKHPHUJHGGDWDVHW. 
 
Calculation of Eigen-values, principal components and production of an MDS plot  
The following commands were used to convert the merged dataset (in PLINK binary 
format) into EIGENSTRAT format.  
plink --bfile merge_ACCYqc --recode --out merge_ACCYqc --noweb 
../bin/convert -p par.PED.EIGENSTRAT 
)LOHµpar.PED.EIGENSTRAT¶FRQWDLQV parameters for EIGENSTRAT µFRQYHUW¶ 
command, which consists of the following lines: 
genotypename: merge_ACCYqc.ped 
snpname: merge_ACCYqc.map 
indivname: merge_ACCYqc.ped 
outputformat: EIGENSTRAT 
genotypeoutname: merge_ACCYqc.eigenstratgeno 
snpoutname: merge_ACCYqc.snp 
indivoutname: merge_ACCYqc.ind 
familynames: YES 
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The principal component analysis was executed using the following command, 
../bin/smartpca.perl -i merge_ACCYqc.eigenstratgeno -a merge_ACCYqc.snp -
b  merge_ACCYqc.ind -k 10 -o merge_ACCYqc.pca -p merge_ACCYqc.plot -e 
merge_ACCYqc.eval -l merge_ACCYqc.log 
µ-L¶µ-D¶DQGµ-E¶VSHFLI\WKHLQSXWILOHVLQ(,GENSTRAT format - genotype file 
µHLJHQVWUDWJHQR¶, SNP file (µVQS¶) and individual file (µLQG¶).µ-k 10¶indicates the 
number of PCs to be shown in the output is equal to 10. µ-R¶VSHFLILHV the output file 
for storing PC values. ¶-H¶VSHFLILHVWKHRXWSXWILOH for storing Eigen-values.  
µ-l¶VSHFLILHVname of the log file.  
Although not explicitly stated in the command line, several useful outputs were 
generated as listed: 
x a multidimensional scaling (MDS) plot in both µ.ps¶ and µ.pdf¶ format.  
x a µH[HF¶ILOH, which was used to calculate genomic control inflation factor (O) 
by EIGENSTRAT, as well as to create the covariate file for subsequent 
GWAS analysis using PLINK.  
x genetic outliers, which were calculated automatically. The results can be 
found in the µlog¶ file.  
The significance of each PC axes were calculated using the following command 
(µtwtable¶ is a pre-made reference table, which was copied into the working directory).  
../bin/twstats -t twtable -i merge_ACCYqc.eval > merge_ACCYqc.Sout 
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Calculation of genomic control inflation factor (O) 
Genomic control inflation factor (O) is an important estimator of population 
stratification. The high ɉ value indicates the data is inflated, and the corresponding 
analysis is more likely to generate false positive outputs as a result. A O value of 
equal or greater than 1.1 is often treated as unacceptable, and is an indication of the 
existence of significant bias in the GWAS data. EIGENSTRAT provides tools to 
calculate the genomic control inflation factor for data with and without correction of 
the PCs.  
Genetic outliers were removed from the merged data XVLQJµ--UHPRYH¶FRPPDQG in 
PLINK, 
plink --bfile study_data --remove outlier.txt --make-bed --out new_dataset 
µRXWOLHUW[W¶consists of a list of individuals identified as genetic outliers (one individual 
per row).   
In order to proceed with the calculation, the phenotype data in PLINK PED file was 
replaced with the actual phenotype values (e.g. age-at-death (AAD) values as 
described in Chapter 5). The PLINK binary format was converted into EIGENSTRAT 
format using the µFRQYHUW¶FRPPDQG as mentioned.  
7KHµ.pFD¶ILOHZDVJHQHUDWHGXVLQJFRPPDQG  
evec2pca.perl 10 merge_ACCYqc.pca.evec merge_ACCYqc.ind 
merge_ACCYqc.pca 
The command is in a format:  
evec2pca.perl $k $evec $b $o, where $k, $b and $o  
$k, $b and $o corresponds WRµ-N¶µ-E¶DQGµ-R¶as previously described, and $evec 
specifies tKHµHYHF¶ILOHQDPHJHQHUDWHG using the same methods as described.   
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Finally, the genomic control inflation factor was calculated using command, 
../bin/smarteigenstrat.perl -I study_data.eigenstratgeno -a study_data.snp -
b study_data.ind -k 10 -p merge_ACCYqc.pca -q YES -l smarteigenstrat.log -o 
study_data.chisq 
../bin/gc.perl study_data.chisq study_data.chisq.GC 
µ-N¶VSHFLILHV the number of PCs to be adjusted for calculation of ɉ value. µ-o¶VSHFLILHV
WKHRXWSXWµ*&¶ILOHQDPHµ-S¶VSHFLILHVWKHLQSXWµSFD¶ILOHQDPHIURPSUHYLRXV
DQDO\VLVµ-T<(6¶LQGLFDWHVWKDWWKHDQDO\VLVXVHG are in quantitative trait phenotypes 
This analysis was performed iteratively, including between 0 and 10 PCs. Each 
calculation generated a single O value (11 O values in total). The number of PC axes 
to be included as covariates in the GWAS analysis is ascertained when the lowest O 
value was acquired after comparison of all 11 O values (see Chapter 5 for details).  
 
Generate a Q-Q plot 
A Q-Q plot is useful in examining the general quality of GWAS data. Two publicly 
available methods are available to draw a Q-Q plot - WKHµHVWODPEGD¶IXQFWLRQLQ
GenABEL (v 1.6.5) (Aulchenko et al., 2007) DQGµJJGTTSORW¶IXQFWLRQ(Turner et al., 
2011). Both methods are written in R statistical programming language.  
GenABEL µestlambda¶LV more flexible than the µggd.qqplot¶PHWKRG. The former 
allows the user to specify the plot range using µxlim¶DQG µylim¶SDUDPHWHUV 
Furthermore, *HQ$%(/µHVWODPEGD¶provides an approximate estimation of genomic 
control inflation factor, though not to the same accuracy of EIGENSTRAT 
calculations.   
Data was loaded into R using command: 
> mydata <- ǤȋǲǤǳǡ ?Ȍ 
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µHVWODPEGD¶ function in GenABEL was executed using the following commands: 
> library(GenABEL) 
> estlambda(mydata$P) 
The following function was needed to run in R µJJGTTSORW¶ 
ggd.qqplot = function(pvector, main=NULL, ...) { 
o = -log10(sort(pvector,decreasing=F)) 
e = -log10( 1:length(o)/length(o) ) 
plot(e,o,pch=1,cex=1, main=main, ..., 
xlab=expression(Expected~~-log[10](italic(p))), 
ylab=expression(Observed~~-log[10](italic(p))), 
xlim=c(0,max(e)), ylim=c(0,max(o))) 
lines(e,e,col="red") 
} 
µJJGTTSORW¶was executed by typing the following command in R: 
> ggd.qqplot(mydata$P) 
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2.4 Bioinformatics tools for next generation sequencing data analysis 
Next generation sequencing is a high-throughput sequencing technology, which 
generates enormous amount of sequencing data with a much lowered financial cost 
than traditional Sanger sequencing. The innovation in the sequencing technology 
leads to profound changes in methods of analysing the sequencing data. 
This methods section describes a number of bioinformatics tools for next generation 
sequencing data analysis as described in Chapter 4.  
2.4.1 Read alignment and basic data format and manipulation 
BioScope® (v 1.3) 
BioScope® is a commercial software package, which is part of ABI SOLiDTM 
sequencing pipeline. The ABI SOLiDTM V\VWHPXVHVDWHFKQRORJ\NQRZQDVµFRORXU
VSDFH¶V\VWHPRUµ-EDUFRGHGHQFRGLQJV\VWHP¶ZKLFKPHDQVHYHU\VLQJOH
nucleotide is interrogated twice. The SOLiDTM system claims to be highly accurate 
with the majority of base calls achieving accuracy in excess of 99.99%.  
BioScope® (v 1.3) was used to perform conversion of SOLiD colour space (CS) calls 
into nucleotide calls and perform alignment of short sequencing reads to the current 
reference genome sequences (human genome build 19 GRCh37/hg19 assembly).   
The BioScope® alignment algorithm produces mapping statistics and generates a 
mapping quality value (range 0 - 100) for each read, which can be used to filter 
poorly aligned reads.  
BioScope® is capable of aligning both µmate-pair¶ and µpaired-end¶ library runs 
(Chapter 4). The output of BioScope® alignment is a mapped BAM file and a 
detailed report of mapping statistics.  
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The SNP calling algorithm and associated tools provided in BioScope® are only 
suitable for individual barcoded data, and not appropriate for pooled next generation 
sequencing data.  
SAMtools 
The SAM file (sequence alignment/map) and BAM file (binary format of SAM) are 
generic file formats for storing aligned next generation sequencing data (Li et al., 
2009).  
A number of tools are provided by SAMtools to manipulate the next generation 
sequencing data, which are compulsory for downstream analysis such as SNP 
calling.  
After the BioScope® alignment, two BAM files were generated (separate case control 
pools) from the CSFASTQ and QV files. CSFASTQ and QV files are the original raw 
data file formats representing colour space FASTQ file and quality value file, 
respectively. Each of the colour space calls stored in the CSFASTQ file is provided 
with a quality score which is saved in the QV file.  
Both BAM files are sorted and indexed using SAMtools commands: 
samtools sort F3_Morgan_control.renum.csfasta.ma.bam 
F3_Morgan_control.renum.csfasta.ma.sorted 
samtools sort F3_Morgan_case.renum.csfasta.ma.bam 
F3_Morgan_case.renum.csfasta.ma.sorted 
samtools index F3_Morgan_control.renum.csfasta.ma.sorted.bam 
samtools index F3_Morgan_case.renum.csfasta.ma.sorted.bam 
Aligned reads for the two TRIM15 IUDJPHQWVµ$¶DQGµ%¶ were extracted from the 
control datasets: 
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samtools view F3_Morgan_control.renum.csfasta.ma.bam 6:30130365-
30143332 -bo TRIM15_AandB_BioScope1.3_Control.bam   
µ-ER¶VSHFLILHVoutput filename (in binary format). 
The SAMtools µYLHZ¶IXQFWLRQZDVXVHG to convert BAM to SAM, as well as to retrieve 
a subset of next generation sequencing data. The retrieved sequencing data was 
sorted and indexed (which generates a new index BAI file):  
samtools sort TRIM15_AandB_BioScope1.3_Control.bam 
TRIM15_AandB_Bioscope1.3_ControlS 
samtools index TRIM15_AandB_BioScope1.3_ControlS.bam 
The genome reference FASTA file was indexed XVLQJµIDLG[¶function in SAMtools 
(which generates a new FASTA index FAI file): 
samtools faidx valid_6.fa 
A pileup file (position based output) was generated using the µSLOHXS¶IXQFWLRQ 
samtools pileup -vcf valid_6.fa TRIM15_AandB_BioScope1.3_ControlS.bam 
The same commands were used for extracting, indexing and sorting of sequencing 
reads for the case pool.  
Additional functions are provided in SAMtools,  
x µPHUJH¶ function, which allow user to merge multiple sorted BAM files 
x µWYLHZ¶IXQFWLRQ, an alignment viewer.  
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SAM file format 
SAM file is in a tab-delimited text file format which consists of an optional header 
section and a compulsory alignment section. Each header starts with the µ#¶V\PERO 
and is followed by a two-letter code (e.g. @RG) and DFRORQµ¶. Table 2.5 lists all 
these two-OHWWHUFRGHVNQRZQDVµTAGs¶ and their definitions. 
An example header row is shown: 
@RG ID:20101014202018783PL:SOLiDLB:lib1-50FPI:0 DT:2010-10-
14T13:20:18-0700 SM:Morgan_controlCN:freetext 
This read header can be interpreted as shown:  
x Read group (RG) identifier (ID): 20101014202018783 
x Platform (PL): SOLiD 
x Library (LB): 1 to 50F 
x Predicted median insert size (PI): 0 
x Date of the run was produced (DT): 2010-10-14T13:20:18-0700 
x Sample (SM): Morgan_control 
x Name of the sequencing centre producing the read: freetext 
It is noteworthy that each read from an individual pool is labelled with the same @RG, 
reflecting the pooling strategy used.  
In the alignment section, each read occupies one row, consists of 11 mandatory 
fields for storing essential alignment information, as well as variable number of 
optional fields for flexibility (Figure 2.7). 
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Table 2.5 Header summary of the SAM file format. Figure showing a list of two-
letter header codes and their definitions (Adopted from Li et al., 2009).   
Tag Description 
@HD The header line. The first line if present. 
 
 
 
VN* Format version. Accepted format: /^[0-9]+\.[0-9]+$/. 
SO 
 
Sorting order of alignments. Valid values:  unknown (default), unsorted, queryname and 
coordinate. For coordinate sort, the major sort key is the RNAME field, with order defined by the 
order of @SQ lines in the header. The minor sort key is the POS field. For alignments with equal 
RNAME and POS, order is arbitrary. All alignments with `*' in RNAME field follow alignments with 
some other value but otherwise are in arbitrary order.  
@SQ Reference sequence dictionary. The order of @SQ lines defines the alignment sorting order. 
 
 
 
SN* 
Reference sequence name. Each @SQ line must have a unique SN tag. The value of this field is used 
in the alignment records in RNAME and PNEXT fields. Regular expression: [!-)+-<>-~][!-~]* 
LN* Reference sequence length. Range: [1, 229 -1] 
AS Genome assembly identifier. 
M5 MD5 checksum of the sequence in the uppercase, with gaps and spaces removed. 
SP Species. 
UR 
URI of the sequence. This value may start with one of the standard protocols, e.g http: or ftp:.  
If it does not start with one of these protocols, it is assumed to be a file-system path. 
@RG Read group. Unordered multiple @RG lines are allowed. 
 
ID* 
Read group identifer. Each @RG line must have a unique ID. The value of ID is used in the RG tags 
of alignment records. Must be unique among all read groups in header section. Read group 
IDs may be modified when merging SAM files in order to handle collisions. 
CN Name of sequencing center producing the read. 
DS Description. 
DT Date the run was produced (ISO8601 date or date/time). 
FO 
Flow order. The array of nucleotide bases that correspond to the nucleotides used for each flow of 
each read. Multi-base flows are encoded in IUPAC format, and non-nucleotide flows by various 
other characters.  Format: /\*|[ACMGRSVTWYHKDBN]+/ 
KS The array of nucleotide bases that correspond to the key sequence of each read. 
LB Library. 
PG Programs used for processing the read group. 
PI Predicted median insert size. 
PL 
Platform/technology used to produce the reads. Valid values: CAPILLARY, LS454, ILLUMINA, 
SOLID, HELICOS, IONTORRENT and PACBIO. 
PU Platform unit (e.g. flowcell-barcode.lane for Illumina or slide for SOLiD). Unique identifier. 
SM Sample. Use pool name where a pool is being sequenced. 
@PG Program. 
 
ID* Program record identifier. Each @PG line must have a unique ID. The value of ID is used in the 
alignment PG tag and PP tags of other @PG lines.  PG IDs may be modified when merging SAM 
files in order to handle collisions. 
PN Program name 
CL Command line 
PP Previous @PG-ID. Must match another @PG header's ID tag. @PG records may be chained using 
PP tag, with the last record in the chain having no PP tag. This chain defines the order of programs 
that have been applied to the alignment. PP values may be modified when merging SAM files in 
order to handle collisions of PG IDs. The first PG record in a chain (i.e. the one referred to by the 
PG tag in a SAM record) describes the most recent program that operated on the SAM record. The 
next PG record in the chain describes the next most recent program that operated on the SAM 
record. The PG ID on a SAM record is not required to refer to the newest PG record in a chain. It 
may refer to any PG record in a chain, implying that the SAM record has been operated on by the 
program in that PG record, and the program(s) referred to via the PP tag. 
VN Program version 
@CO One-line text comment. Unordered multiple @CO lines are allowed. 
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Figure 2.7 Summary of SAM file format. Figure showing all elements of an individual read in the SAM file format, and corresponding 
descriptions. µ¶LQGLFDWHVWKHUHOHYDQWILHOGLVLQDSSOLFDEOHWRWKHµSDLUHGHQG¶VHTXHQFLQJGDWD6HHChapter 4 for definition).  
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PILEUP file format 
Each row of the pileup file describes alignment information of reads at each 
nucleotide base position. There is no header section in the pileup file.  
Two pileup formats are in use. TKHµVtandard sequence pileup¶IRUPDWconsists of six 
columns: chromosome number, base pair position, reference nucleotide base, 
number of reads aligned to this site, read bases and base qualities.  
 An example row of the SAMtools standard µSLOHXS¶ILOHLVVKRZQ  
1  10000 T 22 ....,,.,.,.C.,,,.,..G. 
+7<;<<<<<<<&<=<<:;<<&< 
 
In this example, there are 22 reads mapped to this chromosomal position, on 
chromosome 1, at base coordinate 10000 and with the reference allele µ7¶7KHGRW
(µ.¶) symbol in read bases represent a single read is mapped to the forward strand 
and the base matches the reference allele µ7¶. The comma (µ,¶) symbol indicates a 
read, which matched to the reference allele, however mapped to the reverse strand. 
Any other letters iQGLFDWHDSRVVLEOHYDULDQWHJµ&¶DQGµ*¶LVVKRZQLQWKLV example), 
where uppercase lettering indicates a non-reference nucleotide base mapped to the 
forward strand and a lowercase indicates the base is mapped to the reverse strand. 
The quality of each nucleotide base was represented in a single ASCII code 
(+7<;<<<<<<<&<=<<:;<<&<); interpretation of this code is discussed in more detail 
in Chapter 4, Table 4.1.  
µConseQVXVVHTXHQFHSLOHXS¶IRUPDWGLIIHUV IURPWKHµVtaQGDUGVHTXHQFHSLOHXS¶
where it consists of four DGGLWLRQDOFROXPQVEHWZHHQWKHµUHIHUHQFHnucleotide bDVH¶
DQGµQXPEHURIUHDGVDOLJQHG¶FROXPQs. These four columns are consensus base, 
consensus quality, SNP quality and maximum mapping quality, respectively.   
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2.4.2 FastQC (v0.9.4) quality assessment 
FastQC is a bioinformatic program designed for assessment of quality of raw next 
generation sequencing data. Obvious sequencing errors can be effectively revealed 
by performing QC checks using the software.  
Several input formats are supported, including SAM, BAM, FASTQ and CSFASTQ.  
The program performs a series QC checks: basic sequence stats, sequence quality 
(per base and per read), per base sequence content, per base GC content, per 
sequence GC content, sequence length distribution and any evidence of sequence 
over-representation.  
Each of the tests performed is automatically flagged as a pass (green tick), warning 
(an orange warning sign) or failed (a cross symbol in red) according to the QC 
calculations.  
The software is written entirely in Java and provided with a graphical user interface 
(GUI). The analysis reports from FastQC can be saved in HTML format via µ)LOH-> 
6DYH¶ 
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2.4.3 SNP calling 
Syzygy (v 1.1.0) 
Syzygy is a SNP calling software designed specifically for pooled next generation 
sequencing data analysis. Syzygy is written in python programming language, which 
has several pre-requisites which influence how the program is installed in Linux. One 
of the pre-requisites is SAMtools as mentioned earlier.  
Syzygy calls SNPs and calculates error rates of each prediction based on error 
models. Error models are generated while performing the analysis and calling SNPs. 
The error rates generated determine whether the non-reference observations from 
sequencing are variants or errors. Syzygy takes into account allele strand biases and 
calculates a LOD score of strand bias (also known DVµ6/2' score¶), allowing a 
genuine SNP call to be distinguished from errors.   
Syzygy input file format 
Two compulsory files are required by Syzygy - µ7DUJHW,QIR)LOH¶µtgf¶ILOH) which 
contains information about the sequencing target (DNA amplicons) and µ3RRO,QIR)LOH¶
(µpif¶ILOH) which contains information about the pooling strategy.  
7KHµ.tgf¶ILOH has six columns and µ.pif¶ILOH has four columns, and must be generated 
in the format demonstrated in Table 2.6.   
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Table 2.6 Syzygy input files (µ.tgf¶ and µ.pif¶ file) for TRIM15 µA¶DQG µB¶
amplicons. µWJI¶DQGµSLI¶ILOHIRUPDWVIRUWKHTRIM15 µ$¶DQGµ%¶DPSOLFRQVLQFOXGLQJ
the obligatory header sections. 
 µWJI¶ILOH 
FEATURE_NAME CHR START_POSITION END_POSITION LENGTH GENOME_BUILD 
TRIM15_AandB 6 30130365 30143332 12968 19 
 
µSLI¶ILOH 
PoolBAM Phenotype Inds Chroms 
TRIM15_AandB_BioScope1.3_ControlS.bam 0 75 150 
TRIM15_AandB_BioScope1.3_CaseS.bam 1 75 150 
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Syzygy Implementation 
Syzygy was executed using the following command: 
 syzygy --pif TRIM15.pif --tgf TRIM15.tgf --samtoolspath /usr/bin --outputdir 
/home/mrxhs/deepseq/job6 --hg 19 --ref valid_6.fa --dbsnp TRIM15.dbsnp -
-skipannot true --mqthr 50 --bqthr 10 --power --rarethr 0.01 
µ--VDPWRROSDWK¶VSHFLILHVWKHILOHGLUHFWRU\ORFDWion of SAMtools programµ--RXWSXWGLU¶
VSHFLILHVWKHRXWSXWGLUHFWRU\µ--KJ¶LQGLFDWHVKXPDQJHQRPHEXLOGZDVXVHGLQ
WKHDQDO\VLVµ--UHI¶VSHFLILHVWKHUHIHUHQFHVHTXHQFH)$67$ILOHµ--GEVQS¶VSHFLILHV
the dbSNP file (which was downloaded from UCSC website). µ--bqthr 10¶DQGµ--mqthr 
¶indicate the threshold for base call quality and mapping quality is equal to 10 and 
50, respectivelyµ--SRZHU¶LQVWUXFWV6\]\J\WRFDOFXODWHSRZHUIRUGHWHFWLRQRID
singleton. µ--UDUHWKU¶LQGLFDWHV the rare variant threshold is equal to 0.01.  
FreeBayes (v 0.4.2) 
FreeBayes is a bioinformatic tools for calling SNPs developed by Marth and 
colleagues at Boston College (http://bioinformatics.bc.edu/marthlab/FreeBayes). It is 
an extension of the original Bayesian SNP caller PolyBayes (Marth et al., 1999). 
FreeBayes supports analysis of both pooled sequencing data and individually 
barcoded data.  
FreeBayes is flexible and fast, and provides accurate estimations of allele 
frequencies together with useful information including read depth of the nucleotide 
base, alternative allele counts and number of reads aligned to the forward and 
reverse strand.   
FreeBayes generates results in Variant call file (VCF) format, a format which has 
been widely adopted for next generation sequencing data analysis.   
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The software can also accommodate insertions and deletions YLDWKHLQFOXVLRQRIµ--
LQGHOV¶DQGµ--left-align-LQGHOV¶ 
One of the limitations of FreeBayes is that it does not distinguish between high and 
low quality SNPs as does Syzygy. Furthermore, although the software provides an 
HVWLPDWLRQRI613TXDOLW\E\µpval¶S-value) in the output, it is not sufficiently 
stringent, as reflected by unrealistic number of predicted SNPs acquired µSYDO¶YDOXH
of 1 (the highest p-value allowed to be specified). 
The following command was used for analysis of TRIM15 µ$¶DQGµ%¶DPSOLFRQs (as 
described in Chapter 4). 
freebayes --fasta-reference valid_6.fa 
TRIM15_AandB_BioScope1.3_ControlS.bam --pooled --ploidy 150 --pvar 1 --
min-mapping-quality 50 --min-base-quality 10 --region 6: 
30130365..30143332 
µ--fasta-UHIHUHQFH¶ specifies the genome refeUHQFHµID¶RUµIDVWD¶DQGQH[W
generation data file in BAM format. µ--SYDU¶LQGLFDWHs the p-value (confidence of 
FDOOLQJD613LVHTXDOWRµ--min-mapping-TXDOLW\¶LQGLFDWHs the mapping quality 
threVKROGLVHTXDOWRDQGµ--min-base-TXDOLW\¶LQGLFDWHs the base quality 
threshold iVHTXDOWRµ--region 6:30138938..30143332¶ specifies the region 
analysed is on chromosome 6, base pair position from 30138983 to 30143332.   
VCF file format 
VCF (variant call file) is a generic file format designed for storing variants information 
(including SNPs, Indels and structural variants) together with detailed annotations. 
The VCF format is compact in size and both flexible and easily extensible for further 
development. Furthermore, VCF files can be indexed by a program known as µWDEL[¶
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allowing fast and simple data retrieval of variants from a range of positions on the 
reference genome (Li, 2011). An example command is as shown: 
tabix -hf ftp://ftp.1000genome.ebi.ac.uk/vol1/ftp/release/20101123/ 
interim_phase1_release/ALL.chr6.phase1.projectConsensus.genotypes.vcf.gz 
6:30139699-30139699 
The VCF file is comprised of three sections: meta-information, header section and 
data section.  
Meta-information (starts with aµ¶ sign) stores: 
x VCF file version (depicted as µILOHIRUPDW¶ 
x Date, 
x Source (e.g. syzygy 1.1.0),  
x Filename of the reference genome, and  
x Definitions of all annotations included in the VCF file.  
+HDGHUOLQHVWDUWVZLWKDµ¶VLJQFRQVLVWVRIHLJKWPDQGDWRU\ILHOGVDVOLVWHG 
x CHROM - chromosome number  
x POS - base pair position 
x ID - dbSNP rs number 
x REF - reference bases 
x ALT - alternative base, 
x QUAL - Phred scaled quality score of the alternative allele 
x FILTER - quality filters 
x INFO - and additional information in format <key>=<data>  
Predicted SNPs (third section) are presented in an ascending order of base pair 
positions (one SNP per row). An example VCF file downloaded using tabix from 1000 
genome project is shown in Figure 2.8. 
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Figure 2.8 Summary of VCF format. Figure showing an example VCF file from 1000 genome project accessed using tabix software. 
The 1000 genome project data is freely available at website ftp://ftp.1000genome.ebi.ac.uk. A known SNP (rs929156) at chromosome 6 
base pair position 30139699 is shown together with a novel SNP at chromosomal 6 base pair position 30130617.  
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2.4.4 SNPs annotation 
Variant Classifier 
Variant Classifier is a program which annotates genetic variants (SNPs, insertion and 
deletion) from analysis of next generation sequencing data.   
A list of all cuUUHQWGDWDEDVHVZDVGLVSOD\HGXVLQJVFULSWµ6KRZB/DWHVWB'DWDEDVHVSO¶
included in the program. The latest annotation data (µFRGLQJBLQIR¶ file) and the 
corresponding reference sequence µIDVWD¶file were downloaded from the most up-to-
date Ensembl database using command: 
perl Extract_Cding_Info.pl -c 6 -b 30130365 -e 30143332 -ǲǳ-
B 60 -A 37e -f TRIM15_AandB_BioScope1.3 -x 
µ-c 6¶LQGLFDWHs chromosome number LVHTXDOWRµ-E¶DQGµ-H¶VSHFLILHV the start and 
end base pair coordinatesµ-2KRPRVDSLHQV¶LQGLcates that human species is 
VHOHFWHGµ-%¶LQGLFDWHs the retrieved data is in NCBI build version µ¶µ-$H¶
indicates the NCBI assembly version is µ37e¶. µ-I¶specifies the output filename. µ-[¶
instructs the software to extend the coverage to include the whole gene if necessary.  
7KHDQQRWDWLRQIXQFWLRQRI9DULDQW&ODVVLILHUUHTXLUHVDQLQSXWILOHµLQSXWBVQSV¶, which 
is comprised of 4 columns as listed:  
x column 1 - SNP starting base pair position (it is compulsory that this position 
matches the FRRUGLQDWHVDYHGLQWKHµcoding_info¶ file); 
x column 2 - SNP ending position (starting position plus 1);  
x column 3 - strand (positive strand is noted as 1 and negative strand is 
denoted as 2); 
x column 4 - alternative allele.  
This input file does not include any header.  
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The annotation was executed using the commands: 
perl Classify_SNPs.pl -s input_snps -c 
TRIM15_AandB_BioScope1.3.coding_info -n 
TRIM15_AandB_BioScope1.3.fasta -o results.txt 
µ-V¶VSHFLILHVWKHLQSXWILOHQDPHDVGHVFULEHGµ-F¶DQGµ-Q¶VSHFLI\WKHDQQRWDWLRQGDWD
file (µFRGLQJBLQIR¶) and reference sequence file (µIDVWD¶), respectively. µ-R¶specifies 
the output file name.   
Two result files were generated - µRXWSXWQRUPDO¶DQGµRXWSXWGHQRUPDO¶Both files 
contain WKHVDPHLQIRUPDWLRQZKHUHµRXWSXWGHQRUPDO¶LVGHVLJQHGWREHUead and 
manipulated by computer.   
Polyphen-2 
Polyphen-2 is a web-based bioinformatic tool for predicting SNP pathogenicity. It 
measures possible impact of an amino acid substitution on the structures and 
functions of the encoded protein (Adzhubei et al., 2010). Non-synonymous SNPs are 
characterized into three distinct risk groups - benign, possibly damaging and 
probably damaging.  
TRIM15 SURWHLQVHTXHQFHZDVHQWHUHGLQWRWKHµ$PLQRDFLGVHTXHQFHLQ)$67$
IRUPDW¶LQSXWER[7KHDPLQRDFLGSRsition where the change occurred was entered 
LQWRWKHµSRVLWLRQ¶LQSXWER[,Qµ6XEVWLWXWLRQV¶WKHUHIHUHQFHDPLQRDFLGµ$$¶DQG
substituted amiQRDFLGµ$$¶FDXVHGE\WKHPXWDWLRQ) were selected according to 
results obtained from Variant Classifier (See Chapter 4 for details).  
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2.4.5 Visualisation tools 
Integrative Genomic Viewer (IGV) 
IGV is a visualisation tool for µUHDO-WLPH¶H[SORUDWLRQRIODUJH-scale next generation 
sequencing data. The software is implemented in Java (Robinson et al., 2011).   
IGV viewer is freely available at http://www.broadinstitute.org/software/igv/download. 
Two files are required by IGV: a BAM file and a reference genome FASTA file. Both 
files must be sorted and indexed using methods as previously described.   
$µJHQRPH¶ILOHLVJHQHUDWHGautomatically after loading the FASTA file into IGV. An 
input box is provided to enable viewing of a user-specified genomic region.  
UCSC genome browser 
The UCSC genome browser provides a number of useful web-based bioinformatics 
tools - µOLIW2YHU¶µ,Q-6LOLFR3&5¶ and µ8&6&FXVWRPWUDFNV¶ 
liftOver 
Human genome sequence is constantly under review due to technological 
advancement and clarification of existing data. As a result, multiple genome 
sequence assemblies exist, each differs in base pair coordinates. Base pair 
coordinates must be transformed into the same genome build before a comparison 
can be conducted. µOLIW2YHU¶is a tool designed to perform this conversion.  
The latest genome assembly (Hg19) is currently in operation and was used by the 
1000 genome project (The 1000 Genomes Project Consortium, 2010). Base pair 
coordinates (in BED format) DUHUHTXLUHGIRUµOLIW2YHU¶IXQFWLRQ 
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In-Silico PCR 
The µ,Q-6LOLFR3&5¶ program on UCSC website allows the user to search for the 
target DNA sequence by simply entering the PCR forward and reverse primer 
sequences. This tool is useful to examine whether the PCR primer designed target 
the correct DNA template sequence of interest.  
Input boxes are provided to allow PCR primers to be uploaded. Adjustment of µmax 
SURGXFWVL]H¶PD\EH necessary depending on the size of expected PCR amplicon.  
UCSC custom track 
The custom track function allows users to view their own data in the UCSC genome 
browser and to be displayed DVDµFXVWRPWUDFN¶&XVWRPWUDFNVLQ%('DQG:,*
format) can be loaded into UCSC genome browser XVLQJWKHµEURZVH¶EXWWRQ
provided. These input files were used to display TRIM15 µ$¶DQGµ%¶DPSOLFRQV
(Chapter 4) as documented in Appendix 8.5.  
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Chapter 3:    Analysis of Genome Wide Association Study 
(GWAS) data looking for replicating signals in LOAD 
3.1 Introduction 
$O]KHLPHU¶VGLVHDVHLVWKHPRVWprevalent form of dementia. As life expectancies 
continue to rise, an increasing number of individuals are expected to develop AD. 
The number of LOAD cases worldwide was recorded as 26.6 million in 2007, this 
figure has been estimated to rise to over 100 million by 2050 (Brookmeyer et al., 
2007). Understanding the genetic aetiology of LOAD could enable the development 
of effective therapeutic treatment. 
Despite tremendous efforts over the last few decades, identification of genetic loci 
underlying LOAD has been proven difficultZLWKWKHİDOOHOH of APOE being the only 
established, reproducible genetic risk factor prior to the discovery of new LOAD risk 
genes in 2009 (Harold et al., 2009). Genes explored in previous candidate gene 
studies are often based on pre-conceived functional and biological hypotheses. As a 
result, genes that are closely related to AE and tau have been extensively studied in 
the pathogenesis of LOAD. However, genetic defects found in genes such as APP, 
PSEN1 and PSEN2 do not appear to contribute to risk for LOAD, but are tightly 
linked to HDUO\RQVHW$O]KHLPHU¶VGLVHDVH (Bertram, 2011).  
GWAS in LOAD has generated significant, reproducible findings and given insight 
into the biological aetiology of LOAD. Nine new LOAD genes (CLU, PICALM, CR1, 
BIN1, ABCA7, MS4A6A, CD33, CD2AP and EPHA1) have been identified through 
recent large GWAS (Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 
2009; Naj et al., 2011; Seshadri et al., 2010). These genes provide new impetus for 
drug development which could aid in slowing down disease progression and 
ultimately developing a cure based on the grounds of genetic associations with 
LOAD.  
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Insufficient power has meant a large number early GWAS failed to generate any 
VLJQLILFDQWµKLWV¶(McCarthy et al., 2008). These GWAS lacked the numbers of cases 
and controls required to detect a modest effect (ORs = ~1.25) from a common variant 
(Bertram et al., 2007). Despite these power issues, they are still a valuable source of 
data for meta-analysis purposes. Combining individually underpowered GWAS could 
increase power thus allowing identification of genuine associations and previous 
spurious associations will likely diminish.  
Unfortunately, there are a number of constraints that have limited the effectiveness of 
whole-genome meta-analysis to date. Given that GWAS may use different 
genotyping platforms (such as Illumina or Affymetrix) each assaying different panels 
RI613VWKHQXPEHURIµPDWFKHG¶613VDYDLODEOHIRUPHWD-analysis is limited. This is 
often confounded by SNP dropout during quality control procedures. 
 
3.2 Aims 
Genetic markers with suggestive association p-value (5 x 10-5 < p < 5 x 10-8) may be 
genuine AD candidates that due to power constraints, have failed to reach genome-
wide significance (p < 5 x 10-8).   
The aim of this study was to select genes/regions that merit further investigation by 
identifying all SNPs with p-values within this range (5 x 10-5 < p < 5 x 10-8) and 
comparing their effects across several GWAS, either directly or by using a perfect 
proxy (r2 = 1).  The approaches employed to identify replicating signals in this study 
can be applied to other studies to search across GWAS data from different platforms. 
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3.3 Strategy 
A cross-platform comparison of four GWAS was conducted using data that are 
readily obtainable; subject-level genotype data from two, Reiman et al., 2007 and 
Carrasquillo et al., 2009, complete summary data from a third Li et al., 2008 and 
summary data of top SNP hits (5 x 10-5 to 5 x 10-8) in the fourth Beecham et al., 2009. 
In each case, quality control measures had been applied by the authors prior to data 
release (Table 3.1). 
Generating SNP results from subject-level genotype data (Carrasquillo et al., 2009; 
Reiman et al., 2007) 
Datasets Reiman et al., 2007 and Carrasquillo et al., 2009 were analysed using the 
PLINK analysis toolset version 1.06 (Methods 2.3.1). GWAS data was converted into 
a file format appropriate for PLINK (PED and MAP) before analysis. GWAS outputs 
ZHUHJHQHUDWHGIURPJHQRW\SLQJGDWDXVLQJµ--DVVRF¶FRPPDQG 
To make the Reiman et al., 2007 Affymetrix data comparable with Carrasquillo et al., 
2009 Illumina data, the SNP ID was translated from Affymetrix SNP ID format to 
dbSNP ID format (rs number). A PERL script was written to perform the translation 
process (Methods 2.3.2; Methods 8.4.1). 
As the sex status of individuals was unspecified in the Reiman et al., 2007 dataset, 
WKHµ--allow-no-VH[¶FRPPDQGwas utilised to instruct PLINK to ignore unspecified sex 
and include all samples in the calculations. 
Only limited information was obtained for the Beecham et al., 2009 and Li et al., 2008 
studies. It was not possible to merge datasets, since the two studies used different 
chip platforms. 
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Table 3.1 Summary of the four GWAS analysed in this study. The number of 
SNPs following QC, the platform utilised and the percentage of SNPs excluded in 
each study is listed. Also shown are the number of perfect proxies (r2 = 1) in the data 
(post QC) together with the number of clusters into which these SNPs fall. The 
number of independent tests for multiple testing corrections of combined p-values is 
shown in the last column and was calculated as described (Methods 2.3.3). 
 
 
  
Study 
Number of 
SNPs (post 
QC) 
CHIP platform Excluded SNPs (%) 
Number of 
SNPs with 
LD (r2  = 1) 
Number of 
LD Clusters 
(r2  = 1) 
Number of 
Independent 
Tests 
Beecham et 
al., 2009 532,000 Illumina 550 4% - - - 
Carrasquillo et 
al., 2009 313,330 Illumina 300 1% 26,284 11,539 298,585 
Li et al., 2008 469,438 Affymetrix 500K 5% 128,139 42,634 383,933 
Reiman et al., 
2007 312,316 
Affymetrix 
500K 38% 83,739 29,678 258,255 
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Comparing p-values across different GWAS  
For each of the GWAS, all SNPs with p-values between 5 x 10-5 to 5 x 10-8 were 
compared across the other studies (where possible) either directly or by using a 
perfect proxy (r2 = 1). SNAP (SNP Annotation and Proxy Search) 
(http://www.broad.mit.edu /mpg/snap) was used to identify SNP proxies using the 
HapMap Resource CEU population - release 23 as the reference dataset (Methods 
2.3.4).  
Direct proxies were used in order to capture the maximum number of SNPs across 
the different chip platforms (each has their own SNP portfolio). Imputation attempts 
for SNPs in TRIM15 using PLINK yielded limited information when merging the 
datasets with the reference datasets. Imputed SNPs generated PLINK INFO 
(information content metric) scores lower than 0.8, indicating unreliably imputed 
SNPs. This low score is due to poor LD architecture within this region and the limited 
availability of data.  
The significance band 5 x 10-5 to 5 x 10-8 was used to search for potential new AD 
candidates that have failed to reach genome-wide significance due to limited power 
of the GWAS to date. Extending to a lower cut-off (p > 10-5) may reveal more 
substantial information and this could well be a viable approach to use on larger 
GWAS datasets as they become available. Any SNPs with p-values below 5 x 10-8 
were not included in this analyses as they would have been identified as genome 
wide significant; effectively this resulted in all SNPs in the APOE region on 
chromosome 19 being removed ± this region replicated across all the studies.  
SNPs were selected for further analysis as described below: 
x SNPs with p-values 5 x 10-5 to 5 x 10-8 were selected from each of the GWAS. 
x SNP p-values were determined for the same SNPs (or proxies r2 = 1) across 
the remaining studies. 
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x 7KH)LVKHU¶VFRPELQHGS-value test was used as a summary statistic to give 
an overall value of association. It has to be noted that this test does not 
correct for disparate effects created by alleles whose direction of association 
differs between studies ± the so-FDOOHGµIOLSSHUV¶)RUWKHUHVXOWDQWS-value to 
be meaningful all effects must be in the same direction.   
x Combined p-values were corrected for the number of independent SNPs on 
the highest density platform utilised following QC (Methods 2.3.3). 
It is only possible WRDFFHVVWKHµWRSKLWV¶IURPBeecham et al., 2009, which limited the 
comparison across all four studies.  
Meta-analysis of odds ratios 
Any SNPs that showed a corrected combined p-value (p < 0.05) were further 
analysed by comparing their corresponding odds ratios across multiple GWAS 
datasets. The random-effects method was implemented in the StatsDirect software 
package. ,QFRQWUDVWWR)LVKHU¶VFRPELQHG probability test, random-effect meta-
analysis accounts for the direction of effect. Significance is only obtained when the 
effects are all in the same direction. A SNP could therefore be significantly 
DVVRFLDWHGXVLQJ)LVKHU¶Vmethod but fail odds ratio meta-analysis. 
Gene-centric analysis for TRIM15 
A gene-centric approach was used to conduct an in depth SNP analysis of TRIM15, 
the only genetic locus achieved VLJQLILFDQWE\ERWK)LVKHU¶VFRPELQHGSUREDELOLW\WHVW
and random-effect meta-analysis (See results for details). The LD architecture 
surrounding this gene was identified using LD plots generated in Haploview (v 4.0) 
using HapMap CEU population data (Methods 2.3.5). SNPs flanking the gene (20 kb 
either side) were also analysed. The base pair coordinates were obtained from 
HapMap database. The study-specific p-values for allelic association for each of the 
TRIM15 SNPs were generated in PLINK using the data from the Reiman et al., 2007 
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and Carrasquillo et al., 2009; the values from the summary data were used for Li et 
al., 2008. 
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3.4 Results 
Analysis of GWAS 
7KH613¶VZLWKS-values 5 x 10-5 to 5 x 10-8 were identified for each study and then 
compared across all datasets. Four tables were created, one table for each of the 
GWAS listing the SNPs that were in this significance band together with the 
corresponding SNP p-values in the three other GWAS (irrespective of their 
significance values). Table 3.2 compares GWAS output for all four studies, whereas 
tables Table 3.3, Table 3.4 and Table 3.5 compare data from the remaining three 
GWAS. 
Combined p-values were determined for SNPs that occurred in at least two studies. 
SNPs with combined p-values of 10-8 were corrected for multiple testing. Using this 
approach, three SNPs were identified. SNP rs929156 (Table 3.2 ± Beecham et al., 
2009 as primary comparator) had a combined p-value of 8.77 x 10-8, corrected p-
value (p = 0.0467); this occurs in an exonic sequence of the TRIM15 gene on 
chromosome 6. Using Li et al., 2008 as the primary dataset to compare with, SNP 
rs11682545 (Table 3.3) gave a combined p-value of 7.98 x 10-8, corrected p-value (p 
= 0.0306). This SNP occurs downstream of the TFCP2L1 gene on chromosome 2. 
The third SNP (rs7077757) was identified in Table 3.4 (Reiman et al., 2007 as the 
primary dataset) with a combined p-value of 6.35 x 10-8, corrected p-value (p = 
0.0244).  This occurs in intronic sequence of the RBM20 gene on chromosome 10. 
No combined p-values of less than 10-8 were evident using the Carrasquillo et al., 
2009 study as the primary comparator (Table 3.5). 
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Table 3.2 Beecham et al., 2009 GWAS SNPs (5 x 10-5 < p < 5 x 10-8) compared with Reiman et al., 2007, Li et al., 2008 and 
Carrasquillo et al., 2009.  
Each row represents a SNP with a p-value between 5 x 10-5 and 5 x 10-8. The p-values are highlighted yellow if corr-p < 0.05 and 
they replicated across two or more studies. Data from a perfect proxy SNP was used if data for the initial SNP was unavailable. If a 
perfect proxy was used the corresponding rs number is listed. The combined p-values across studies are as shown. The final column 
shows the corrected p-value adjusted as described (Chapter 3 - section 3.3).  
Beecham et al., 2009 Reiman et al., 2007 Li et al., 2008 Carrasquillo et al., 2009 Combined 
p-value 
Corrected 
p-value 
SNP CHR BP Gene Position p-value SNP p-value SNP p-value SNP p-value 
rs9659092 1 50216176   4.54E-06 rs12022125 4.04E-01 rs12022125 1.48E-01 -  2.71E-07  
rs3807031 6 30141863 PPP1R11 Promoter 1.16E-05 -  -  rs3807031 4.94E-01 5.73E-06  
rs1415985 1 49703336   1.23E-05 rs12022125 4.04E-01 rs12022125 1.48E-01 -  7.35E-07  
rs4926831 1 50062688   1.23E-05 rs4926831 6.32E-01 rs4926831 5.17E-01 -  4.02E-06  
rs929156 6 30247678 TRIM15 Exon 7 1.69E-05 rs2844775 2.50E-01 rs2844775 2.34E-01 rs929156 8.87E-02 8.77E-08 4.67E-02 
rs11583200 1 50332407   1.83E-05 -  -  rs11583200 5.75E-01 1.05E-05  
rs11754661 6 151248771 MTHFD1L Intron 2.01E-05 -  -  rs11754661 6.27E-01 1.26E-05  
rs3746319 19 49304071 ZNF224 Exon 6 2.96E-05 -  -  rs3746319 9.85E-01 2.92E-05  
rs2180566 20 29482515 DEFB123 Promoter 3.80E-05 -  -  rs2180566 4.75E-01 1.80E-05  
rs2061332 19 49305501 ZNF224 D'stream 3.93E-05 rs2061332 1.49E-02 rs2061332 7.22E-01 rs2061332 8.70E-01 3.68E-07  
rs2681411 3 123268321 CD86 Intron 4.21E-05 -  -  rs2681411 3.09E-01 1.30E-05  
rs2119067 2 165835529   4.38E-05 -  -  rs2119067 1.58E-01 6.92E-06  
rs1402627 18 4123739   4.42E-05 -  -  rs1402627 8.01E-01 3.54E-05  
rs659628 13 76361237 KCTD12 Promoter 4.46E-05 rs659628 4.49E-01 rs659628 1.00E+00 -  2.00E-05  
rs9455973 6 168325855   4.47E-05 rs9455973 9.79E-01 rs9455973 5.99E-01 rs9455973 6.27E-01 1.64E-05  
rs6059244 20 29474144   4.76E-05 -  -  rs6059244 5.43E-01 2.59E-05  
rs11205641 1 49957662   8.41E-05 rs11205641 3.40E-01 rs11205641 4.79E-01 rs11205641 3.85E-01 5.27E-06  
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Table 3.3 Li et al., 2008 GWAS SNPs (5 x 10-5 < p < 5 x 10-8) compared with Carrasquillo et al., 2009 and Reiman et al., 2007.  
 
Each row represents a SNP with a p-value between 5 x 10-5 and 5 x 10-8. The p-values are highlighted yellow if corr-p < 0.05 and 
they replicated across two or more studies. Data from a perfect proxy SNP was used if data for the initial SNP was unavailable. If a 
perfect proxy was used the corresponding rs number is listed. The same platform was used in the Reiman et al., 2007 and Li et al., 
2008 studies. The combined p-values across studies are as shown. The final column shows the corrected p-value adjusted as 
described (Chapter 3 - section 3.3).  
  
Li et al., 2008 Carrasquillo et al., 2009 Reiman et al., 2007 Combined 
p-value 
Corrected 
p-value 
SNP CHR BP Gene Position p-value SNP p-value SNP p-value 
rs4735627 8 100705091 VPS13B Intron 3.51E-06 rs4735627 8.73E-01 rs4735627 7.66E-01 2.35E-06  
rs7336489 13 59171299 BC041395 Intron 5.38E-06 -  rs7336489 8.78E-01 4.72E-06  
rs370672 5 2501146   9.37E-06 -  rs370672 1.62E-01 1.52E-06  
rs4684083 3 163865   9.73E-06 -  rs4684083 6.72E-01 6.54E-06  
rs11682545 2 121662295 TFCP2L1 Downstream 1.29E-05 -  rs11682545 6.18E-03 7.98E-08 3.06E-02 
rs6805482 3 25435600   1.78E-05 -  rs6805482 9.27E-01 1.65E-05  
rs11166407 1 100410296 LRRC39 Intron 2.00E-05 -  rs11166407 8.62E-02 1.72E-06  
rs8014810 14 35394781 BRMS1L Intron 2.00E-05 rs2274068 2.33E-01 rs8014810 3.84E-01 1.79E-06  
rs541392 10 130941167   2.76E-05 rs476628 3.66E-01 rs541392 4.19E-01 4.23E-06  
rs13180602 5 160213616 ATP10B Upstream 2.79E-05 rs4559036 7.00E-02 rs13180602 4.03E-01 7.87E-07  
rs11751998 6 11297073 NEDD9 Intron 3.42E-05 rs10484448 4.86E-01 -  1.66E-05  
rs6571727 14 35210859 GARNL1 Intron 3.49E-05 rs6571727 2.14E-01 rs10132580 7.61E-01 5.67E-06  
rs4483549 11 90595620   3.58E-05 rs4483549 3.10E-01 rs4483549 2.12E-01 2.35E-06  
rs1914516 2 215270178   3.61E-05 -  rs1914516 2.21E-01 7.98E-06  
rs4905898 14 99345451 EML1 Intron 3.61E-05 rs10141863 7.74E-01 rs4905897 5.44E-01 1.52E-05  
rs4687319 3 193526543 FGF12 Intron 4.60E-05 -  rs4687319 6.18E-01 2.84E-05  
rs16897530 8 100725659 VPS13B Intron 4.74E-05 -  rs16897530 9.66E-01 4.58E-05  
rs4438299 16 60259838 CDH8 Intron 4.90E-05 rs4438299 9.09E-01 rs4438299 8.81E-01 3.93E-05  
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Table 3.4 Reiman et al., 2007 GWAS SNPs (5 x 10-5 < p < 5 x 10-8) compared with Li et al., 2008 and Carrasquillo et al., 2009.  
Reiman et al., 2007 Li et al., 2008  Carrsquillo et al., 2009 Combined 
p-value 
Corrected 
p-value 
SNP CHR BP Gene Position p-value SNP p-value SNP p-value 
rs10824310 10 53680643 PRKG1 Intron 6.03E-07 rs10824310 3.06E-01 -  1.84E-07  
rs17330779 7 107663071 NRCAM Intron 8.80E-07 rs17330779 5.31E-01 -  4.67E-07  
rs6784615 3 52468315 NISCH Intron 9.89E-07 rs6784615 6.14E-01 -  6.07E-07  
rs12162084 16 26553533   1.30E-06 rs12162084 7.61E-01 -  9.88E-07  
rs2517509 6 31138101   1.35E-06 rs2517509 3.83E-01 -  5.16E-07  
rs7077757 10 112527724 RBM20 Intron 1.52E-06 rs7077757 4.18E-02 -  6.35E-08 2.44E-02 
rs249153 12 93837244   2.66E-06 rs249153 8.25E-02 rs249153 7.17E-01 1.58E-07  
rs10747758 12 54287453   3.03E-06 rs10747758 2.45E-01 -  7.42E-07  
rs11958566 5 117719226   4.16E-06 rs11958566 6.16E-01 -  2.56E-06  
rs17505622 13 101759124 FGF14,LOC283480 Intron 5.47E-06 rs17505622 2.55E-01 -  1.39E-06  
rs7079348 10 77742377 C10ORF11 Intron 8.70E-06 rs7079348 3.85E-01 -  3.35E-06  
rs475093 1 43383592 LOC440585 Intron 8.86E-06 rs475093 7.10E-01 -  6.29E-06  
rs11748700 5 15773106 FBXL7 Intron 1.09E-05 rs11748700 2.40E-01 -  2.62E-06  
rs7817227 8 27951747   1.47E-05 rs7817227 4.99E-01 -  7.35E-06  
rs17126808 8 18457737 PSD3 Intron 1.89E-05 rs17126808 7.88E-01 -  1.49E-05  
rs950922 1 21747977 ALPL Intron 1.96E-05 rs950922 3.45E-01 -  6.74E-06 
 
rs16842422 1 196346167   1.99E-05 rs16842422 7.48E-01 -  1.49E-05 
rs4759173 12 54262230   1.99E-05 rs4759173 4.52E-01 rs10876820 4.45E-01 4.00E-06  
rs2122339 4 27290902   2.12E-05 rs2122339 5.96E-01 -  1.27E-05  
rs4394475 9 90496717   2.18E-05 rs4394475 5.23E-01 -  1.14E-05  
rs10783760 12 54260896   2.22E-05 rs10783760 3.65E-01 rs10876820 4.45E-01 3.62E-06  
rs13213247 6 81560955   2.29E-05 rs13213247 5.73E-01 rs16892136 4.17E-01 5.46E-06  
rs7097398 10 91782821   2.60E-05 rs7097398 8.02E-01 -  2.08E-05  
rs9982394 21 41191871   2.68E-05 rs9982394 3.06E-01 -  8.19E-06  
rs9934599 16 69220773 IL34 Upstream 2.68E-05 -  rs9934599 4.46E-01 1.20E-05  
rs7031458 9 84704086   2.74E-05 rs7031458 2.16E-02 -  5.91E-07  
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Each row represents a SNP with a p-value between 5 x 10-5 and 5 x 10-8. The p-values are highlighted yellow if corr-p < 0.05 and 
they replicated across two or more studies. Data from a perfect proxy SNP was used if data for the initial SNP was unavailable. If a 
perfect proxy was used the corresponding rs number is listed. The combined p-values across studies are as shown. The final column 
shows the corrected p-value adjusted as described. DISC1 is starred to indicate that the combined p-value listed has included the data 
(p = 8.20 x 10-3) from the Beecham et al., 2009 study (Chapter 3 - section 3.3).  
rs1923924 9 1581055   2.98E-05 rs1923924 5.00E-01 -  1.49E-05  
rs249154 12 93848520   3.12E-05 rs249154 1.14E-01 rs249153 7.17E-01 2.55E-06  
rs17151710 5 123739233   3.13E-05 rs17151710 7.59E-01 -  2.38E-05  
rs17048904 4 118081372   3.50E-05 rs17048904 1.00E+00 -  3.50E-05  
rs7134292 12 54260239   3.68E-05 rs7134292 3.23E-01 rs10876820 4.45E-01 5.30E-06  
rs7585710 2 10819621 ATP6V1C2 Intron 3.76E-05 rs7585710 1.00E+00 -  3.76E-05  
rs12044355 1 229901524 DISC1* Intron 3.93E-05 rs12044355 9.07E-01 -  2.92E-07*  
rs6888935 5 117745419   3.93E-05 rs6888935 9.96E-01 -  3.92E-05  
rs17586545 14 51101242 LOC645380,LOC651876 Intron 4.11E-05 rs17586545 8.87E-01 -  3.65E-05  
rs1038891 11 40877959   4.48E-05 rs1038891 4.84E-01 -  2.17E-05  
rs6094514 20 44993488 EYA2 Intron 4.49E-05 rs6094514 3.40E-01 rs11700355 5.60E-01 8.54E-06  
rs10248657 7 112741449   4.56E-05 rs10248657 8.88E-01 -  4.05E-05  
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Table 3.5 Carrasquillo et al., 2009 GWAS SNPs (5 x 10-5 < p < 5 x 10-8) compared with Li et al., 2008 and Reiman et al., 2007.  
Each row represents a SNP with a p-value between 5 x 10-5 and 5 x 10-8. Data from a perfect proxy SNP was used if data for the 
initial SNP was unavailable. If a perfect proxy was used the corresponding rs number is listed. The combined p-values across studies 
are as shown. The final column shows the corrected p-value adjusted as described. No SNPs replicated across studies using the 
Carrasquillo et al., 2009 GWAS as the primary dataset (Chapter 3 - section 3.3). 
 
Carrasquillo et al., 2009 Li et al., 2008 Reiman et al., 2007 Combined 
p-value 
Corrected 
p-value 
SNP CHR BP Gene Position p-value SNP p-value SNP p-value 
rs2318144 8 58277297 ncRNA  2.22E-06 rs17194995 2.04E-01 rs17194995 3.13E-01 1.42E-07  
rs1279795 23 123152101   5.02E-06 rs1279795 8.42E-01 -  4.22E-06  
rs3007421 1 6452776 PLEKHG5 Intron 6.54E-06 rs3007421 6.51E-01 rs3007421 4.68E-01 1.99E-06  
rs6546452 2 25834776   8.55E-06 rs17680828 9.00E-01 rs17680828 9.68E-01 7.45E-06  
rs7318037 13 81367146   1.15E-05 rs4456389 9.82E-01 rs4456389 2.39E-01 2.70E-06  
rs2118732 5 79419032   1.32E-05 rs7736549 5.49E-01 -  7.25E-06  
rs8039031 15 34954382 MEIS2 Downstream 2.26E-05 rs8039031 5.04E-01 rs8039031 9.92E-02 1.13E-06  
rs7245160 18 70417826 AK056288/LOC400657 Upstream 2.66E-05 rs7245160 4.60E-01 rs7245160 4.15E-01 5.08E-06  
rs856675 14 84405968   3.83E-05 rs17737309 7.10E-01 rs17737309 2.87E-01 7.81E-06  
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Meta-analysis of odds ratio for candidate SNPs 
A random-effects meta-analysis (also known as DerSimonian-Laird test) of the allelic 
odds ratios was performed for the three SNPs identified as mentioned (DerSimonian 
and Laird, 1986). The TRIM15 SNP (rs929156) gave odds ratios in the same 
direction (causative, Table 3.6) across three studies and random effect meta-
analysis gave an odds ratio of 1.1 (95% CI 1.0-1.2; p = 0.03). RBM20 (p = 0.95) and 
TFCP2L1 (p = 0.74) SNPs were not significant following meta-analysis.   
Gene-centric analysis of TRIM15 
A gene-centric analysis of TRIM15 was undertaken (Figure 3.1) to explore the 
genetic architecture in more detail. The histogram shows the SNPs present in three 
different GWAS (Carrasquillo et al., 2009; Li et al., 2008; Reiman et al., 2007), their 
associated p-values together with their degree of linkage.  
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Table 3.6 Comparison of odds ratios across GWAS for selected SNPs. If the 
SNP was not present in a GWAS, odds ratio of a perfect proxy (r2 = 1) was used. The 
proxy SNP ID is shown underneath the corresponding odds ratios. The data shown is 
for the allelic association model. The 95% confidence interval (CI) for odds ratios are 
shown in brackets. The results from random effects meta-analysis of these odds 
ratios are given in the final column. 
 
 
 
 
 
 
 
  
Gene 
OR (95% CI) 
Reiman et 
al., 2007 
Carrasquillo 
et al., 2009 
Li et al., 
2008 
Random effects 
Meta-analysis of 
25¶V 
TRIM15 
(rs929156) 
1.1 
(0.9-1.3) 
(rs2844775) 
1.1 
(1.0-1.3) 
1.1 
(0.9-1.3) 
(rs2844775) 
1.1 
(1.0-1.2) 
p = 0.03 
TFCP2L1 
(rs11682545) 
0.8 
(0.7-0.9) - 
1.3 
(1.1-1.5) 
1.0 
(0.7-1.6) 
p = 0.95 
RBM20 
(rs7077757) 
0.6 
(0.5-0.8) - 
1.3 
(1.0-1.5) 
0.9 
(0.5-1.7) 
p = 0.74 
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Figure 3.1 Schematic overview of the TRIM15 gene and the LD plot for this 
region. The histogram depicts all GWAS SNPs in TRIM15, their p-values and IDs 
are shown at the top of the figure. These studies are colour-coded as indicated at the 
top of the figure. The two TRIM15 isoforms and their chromosomal positions are as 
depicted in HapMap (release 23). The LD plot is for the GWAS variants (Haploview 
4.0, r2 values with r2 colour scheme). The positions of SNPs with respect to the gene 
are indicated on the LD plot. The SNPs at the boundaries of this LD block are also 
shown. LD values are represented by different colours (black - strong LD, grey - 
moderate LD, and white - no evidence of LD). 
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3.5 Discussion 
The APOE region on chromosome 19 was confirmed as a genetic-risk factor in 
LOAD by all four GWAS with SNP p-values ranging from 10-36 to 10-44. Apart from 
those in LD with the APOE locus, there were no other SNPs across the four GWAS 
with p-values less than 10-8. Genes with suggestive significance (10-5 < p < 10-8) 
across different GWAS may infer a genuine LOAD candidate. 
Approximately 700 genes and 3000 polymorphisms have been assessed as genetic 
risk factors in association with AD (http://www.alzgene.org/) as of October 2011 
(Bertram et al., 2007). Except for the APOE gene, most of the genes have conflicting 
reports with regard to their associations. However, each of the studies often uses 
different populations with varying male and female percentages, as well as differing 
age ranges and sample sizes. Results are therefore not always directly comparable 
between different studies (Bertram et al., 2007). The study approach used here may 
help identify potential LOAD candidate genes whose signals replicate across studies. 
GWAS association analysis uses very stringent significance levels to avoid the large 
number of false positives potentially arising from the confounding effects of 
population substructure and testing of a very large number of SNPs simultaneously 
(Bodmer and Bonilla, 2008). For example, in a GWAS using 500,000 independent 
markers, 25,000 can be expected to show a nominal p-value (p < 5 x 10-2) by chance 
alone and five out of this 25,000 may be significant with p-values (p < 1 x 10-5). A 
widely accepted p-value (p < 5 x 10-8) is used to indicate a genuine disease 
association in GWAS (Bertram and Tanzi, 2008). However, the SNPs on different 
chip platforms are often not independent. Many SNPs are in LD with other SNPs, 
potentially reducing the number of independent markers available for analysis. 
Secondly, the genotyping rate never reaches 100%, and after quality control, 
significant numbers of SNPs are excluded from study (Table 3.1). This suggests that 
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a p-value of < 5 x 10-8 may in some instances be too stringent and SNPs with p-
values between 10-5 and 10-8 might well harbour genuine associations. 
The potential role of TRIM15 
TRIM15 is a member of the tripartite motif (TRIM) family. The TRIM motif includes 
three zinc-binding domains, a RING, a B-box type 1 and B-box type 2, and a coiled-
coil region. The protein is localized to the cytoplasm. Two isoforms have been 
identified and described, however their biological functions have not as yet been 
identified. TRIM15 is ubiquitously expressed in various tissues. However, the 
biological role of TRIM15 has not yet been determined (Shiina et al., 2006). 
SNP rs929156 in TRIM15 is located in an exon in one of the two TRIM15 transcripts. 
It changes the amino acid from a small, polar Serine to a medium-sized, polar 
Asparagine. It is located in a B30.2 SPRY like domain (position: 276-465 amino 
acids). The B30.2-like domain is a conserved domain found in nuclear and 
cytoplasmic proteins, as well as transmembrane and secreted proteins. The B30.2-
like domain may also be associated with a zinc-binding B-box domain in the N-
terminal (Henry et al., 1998). The SPRY domain is proposed to be a protein 
interacting module, which recognizes and interacts with specific individual partner 
proteins (Woo et al., 2006). The potential effects of this SNP on protein structure 
require further investigation.  
The only other TRIM15 SNP in these GWAS rs9261536 LVORFDWHGLQWKH¶
untranslated region (UTR), which may harbour potential regulatory elements (i.e. a 
promoter region or a binding site for an associated transcription factor - Figure 3.1). 
Possible linkage has been observed between this TRIM15 SNP and SNPs in Human 
leukocyte antigen A (HLA-A) with r2 value 0.77 (Figure 3.2).  
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Figure 3.2 Illustration of LD between TRIM15 and HLA-A genes. The red ellipse 
highlights the linkage between TRIM15 SNP rs9261536 (shown in bold) and three 
known SNPs (rs2916801, rs2571381 and rs2499) in HLA-A with r2 value = 0.77. The 
LD plot was generated using HapMap data (CEU population release 23) and the 
program Haploview version 4.0 (Methods 2.3.5). 
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TRIM15 is surrounded by a number of HLA genes which are associated with the 
human immune system. This group of HLA genes encode cell-surface antigen-
presenting proteins, which are essential elements in human immune responses. 
HLA-A is necessary for immune recognition and apoptosis, and mutations in HLA-A 
have been reported as risk factors for various cancers (Hu et al., 2009). Ma et al., 
2008 showed that mutations in HLA-A are associated with earlier age at onset of AD 
(2.4 years, p = 0.03) for non-carriers of APOE H4 (Ma et al., 2008). 
The significance of identified SNPs 
In this study, an approach was described to detect replicating signals across different 
GWAS platforms in an effort to identify LOAD candidate genes that have failed to 
reach genome-wide significance previously. Using the data from the four studies 
listed has generally failed to produce any convincing replicating signals with the 
possible exception of the TRIM15 gene which contains the only SNP (rs929156) 
whose combined p-value (p = 8.77 x 10-8) survives multiple testing correction (corr-p 
= 0.0467) and where the meta-analysis of odds ratios is also tentatively significant 
(OR = 1.1, 95% CI 1.0-1.2, p = 0.03) with no evidence of between-study 
heterogeneity (Breslow-Day p = 0.90) (Figure 3.3). 
The remaining two SNPs that had p-values of 10-8 failed the meta-analysis of odds 
ratios because their effects were discordant between studies (Table 3.6). 
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Figure 3.3 Forest plot depicting effects of SNP rs929156 from different GWAS. 
The effect of SNP rs929156 for each individual GWAS together with the meta-
analysis results (combined [random]) are as indicated. The size of the squares 
represents the weight (Mantel-Haenzel weight) of the corresponding study in the 
meta-analysis. The line either side of the square represents 95% confidence intervals 
for the odds ratio. Confidence intervals of pooled estimates are displayed as a 
horizontal line through the diamond. The dashed vertical line (linking squares and the 
diamond) represents the odds ratio of the meta-analysis. Odds ratio and 95% 
confidence interval of each study and combined are documented to the right of the 
forest plot.  
  
Odds ratio meta-analysis plot [random effects]
0.5 1 2
Carrasquil lo et al, 2009 1.13 (0.98, 1.31)
Li et al, 2008 1.08 (0.90, 1.28)
Reiman et al, 2007 1.11 (0.93, 1.33)
combined [random] 1.11 (1.01, 1.22)
odds ratio (95% confidence interval)
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In the UK LOAD GWAS paper (Harold et al., 2009) the TRIM15 SNP, rs929156, was 
shown to be modestly associated with AD (p = 0.049). Adding this data results in a 
)LVKHU¶VFRPELQHGS-value of 4.30 x 10-9 strengthening the evidence of association 
for this SNP. The odds ratio from the UK GWAS (OR = 1.07) was also compatible 
with the odds ratio observed in the random effect meta-analysis in this study (OR = 
1.11). 
An issue which is evident in this study is the difficulty that exists when trying to 
compare data across different chip platforms where the SNP complement differs. 
Surprisingly few perfect proxies available resulted in a significant loss of data and a 
reduction of power to detect new signals.  
Technology continues to advance; the latest Illumina GWAS chip is capable of 
genotyping ~5 million SNPs from the international HapMap project, as well as SNPs 
identified by the 1000 genomes project with MAF above 1%. The approach described 
may prove to be useful when larger datasets (generated using these chips) are 
analysed.  
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3.6 Bioinformatics Application Note 
As the number of publically available GWAS datasets continues to grow, 
bioinformatic tools which enable routine manipulation of data are becoming 
increasingly useful. In addition, whole genome meta-analysis is labour intensive 
without suitable bioinformatics software.  
AQµ/'DZDUH¶ELRLQIRUPDWLFVDSSOLFDWLRQ was developed enabling efficient 
comparison of SNPs HIIHFWVDFURVVPXOWLSOH*:$6GDWDVHWVXVLQJ)LVKHU¶VFRPELQHG
SUREDELOLW\WHVWIURP3/,1.Yµ/'FOXPSHG¶RXWSXW (Appendix 8.4.3). 
Implementation 
PLINK (v1.06) SURYLGHVDQµOG-FOXPS¶DQDO\VLVZKLFKDOORZVDXWRPDWLFFDOFXODWLRQRI
µFOXPSV¶EORFNVRI613VLQ/'DFURVVJHQRW\SLQJ chip platforms. The software 
developed uVHVWKHRXWSXWILOHIURPWKLVµ/'FOXPS¶DQDO\VLVDQGSHUIRUPVWKH
downstream meta-analysis of SNPs in each clump (taking one SNP/proxy (r2=1) from 
each study and combining their p-values). 
The applicaWLRQFRQVLVWVRIWZRILOHVµPHWDBDQDO\VLVSO¶µPRGXOHsSP¶ZKHUH
µPHWDBDQDO\VLVSO¶LVDQH[HFXWDEOHILOHZhen PERL language is installed. 
µPHWDBDQDO\VLVSO¶ILOHFDQEHHGLWHGXVLQJDFRQYHQWLRQDOWH[WILOHHGLWRUDQGDOORZV
users to define two parameters; i) the location and the filename of the input 
µOGBFOXPS¶ILOHJHQHUDWHGLQ3/,1.DQGLLWKHW\SHRIWKHVWXG\- case/control (CC) 
analysis or quantitative trait (QT) analysis. Fields requiring modification were 
DQQRWDWHGLQWKHµPHWDBDQDO\VLVSO¶ILOH7KHGHIDXOWLQSXWLVµcase/control¶ analysis. 
Failure to adjust the parameter for the correct type of analysis will generate false 
output in the results file.  
 Analysis of GWAS data looking for replicating signals in LOAD 
131 
 
The program was designed to handle an unlimited number of GWAS datasets and 
unlimited SNPs. However, currently the application has only been validated using up 
to ten modelled datasets. 
Issues and problem-solving 
,WLVZRUWKQRWLFLQJWKDWZKHQJHQHUDWLQJWKHµFOXPS¶ILOHV3/,1.UHTXLUHVDUHIHUHQFH
GWAS dataset (e.g. HapMap data) to calculate LD values between two SNPs. Given 
that LD values vary between ethnic populations, it is imperative that the reference 
dataset and the GWAS datasets are from the same population thus avoiding 
stratification issues.  
It is common that a SNP in one GWAS has multiple perfect SNP proxies (r2= 1) in 
another independent GWAS. In this situation, although it is considered appropriate to 
use any pair of SNPs to perform meta-analysis, the application decides which proxy 
to use based on which proxy is closest to the index SNP (as in physical distance). 
The distance between the SNP/proxy and the index SNP is annotated in the results 
file. It should be noted that if an index SNP is unique to one study and does not have 
a perfect proxy in any other studies, no meta-analysis results will be displayed for this 
SNP. 
This application only uses perfect proxies (r2 = 1). This is a limitation of the software 
as using imperfect proxies (r2 < 1) will increase the number of comparable SNPs 
between studies. Currently, there is no weighting algorithm implemented in the 
program therefore any SNP p-value inferred from a proxy with r2 < 1 will be 
inaccurately treated as a perfect match.  
To use imperfect proxies, simply alter the (--clump-r2) parameter in PLINK, and run 
the application as usual. This may indeed be a valuable approach to increase 
coverage, analogous to imputation, but until the output is weighted accordingly, the 
results will have to be interpreted with caution.  
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$µIOLSSHU¶UHIHUVWRD SNP or SNP proxy in one dataset which has the opposite effect 
to that observed in the original study. This application compares the OR (case/control 
analysis) or regression coefficient (from quantitative trait analysis) of all SNP pairs 
from different studies, and annotates according to the following rules;  
Lµ<(6± fOLSSHU¶± ORs are in opposite directions in two (or more) GWAS studies, 
LUUHVSHFWLYHRIPLVVLQJ25GDWDLQDGGLWLRQDOVWXGLHVLLµ12- non-IOLSSHU¶- all SNPs 
25LQWKHVDPHGLUHFWLRQDQG25GDWDLVSUHVHQWIRUDOOVWXGLHVDQGLLLµ1$- not 
DSSOLFDEOH¶ - there is either no OR data, or datasets are missing OR data making it 
LQDSSURSULDWHWRFDOODµQRQ-IOLSSHU¶,QVWXGLHVZLWKPLVVLQJ25RU%(7$WKHILHOGKDV
WREHHQFRGHGDVµ-¶LQWKHµDVVRF¶ILOHIRUVXEVHTXHQWµOG-FOXPSLQJ¶DQDO\VLVLQ
PLINK.  
The application DXWRPDWLFDOO\UHFRJQL]HVWKHQXPEHURI*:$6IURP3/,1.µOG-FOXPS¶
output files and tabulates the results accordingly. Although the application was 
designed for GWAS meta-analysis, the user can perform analysis on much smaller 
datasets.  
This approach is advised to be used prior to more formal meta-analysis. It is 
essential that any potential finding that emerges using the application is verified by 
further investigation in a rigorous manner. Adjusting the genotypic data for covariates 
and taking into account heterogeneity between studies/samples will verify if 
REVHUYDWLRQVLQYROYLQJERWKµIOLSSLQJ¶DQGµQRQ-IOLSSLQJ¶DOOHOHVDUHOLNHO\WREHJHQXLQH
and worthy of downstream study. 
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An example 
Two late-RQVHW$O]KHLPHU¶VGLVHDVH/2$'*:$6GDWDVHWV- Carrasquillo et al., 
2009 and Reiman et al., 2007 DQGWKHµWRSKLWV¶WDEXODWHGLQBeecham et al., 2009 
were used to test the performance of the application. The sample sizes and 
genotyping platforms for the three studies are - Carrasquillo et al., 2009, 799 LOAD 
cases and 1199 controls on Illumina 300 chip, Reiman et al., 2007, 859 LOAD cases 
and 552 controls on Affymetrix 500K chip and Beecham et al., 2009, 492 LOAD 
cases and 496 controls on Illumina 550 chip. The total sample size of all three GWAS 
is 4,397 (2,150 LOAD cases and 2,247 controls). No apolipoprotein E (APOE) related 
SNPs were listed in Beecham et al., 2009 µWRSKLWV¶These samples were estimated 
to provide over 93% power to detect an association with a common SNP (MAF > 10% 
and OR > 1.3). This estimation has to be treated with caution as it is based on a 
number of assumptions (such as effect size and mode of inheritance), and gene-
environment interaction (GxE) has not been taken into account.  
Before using the software, a number of PLINK analyses were undertaken.  
1) Subject-level genotype data was obtained from Carrasquillo et al., 2009 and 
Reiman et al., 2007. The files were converted into PLINK format where necessary, 
and the SNP identifiers were converted into dbSNP rs number using an µLQKRXVH¶
program written in PERL (Methods 2.3.2). The GWAS output was generated using 
the 3/,1.µ--DVVRF¶FRPPDQG 
2) As Beecham et al., 2009 GWAS data was not available, a file called 
µ%HHFKDPDVVRF¶ZDVPDQXDOOy generated conforming to the format of a PLINK 
µDVVRF¶ILOH (Methods 2.3.1)7KUHHFRPSXOVRU\FROXPQVDUHUHTXLUHGLQWKHµDVVRF¶ 
file with the headers µ613¶µ25¶DQGµ3¶. $OORWKHULQIRUPDWLRQVXFKDVµ%3¶µ&+5¶
µ$¶LQWKHVWDQGDUGµDVVRF¶ILOHDUHQRWUHTXLUHGDQGFDQVLPSO\EHLJQRUHG$V25
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data was not included in the Beecham et al., 2009 GDWDWKHVHYDOXHVZHUHVHWWRµ-¶
LQWKHµ25¶FROXPQ 
7KHµOG-FOXPS¶DQDO\VLVZDVSHUIRUPHGXVLQJ3/,1. (v1.06) using the three files 
JHQHUDWHGµ&DUUDVTXLOORDVVRF¶µ5HLPDQDVVRF¶DQGµ%HHFKDPDVVRF¶ The filtered 
version of HapMap data (CEU population, release 23) in PLINK binary format (BED, 
BIM and FAM) was downloaded from the PLINK website 
µhttp://pngu.mgh.harvard.edu/~purcell/plink/res.shtml¶ (Purcell et al., 2007). The 
HapMap data contains 2.3 million SNPs.  
7KHµOG-FOXPS¶DQDO\VLVZDVSHUIRUPHGXVLQJWKHIROORZLQJ3/,1.FRPPDQG 
plink --bfile HapMapCEU23 
--clump Carrasquillo.assoc,Reiman.assoc,Beecham.assoc 
--clump-verbose 
--clump-annotate OR 
--clump-p1 1 
--clump-p2 1 
--clump-r2 0.99 
--out ld_clump 
--noweb 
7KH3/,1.PHWKRGUHDGVµ--EILOH¶WKH+DS0DSGDWDLQ3/,1.IRUPDWDQGµFOXPSV¶ 
the three datasets based on HapMap LD r2 values. µ--clump-verbose¶LQVWUXFWV3/,1.
to generate a detailed report of SNPs in each clump. The output of ORs was 
VSHFLILHGXVLQJµ--clump-DQQRWDWH25¶µ--clump-DQQRWDWH%(7$¶ZDVXVHGIRU
quantitative trait analysis). All SNPs were used WRSHUIRUPWKHµOG-FOXPS¶DQDO\VLV
irrespective of p-YDOXHVµ--clump-S¶DQGµ--clump-p2 ¶µ--clump-U¶HQVXUHV
that only SNPs which are perfect proxies (r2 !DUHFOXPSHGµ--clump-U¶GRHV
not work). 
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A single output file µOGBFOXPSFOXPSHG¶ZDVJHQHUDWHGXVLQJµ--RXWOGBFOXPS¶$OO of 
WKHVHFRPPDQGVOLVWHGDUHFRPSXOVRU\WRWKHVXEVHTXHQWDQDO\VLVH[FHSWµ--clump-
S¶DQGµ--clump-S¶ZKLFKDOORZWKHXVHUWRadjust p-value threshold. 
7KHµPHWDBDQDO\VLVSO¶ILOHZDVHGLWHG using a text file editor to ensure it contains 
the correct PLINK µOG-FOXPS¶RXWSXWILOHQDPHDQGFRUUHFWW\SHRIDQDO\VLVas 
described earlier. 
5) The application was executed and a rHVXOWVILOHQDPHGµUHVXOWVW[W¶ZDVJHQHUDWHG
automatically.  
The top 6 results in Table 3.7 illustrate the utility of this application. The top 2 SNPs 
are in LD with the APOE locus and demonstrate highly significant p-values as 
H[SHFWHGUV)LVKHU¶VPHWKRGS-value 1.09 x 10-9 DQGUV)LVKHU¶V
method p-value 1.13 x 10-7); the first SNP exceeded genome-wide significance (p = 
1.67 x 10-7) after correcting for the number of independent tests (Methods 2.3.2) and 
the second SNP approached this value. 
Sub-significant hits may prove to be genuine when more datasets are included. SNP 
rs2318144 is located 200kb upstream of the inositol monophosphatase domain 
containing 1 gene, IMPAD1; as of October 2011 this gene has yet to figure as an AD 
candidate in the AlzGene forum (Bertram et al., 2007). rs3746319 (p = 4.34 x 10-7) 
was found to be located in an exon of the zinc finger protein (ZNF224). Although this 
SNP is in vicinity to the APOE region, the effect has been suggested to be 
independent of APOE status (Beecham et al., 2009). rs11205641 demonstrates a 
dichotomy of effecWLHLW¶V25LVQRWFRPSDUDEOH between datasets (shows opposing 
HIIHFWVDQGLVWKXVLQGLFDWHGDVDµIOLSSHU¶UVp = 1.15 x 10-6) is located 
~120kb upstream of Amyloid-beta precursor protein (APP) gene. 
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Table 3.7 Results from Meta-analysis of Carrasquillo et al., 2009, Reiman et al., 2007 and Beecham et al., 2009. The table shows 
613VZLWK)LVKHU¶VFRPELQHGSUREDELOLW\WHVWS-value less than 1 x 10-5. F1, F2 and F3 refers to the studies which have been inputted to 
perform the meta-analysis (1, 2 and 3 refers to Carrasquillo et al., 2009, Reiman et al., 2007 and Beecham et al., 2009, respectively). 
KB1 and RSQ1 refer to the distance and LD between the index SNP and PROXY1. The same rule applies to KB2 and RSQ2. The suffix 
(1, 2 or 3) on column headers Pvalue indicated p-value in each study individually as listed. ClumpNo - index number ranked based on 
descending p-value in each study, CHR - chromosome number, FISHER - )LVKHU¶VFRPELQHd probability test p-value and FLIPPER - 
LQGLFDWHVZKHWKHUWKH613LVDµIOLSSHU¶ 
ClumpNo SNP F1 CHR PROXY1 F2 KB1 RSQ1 PROXY2 F3 KB2 RSQ2 FISHER FLIPPER Pvalue1 Pvalue2 Pvalue3 
1  rs1114832  1  19  rs1114832  2  0  1  - - - - 1.09E-09  NO  1.37E-06  0.000799  - 
4  rs10402271  1  19  rs10402271  2  0  1  - - - - 1.13E-07  NO  4.54E-06  0.0248  - 
2  rs2318144  1  8  rs6982990  2  0.532  1  - - - - 3.57E-07  NO  2.22E-06  0.161  - 
20  rs3746319  3  19  rs3746319  1  0  1  rs2061332  2 1.43 1 4.34E-07  NA  0.985  0.0149  2.96E-05  
7  rs11205641  3  1  rs11205641  1  0  1  rs11205641  2 0 1 1.10E-06  YES  0.385  0.34  8.41E-06  
107  rs468345  2  21  rs468345  1  0  1  - - - - 1.15E-06  NO  0.00353  0.000326  - 
42  rs7679738  1  4  rs510115  2  2.67  1  - - - - 1.63E-06  NO  9.72E-05  0.0168  - 
5  rs9659092  3  1  rs12022125  2  -83.5  1  - - - - 1.83E-06  NA  - 0.404  4.54E-06  
3  rs249153  2  12  rs249153  1  0  1  - - - - 1.91E-06  NO  0.717  2.66E-06  - 
68  rs9474661  2  6  rs4486000  1  -2.44  1  - - - - 2.19E-06  NO  0.0142  0.000154  - 
16  rs8039031  1  15  rs8039031  2  0  1  - - - - 2.24E-06  NO  2.26E-05  0.0992  - 
86  rs4693305  2  4  rs4693305  1  0  1  - - - - 2.64E-06  NO  0.0119  0.000222  - 
10  rs7318037  1  13  rs4456389  2  11.5  1  - - - - 2.75E-06  YES  1.15E-05  0.239  - 
6  rs3007421  1  1  rs3007421  2  0  1  - - - - 3.06E-06  NO  6.54E-06  0.468  - 
74  rs385771  1  5  rs385771  2  0  1  - - - - 3.78E-06  YES  0.000163  0.0232  - 
76  rs10501120  1  11  rs10501120  2  0  1  - - - - 4.00E-06  NO  0.000171  0.0234  - 
9  rs4313171  2  8  rs359819  1  -169  1  - - - - 5.01E-06  NO  0.501  1.00E-05  - 
144  rs6695249  1  1  rs17113051  2  4.38  1  - - - - 5.40E-06  NO  0.00045  0.012  - 
11  rs3807031  3  6  rs3807031  1  0  1  - - - - 5.73E-06  NA  0.494  - 1.16E-05  
25  rs2119067  3  2  rs2119067  1  0  1  - - - - 6.92E-06  NA  0.158  - 4.38E-05  
35  rs11033712  2  11  rs12271660  1  26.9  1  - - - - 7.85E-06  YES  0.127  6.18E-05  - 
8  rs6546452  1  2  rs17680828  2  9.37  1  - - - - 8.28E-06  NO  8.55E-06  0.968  - 
14  rs4759173  2  12  rs10876820  1  -22.7  1  - - - - 8.86E-06  NO  0.445  1.99E-05  - 
22  rs2387100  3  13  rs2387100  1  0  1  rs9551404  2 -12.5 1 9.40E-06  NA  0.644  0.382  3.82E-05  
31  rs7537266  2  1  rs7537266  1  0  1  - - - - 9.52E-06  NO  0.186  5.12E-05  - 
17  rs13213247  2  6  rs16892136  1  -115  1  - - - - 9.55E-06  NO  0.417  2.29E-05  - 
79  rs4904864  1  14  rs10484035  2  14  1  - - - - 9.58E-06  YES  0.000186  0.0515  - 
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3.7 Conclusion 
An approach has been described in this chapter to detect replicating signals across 
different GWAS in an effort to identify LOAD candidate genes that have failed to 
reach genome-wide significance previously.  
Using data from four studies (Table 3.1) revealed a single SNP rs929156 (located in 
exon 7 of TRIM15 gene) whose combined p-value (p = 8.77 x 10-8) withstands 
multiple testing correction (p = 0.0467) using perfect proxies and where the meta-
analysis of odds ratios is also significant (OR 1.1, 95% CI 1.0-1.2, p = 0.03). Using 
imperfect proxies (r2 < 1) (i.e. relaxing the condition of perfect LD) in this approach 
would likely further reduce the number of independent test, thereby lowering the 
genome-wide significant threshold, and more SNPs with suggestive p-values may 
reach genome wide significance. However, such results would need to be interpreted 
with caution, as lowering the LD r2 value is likely to introduce errors. The relationship 
between the LD r2 value and the amount of noise introduced by using imperfect 
proxies requires further investigation.  
The next chapter (Chapter 4) describes a study investigating if the gene 
encompassing this SNP harbours multiple rare variants that may be associated with 
the disease using ABI SOLiD® next generation sequencing.  
An important argument for GWAS is that the genes in which common variants are 
found, or genes nearby, may well contain functional rare variants; these may have 
high enough penetrance to be considered as candidates for possible preventive 
screening strategies in the future (Bodmer and Bonilla, 2008).   
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Chapter 4:         Next generation sequencing (NGS) of tripartite 
motif-containing 15 (TRIM15) gene using pooled DNA samples 
4.1 Introduction 
Comparing DNA sequence of LOAD patients against those free of disease symptoms 
allows identification of underlying genetic loci, which has been estimated to account 
for up to 76% of the disease risk (Gatz et al., 2006). However, in order to differentiate 
true signals from background noise and achieve statistical significance, sequencing 
of a large number of individuals is essential.  
DNA sequencing technology has evolved rapidly over the last few years, with the 
advent of NGS enabling both reliable and economically affordable sequencing of 
large-scale DNA sequence (such as whole exome and whole genome sequencing) in 
a large number of individuals (Metzker, 2010). This enhanced capability of 
sequencing provides unprecedented opportunity to address major biological 
questions, such as the search for genetic heritability of LOAD attributable to rare 
variants.  
Existing GWAS is not designed for capturing rare variants with allele frequency less 
than 5%, and insufficient coverage meant that some of the common variants are also 
not accounted for (Cirulli and Goldstein, 2010). NGS of targeted genomic regions 
using pooled DNA samples is capable of testing genetic associations of all variants 
within target regions provided there is sufficient power.   
Sanger sequencing 
Sequencing of DNA and RNA has solely relied on Sanger sequencing technology for 
almost 30 years since it was first developed by Frederick Sanger in 1977 (Sanger et 
al., 1977). It was the key technology used in identification of SNPs, copy number 
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variations (CNVs) and structural variants (such as insertions and deletions) prior to 
the advent of the NGS technology.  
Automated Sanger sequencing was used for the Human Genome Project, which 
produced the first sequence data of the complete human genome encompassing ~3 
billion nucleotide bases (International Human Genome Sequencing Consortium, 
2004). The project was accomplished in 2003 through intensive worldwide 
collaboration and cost ~$3 billion.  
Sanger sequencing is based on using fluorescently labelled dideoxynucleotide 
triphosphate (ddNTPs) as DNA chain terminators. As GG173VODFNWKH¶-OH group 
required to form the next phosphor-diester bond, addition of ddNTPs terminates the 
chain elongation reaction (facilitated by Taq polymerase and dNTPs). The 
concentrations of ddNTPs are much lower than dNTPs, thus they would occasionally 
incorporate into a growing DNA chain at random, and stop further synthesis.  
The final product of Sanger sequencing is a mixture of various sizes of nucleotide 
fragments. Capillary electrophoresis of these short nucleotide fragments enables the 
DNA sequence to be recorded, facilitated by a laser and a detector (Figure 4.1). The 
Sanger sequencing method generates the DNA sequence in a format known as an 
electropherogram.  
6DQJHU¶VPHWKRG is limited by its throughput of sequencing of only ~1kb DNA 
template per experiment run. Additionally, the first ~50 bases of reads are often 
found to be of poor quality, a result likely to be due to the presence of residual 
unincorporated fluorescently labelled ddNTPs (Wallis and Morrell, 2010).  
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Figure 4.1 Schematic diagram of Sanger sequencing. In Sanger sequencing, Taq polymerase, dNTPs and fluorescently labelled 
ddNTPs, sequencing primer and DNA template are added together. A range of different lengths of nucleotide fragments are generated, 
which are subjected to capillary gel electrophoresis. The fluorescent signals emitted by the labelled the ddNTPs, each corresponding to 
the point at which the chain growth is terminated, are detected using a laser and a detector. The sequence results are in the form of an 
electropherogram.  
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Next generation sequencing 
The major advantage of next generation sequencing technology is the ability of 
generating enormous amounts of sequencing data quickly and at substantially 
lowered expenditure. Millions of short reads, each of 35-150 base pair in length, can 
be generated in a single experiment run using the technology (Mardis, 2011; Metzker, 
2010).  
There has been fierce competitions in the field of next generation sequencing 
technology, leading to rapid evolution of technology with respect to its accuracy, 
throughput and speed (Metzker, 2010).  
Next generation sequencing platforms 
The currently available next generation sequencing platforms are Roche 454, ABI 
SOLiD and Illumina platforms (Genome Analyzer IIx, HiSeq 1000/2000 and 
HiScanSQ). Each of these platforms uses distinct chemistry, both Roche 454 and 
Illumina platforms use a PHWKRGNQRZQDVµVHTXHQFLQJE\V\QWKHVLV¶compared to 
µVHTXHQFLQJE\OLJDWLRQ¶XVHGE\$%,62/L'®.  
Roche 454, also known as pyrosequencing, detects each polymerase catalysed 
nucleotide incorporation event marked by the release of an inorganic pyrophosphate. 
Unlike Illumina platforms, which use modified nucleotides, the pyrosequencing 
method adds only a single type of dNTP (i.e. dATP, dCTP, dTTP or dGTP) at a time. 
This extension step is immediately followed by a temporary pause, allowing the 
signal (release of inorganic pyrophosphate) to be detected by non-electrophoretic 
bioluminescence (Ronaghi et al., 1998). The signal intensity is directly proportional to 
the number of incorporated nucleotides, where incorporation of three dATPs would 
result in three times the intensity of a signal observed from incorporation of a single 
dATP. However, incorporation of eight or more of the same nucleotides can cause 
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the signal to become saturated, prohibiting detection of longer repetitive nucleotide 
sequences (Metzker, 2010).  
Illumina platforms use a method known as cyclic reversible termination, where each 
cycle comprises nucleotide incorporation, fluorescence imaging and cleavage 
(Metzker, 2005). Like Sanger sequencing, the Illumina platform utilizes chain 
terminators, with the exception that chain termination is reversible and the reaction 
restarts after imaging has taken place.   
ABI SOLiD uses a technique known as WKHµFRORXUVSDFH¶V\VWHP RUµ-barcoded 
HQFRGLQJV\VWHP¶. Processes involved in ABI SOLiD next generation sequencing are 
summarized in Figure 4.2. 
  
 Next generation sequencing of TRIM15 gene using pooled DNA samples 
143 
 
 
 
Figure 4.2 Overview of library preparation of ABI SOLiD®. The flow diagram 
summarizes the processes involved in next generation sequencing using the ABI 
SOLiD® sequencer. The LR-PCR amplified DNA was sheared into random sizes 
using the Covaris AFATM  similar technology to a sonicator with improved control of 
wavelengths and isothermal advantage. The sheared DNA¶V are end-repaired, and 
WZRDGDSWRUVNQRZQDVµ3¶DQGµ3¶are ligated to both ends of the DNA fragments. 
A specific length of DNA fragments (e.g. 50bp as used in this study) are extracted 
using a size selection gel. This is followed by amplification via emulsion-PCR using 
two primers: µ$¶DQGµ$¶, which are FRPSOLPHQWDU\WRWKHµ3¶DQGµ3¶DGDSWRUV. µA1¶ 
primers are coated on polystyrene beads, which enable enrichment of DNA 
fragments. These polystyrene beads, with DNA attached, are deposited onto a glass 
slide, where the sequencing reactions take place. The ABI SOLiD® sequencer 
supports flexible slide segmentation (also known as flow cells), which enables 
several independent samples to be run simultaneously. Millions of random short DNA 
fragments are sequenced in parallel using the µFRORXUVSDFH¶V\VWHPwhere each 
nucleotide is interrogated twice.  
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Although the NGS platforms described are distinct from each other in many aspects, 
they share substantial similarities: 
x library preparation  all platforms involve DNA shearing into smaller 
fragments followed by end-repair and addition of adaptors (short DNA 
fragments) onto both ends of the template DNA.  
x amplification of DNA template  all NGS platforms require amplification of 
DNA template, so that the sequencing reaction produces sufficient signals 
ZKLFKFDQEHGHWHFWHGE\WKHLQVWUXPHQWV¶RSWLFDOV\VWHPV*LYHQthat no 
DNA polymerase is 100% accurate, this has been considered to be a 
limitation of NGS technology (Mardis, 2011).  
x repeating steps  all platforms perform sequencing reactions using a series of 
repeating steps, which are performed automatically.  
Sequencing library preparation 
Two major methods exist to create a next generation sequencing library: pair-end 
and mate-paired sequencing libraries, where reads generated from sequencing of 
these libraries are known as paired-end and mate-paired reads, respectively.  
Single-end sequencing, with each DNA fragment only sequenced from one end, has 
been largely superseded by paired-end sequencing as a result of the lack of 
accuracy. Single-end sequencing results in a higher proportion of reads incapable of 
being aligned uniquely, resulting in these reads being unsuitable for variant discovery 
(Mardis, 2011).  
Paired-end sequencing allows a DNA fragment to be sequenced from both ends, 
thus improving the confidence when it comes to calling SNPs (Mardis, 2011).  
It should be emphasized that paired-end reads are from a single location of a 
genome region in comparison to the mate-pair sequencing. The difficulty of mapping 
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reads back to a locus of origin which is repetitive is considered a limitation for paired-
end sequencing.  
This led to the development mate-pair sequencing. Reads in mate-pair sequencing 
are made up of two short DNA segments derived from two genomic locations with the 
distance between the two known (Figure 4.3). Given one end of the read of a mate 
pair uniquely aligns to the reference sequence and the distance between the two 
ends is known, the location of the other end of the read should be obvious. 
Consequently, the use of a mate-pair sequencing library can greatly improve the 
coverage of next generation sequencing across the target regions.  
However, as this technology is based on circularization of large DNA molecules, the 
low yield of circularization (directly proportional to the DNA molecules used) means 
the technology is DNA expensive (Mardis, 2011). Furthermore, mate-pair sequencing 
requires extra experimental steps and raises more challenges for mapping and 
alignment, which in turn could result in more reagent cost and longer time to process 
the data.  
 Next generation sequencing of TRIM15 gene using pooled DNA samples 
146 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 2YHUYLHZRIµPDWH-SDLUVHTXHQFLQJ¶ library preparation. a) summarizes steps involved in library preparation for mate-pair 
sequencing run. DNA template is represented by blue bars. Larger sizes of DNA fragments (e.g. 5 kb) are selected in contrast to the 
library preparation for paired-end sequencing. These DNA fragments are end-repaired with biotin labelled dNTPs, which is followed by 
circularization. Non-circularized DNA fragments are removed by digestion. After further fragmentation, biotin labelled DNA fragments 
are purified. These fragments are then end-UHSDLUHGDQGWZRDGDSWRUVµ3¶DQGµ3¶DUHDdded, attaching to both ends of the amplicon. 
The rest of the sequencing reaction is identical to paired-end sequencing. b) illustrates two scenarios of alignment to the reference 
genome sequence, top  paired-end read is unable to map to repetitive genomic region (highlighted in green) and bottom  as one end 
of the mate-pair read uniquely aligns to a non-repetitive genomic sequence, the locus of origin for the other end is obvious. Mate-pair 
reads outperform paired-end reads on mapping to repetitive genomic regions and thus improve sequencing coverage.
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ABI SOLiD® Colour space system 
SOLiD stands for Sequencing by Oligonucleotide Ligation and Detection. A unique 
feature of SOLiD technology is it uses the colour space system with each nucleotide 
base being interrogated twice. This double interrogation greatly increases the 
accuracy of each nucleotide call.  
SOLiD uses 16 two-base-encoded probes as illustrated in Figure 4.4a. Four specific 
dinucleotides are labelled with a single fluorescent dye, and a total of four fluorescent 
dyes are used in ABI SOLiD® next generation sequencing.  
Colour space calls are converted into nucleotide calls based on the chart shown in 
Figure 4.4a using BioScope®.  
Furthermore, colour space system can easily distinguish a SNP from a reading error 
(Figure 4.4b). As each nucleotide base is determined by two adjacent colours, a 
single colour change is an indication of a reading error.   
Figure 4.5 summarized the processes involved in ABI SOLiD® next generation 
sequencing. Five rounds of ligation reaction (each of ten cycles) are necessary to 
sequence all 50bp reads generated.    
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Figure 4.4 ABI SOLiD® colour space system. a) Each probe consists of i) specific 
dinucleotides at nucleotide bases 1-2, ii) degenerate nucleotides bases (denoted as 
µQ¶ (often RNA nucleotides) DQGµ]¶ (inosine)) at nucleotide bases 3-8, iii) restriction 
site between base pair 5 and 6 and iii) fluorescent dye labelled DWWKH¶HQGThe 
specific dinucleotides of each probe, according to the chart, are as shown. b) 
illustrates a scenario where a sequencing error can easily be distinguished from a 
real SNP call in ABI SOLiD® NGS: a SNP is represented by two adjacent colour 
changes, whereas a single colour change is an indication of a sequencing error.  
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Figure 4.5 Flow diagram of the sequencing reaction of ABI SOLiD® NGS. The 
flow diagram summarizes steps involved in the sequencing reaction using by ABI 
SOLiD®: a) annealing of a universal sequence primer enables one of the 16 
fluorescently labelled probes (complementary to the target sequence) to be ligated 
with the universal primer facilitated by ligase, b) four-colour imaging c) nucleotide 
bases 6-8 (denoted as µ]¶ (inosine) in Figure 4.4a) are subsequently cleaved off, 
OHDYLQJD¶SKRVSKDWHJURXSIRUIXUWKHUOLJDWLRQUHDFWLRQs, d) nine more cycles of the 
sequencing step is required to interrogate all nucleotide bases, e) the DNA is 
denatured and the complementary strand is discarded. A new universal sequence 
primer which binds tRµQ-¶SRVLWLRQLVDGGHGDQG is subjected to another ten cycles 
of ligation reactions. A total of five ligation rounds are performed in ABI SOLiD® NGS. 
(Adapted from Metzker, 2010) 
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Challenge of analysing NGS data 
The distinct chemistry of NGS results in fundamental changes to the way that the 
data are analysed in comparison with analysing the capillary data from Sanger 
sequencing. An analysis pipeline of NGS data from the pooled DNA samples using 
ABI SOLiD® is described later in this chapter.   
Furthermore, it is conceivable that the production of millions of NGS reads causes 
challenges to the management of information technologies such as data transfer, 
storage and quality control. Some NGS systems are able to generate over one billion 
short reads per instrument run. Therefore, sufficient large data storage and transfer 
devices are essential.   
The delivery of high quality genome sequence and SNP calling is challenging, and is 
dependent upon development of suitable bioinformatics software and sufficient 
computing power in order to analyse the large-scale data. This includes accurate 
alignment/assembly of read data and production of error models to permit confident 
calling of novel rare SNPs (Metzker, 2010).  
The accuracy of the alignment has a crucial role in variant detection. Incorrectly 
aligned reads may lead to errors in SNP and genotype calling. Therefore, it is 
important for alignment algorithms to be able to cope with sequencing errors, as well 
as potential real differences (e.g. SNPs and Indels) between the reference genome 
and the sequenced genome.  In addition, the aligner must also be able to produce 
well-calibrated alignment quality values, as variants calls are dependent on those 
scores (Nielsen et al., 2011).   
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4.2 Aims 
An important argument for GWAS is that the genes in which common variants are 
found, or genes nearby, may well contain functional rare variants; these may have 
high enough penetrance to be considered as candidates for possible preventive 
screening strategies (Bodmer and Bonilla, 2008).  
The aims of this study were to i) investigate if the TRIM15 JHQHDPSOLFRQVµ$¶DQGµ%¶
(Figure 4.6) harbour multiple rare variants (with allele frequency between 1% to 5%) 
by analysing the next generation sequencing data, and ii) prioritizing these SNPs 
according to their potential biological functions and associations with the risk of 
LOAD.  
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Figure 4.6 Conservation plot using VISTA browser. Figure showing genomic 
position of TRIM15 µ$¶DQGµ%¶DPSOLFRQVZKLFKwere sequenced using ABI SOLiD® 
NGS. The blue vertical lines represent the locations of SNPs on the genotyping chips 
(Chapter 3). Conserved regions are indicated between the solid red lines, and the 
actual TRIM15 µ$¶DQGµ%¶DPSOLFRQVDUHindicated between the dotted red lines. The 
corresponding vertebrate species are documented on the right. Conserved regions 
are also highlighted in colours according to their function (red - introns and intergenic 
regions, blue - exons, cyan - UTRs). 
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4.3 Strategy 
The next generation sequencing pipeline performed in this study are summarized in 
Figure 4.7. The project consists of the following distinct steps: 
x Preparation of DNA samples 
x Ascertainment of DNA region for sequencing 
x Target enrichment using LR-PCR 
x Equi-molar pooling of LR-PCR products 
x Library preparation and the sequencing reaction 
x Quality assessment 
x SNP discovery and identification 
x Validation and replication 
Preparation of DNA samples 
Genomic DNA was extracted from brain tissue using QIAGEN® DNeasy Blood and 
Tissue Kit (Methods 2.2.1). Concentrations of DNA samples were measured using 
NanoDrop® (Methods 2.2.2).  
Ascertainment of DNA region for sequencing 
Two conserved regions of TRIM15 gene located at WKH¶DQG¶HQGs were 
ascertained using VISTA browser (Figure 4.6) (Method 2.3.6). The middle part of 
TRIM15 gene (region beWZHHQWKHµ$¶DQGµ%¶DPSOLFRQs) was sequenced using 
Illumina HiSeqTM (ongoing project). This region was sequenced in 96 LOAD cases 
which were separated into 8 DNA pools, where each pool comprises 12 samples. No 
control subjects were sequenced for this part of the project.   
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Figure 4.7 Overview of the next generation sequencing pipeline in this study. The flow diagram illustrates seven distinct processes 
conducted in this study: target enrichment using LR-PCR, equi-molar pooling of DNA samples, library preparation and sequencing using 
ABI SOLiD® NGS sequencer, translation of colour space calls to nucleotide calls and mapping to the reference genome sequence, 
quality assessment of the raw data, variant discovery and identification, validation using TaqMan® genotyping assays or Sanger 
sequencing. 
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Target enrichment 
Two conserved regions of the TRIM15 gene were enriched using LR-PCR (Methods 
2.2.3) on 150 samples (75 LOAD cases and controls) (Methods 2.1). These LR-PCR 
products were visualized on EtBr stained 0.7% agarose gels under UV light together 
with blank (negative controls) and the GeneRulerTM 1kb Plus DNA ladder (Methods 
2.2.4).  
DNA samples were kept for NGS only if they displayed a strong intensity band on the 
agarose gel of the correct size and no evidence of DNA contamination noted by 
examining the negative control samples. A small number (2-5) DNA samples were 
selected and Sanger sequenced (Methods 2.2.5) to ensure the DNA amplified was 
of the correct sequence by comparison to the reference sequence (hg19) 
downloaded from the NCBI database.  
Equi-molar pooling of LR-PCR products 
Four DNA pools (AD cases and controls) for TRIM15 µ$¶DQGµ%¶DPSOLFRQVZHUH
created E\SRROLQJORIHDFK3&5DPSOLILHG'1$SURGXFWVµ'1$SRROLQJ¶LQ 
Figure 4.7).  
Gel extractions were undertaken for each of the DNA pools to remove non-specific 
PCR products and primer-dimers (Methods 2.2.6). Concentrations of the cleaned 
LR-PCR products were measured using Qubit® (Methods 2.2.2).  
Two DNA pools (case and control) each containing 1µg of DNA were subsequently 
FUHDWHGµ'1$SRROLQJ¶LQFigure 4.7) by adding all LR-PCR amplicons into the pool. 
Volumes were adjusted according to the concentrations measured and the sizes of 
the amplicons.  
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The amount of DNA for each amplicon contributed to the final pool was calculated 
using the equation: 
ۯܕܗܝܖܜܗ܎۲ۼۯ ൌ ܔ܍ܖ܏ܜܐܗ܎܉ܕܘܔܑ܋ܗܖሺ܊ܘሻ ൈ ૚૙૙૙ܖ܏ܔ܍ܖ܏ܜܐܗ܎ܜ܉ܚ܏܍ܜሺ܊ܘሻ  
 
Library preparation and the sequencing reaction 
Library preparation and the sequencing reaction of ABI SOLiD® were performed by 
the next generation sequencing unit at the University of Nottingham. Sequencing 
reads were aligned using BioScope® (Methods 2.4.1).  
Quality assessment 
Raw data generated from the next generation sequencing were assessed using 
FastQC (Methods 2.4.2).  
 
Read depth and coverage 
Read depth was calculated using the formula: 
܀܍܉܌۲܍ܘܜܐ ൌ ۼܝܕ܊܍ܚܗ܎ܚ܍܉܌ܛ ൈ ۺ܍ܖ܏ܜܐܗ܎ܜܐ܍ܚ܍܉܌ܛۺ܍ܖ܏ܜܐܗ܎ܜܐ܍ܜ܉ܚ܏܍ܜܚ܍܏ܑܗܖ  
Fold coverage (per individual and chromosome) was calculated using the formula: 
۱ܗܞ܍ܚ܉܏܍ሺܘ܍ܚܑܖ܌ܑܞܑ܌ܝ܉ܔሻ ൌ ܀܍܉܌۲܍ܘܜܐૠ૞  
۱ܗܞ܍ܚ܉܏܍ሺܘ܍ܚ܋ܐܚܗܕܗܛܗܕ܍ሻ ൌ ܀܍܉܌۲܍ܘܜܐ૚૞૙  
 
 
 Next generation sequencing of TRIM15 gene using pooled DNA samples 
157 
 
An R script was written to draw the histogram depicting the fold coverage:  
rm(mydata) 
rm(count) 
rm(depth_cont) 
mydata <- read.table("mydata.txt", header=T) 
count <- 0 
for (i in mydata$cont_cov) {  
if (count == 0) { 
 depth_cont <- i 
 count <- 1 
} 
if (count > 0) { 
 if (i > 10) { 
depth_cont <- c(depth_cont,i) 
 } 
} 
} 
hist(depth_cont, breaks=300, ylim=c(0,100)) 
 
SNPs discovery and identification 
SNPs were called using Syzygy and Freebayes (Methods 2.4.3). QC thresholds 
were applied to SNP calls:  
x Base quality threshold (--bqthr): 10 
x Mapping quality threshold (--mqthr): 50 
SNPs were separated into high and low quality according to QC criteria: strand bias, 
read depth and error models as created by the software.  
SNP annotation 
SNPs were annotated using the Variant Classifier program (Methods 2.4.4). The 
Variant Classifier input file is shown in Appendix 8.2. The full transcript 
µ(167¶ from the TRIM15 JHQHµ(16*¶ was used. The 
annotation data was downloaded from the most up-to-date Ensembl database. 
)LVKHU¶VH[DFWWHVW-sided) was utilized to examine the association of SNPs 
identified with the risk of LOAD using the estimated allele counts generated from both 
pools (case and control).  
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SNPs identified by NGS were visualized using UCSC custom track (Methods 2.4.5). 
Four custom tracks were entered into the genome browser: power to detect a 
singleton, high quality SNPs (known and novel) and association p-values.  
SNP validation and replication 
SNPs identified by NGS were compared with data documented in the latest SNP 
databases: HapMap (CEU population release 28), dbSNP (release 132) and the 
1000 genome project VCF (variant call file) accessed using the tabix program 
(Methods 2.4.3).  
SNPs showing significant evidence of association (with LOAD), as suggested by 
NGS data, were validated by direct genotyping of samples that were used in creating 
the sequencing library for NGS using Sanger sequencing (Methods 2.2.4) and 
TaqMan® genotyping assay (Methods 2.2.7).  
Replication studies were performed for SNPs that validated. SNPs showing 
consistent MAF were further genotyped in an independent sample cohort (93 AD 
cases and controls) using the TaqMan® genotyping assay (Methods 2.2.7). SNP 
validation and replication experiments were performed by Narat Pititaweewat and 
Rebecca Gibbons (MSc students in our laboratory).  
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4.4 Results 
LR-PCR of TRIM15 µ$¶DQGµ%¶ 
Two conserved regions of TRIM15 gene µ$¶DQGµ%¶ were successfully amplified 
using LR-PCR. The sizes of these two amplicons are 1,984 bp and 4,935 bp, 
respectively (Figure 4.6).  
Coverage of TRIM15 gene 
The latest human genome build hg19/GRCH37 was used as the reference genome 
sequence. BoWKDPSOLFRQVµ$¶DQGµ%¶encompasses the following genomic regions 
of TRIM15 gene: 
Promoter region of TRIM15: 
x 618 bp (chr6: 30130365-30130982) upstream of TRIM15 gene 
Untranslated regions (UTR): 
x FRPSOHWH¶875OHQJWK  bp; chr6: 30130983-30131461) 
x FRPSOHWH¶875OHQJWK 40 bp; chr6: 30140127-30140466) 
Exons: 
x complete exon 1 (length = 381 bp; chr6: 30131462-30131842) 
x complete exon 6 (length = 33 bp; chr6: 30138753-30138785) 
x complete exon 7 (length = 518 bp; chr6: 30139609-30140126) 
Introns: 
x complete intron 6 (length = 823 bp; chr6: 30138786-30139608) 
x 506 bp of intron 1 (chr6: 30131843-30132348) (full size of intron 1 = 3110 bp) 
x 355 bp of intron 5 (chr6: 30138398-30138752) (full size of intron 5 = 359 bp) 
¶GRZQVWUHDPRITRIM15 gene: 
x 2866 bp (chr6: 30140467-30143332) 
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Altogether these genomic regions range from 30130365 to 30143332 on 
chromosome 6.  
LR-PCR optimisation 
Optimisation of conditions for LR-PCR is key to successful amplification of large size 
amplicons (> 1 kb), which are more sensitive to experimental conditions compared 
with amplification of small amplicons (< 1 kb). Furthermore, LR-PCRs require longer 
time to run in comparison to standard PCR using Taq polymerase.  
Experiment conditions were successfully optimised for LR-PCR amplification of 
TRIM15 µ$¶DQGµ%¶IUDJPHQWV, and the optimisation results are shown in Figure 4.8 
(Methods 2.2.3).  
LR-PCR and equimolar pooling 
TRIM15 µ$¶DQGµ%¶DPSOLFRQVwere successfully amplified by LR-PCR, pooled in 
equi-molar amounts and cleaned via gel extraction (Figure 4.9). 
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Figure 4.8 Optimisation of LR-PCR. EtBr stained 0.7% agarose gel depicting PCR optimisation result using temperature gradient 
58°C to 70°C (left), 67°C to 70°C (middle) both in presence and absence of DMSO (middle) and a gradient with varying primer 
concentrations (right). The corresponding temperature and primer concentrations are shown together with sample ID on the top of the 
gel.  B  blank (negative control), L  DNA ladder (GeneRulerTM 1kb ladder)
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Figure 4.9 LR-PCR and equimolar pooling. TRIM15 amplicons (µA¶ and µB¶) were successfully amplified in 75 AD cases and 75 
controls (left). DNA samples of the same amplicon (AD cases and controls) were pooled (middle). Gel extractions were undertaken for 
all DNA pools created, and visualized using EtBr stained 0.7% agarose gel (right).  
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General statistics and quality assessment of raw NGS data 
The raw next generation sequencing data is represented by a total of 78,133,090 
short oligonucleotide reads (case pool: 34,043,745; control pool: 44,089,345).  
82.76% of reads for the control pool (36,489,719 reads) and 87.07% of reads for the 
case pool (29,641,561 reads) were successfully mapped to the reference genome 
sequence (hg19) using BioScope® (v 1.3) (performed by the next generation 
sequencing unit at University of Nottingham). ~15% of reads produced by NGS were 
unable to be mapped to the reference genome sequence, likely to be due to the fact 
that these reads belonged to genome sequences which are repetitive.  
Of those reads that have been mapped to the reference genome sequence, 89.76% 
(26,607,720) and 91.46% (33,372,196) reads were mapped to targeted genome 
regions (i.e. regions which were enriched by LR-PCR).  
Furthermore, almost all mapped reads are of 50bp in length as expected (Figure 
4.10).  
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Figure 4.10 Read length of the control pool. The x and y axis represent read 
length (bp) and corresponding read counts, respectively. Almost all reads are 50bp in 
length as expected. The diagram was generated using FastQC (Methods 2.4.2).  
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Quality scores 
The quality of each sequencing read was measured using two scores: base quality 
and mapping quality. Base quality values are indicated as ASCII codes (range 33-73) 
(Methods 2.4.1), with each ASCII code representing a single PHRED score (range 
0-40). The relationship between a PHRED score and probability of being a wrong call 
is shown (Nielsen et al., 2011): 
۾۶܀۳۲܁܋ܗܚ܍ ൌ െ૚૙ ൈ ܔܗ܏ ࡼሺ܍ܚܚܗܚሻ 
A base quality of 40 is currently the highest quality that the NGS instrument 
(including ABI SOLiD®) can generate, which indicates a p-value of 0.0001 or the 
nucleotide call is 99.99% accurate (Table 4.1).  
Similarly, mapping quality is also represented by PHRED scores with wider quality 
score range (0-100).  
Due to the cyclic nature of the next generation sequencing, base qualities are higher 
in early cycles of the sequencing reaction, and lower in the later cycles (Figure 4.11). 
It is likely that reagents required for the experiment are diminished in the later cycles.  
Number of reads mapped to TRIM15 µ$¶DQGµ%¶DPSOLFRQV 
3,134,504 reads and 3,492,467 reads were mapped to TRIM15 JHQHµ$¶DQGµ%¶
amplicons, respectively.   
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Table 4.1 ASCII codes depicting base qualities in next generation sequencing 
data. The table shows nucleotide base qualities between 0 and 40. ASCII code is 
shown together with corresponding base quality scores (Phred scaled) and p (error) 
 likelihood of being a wrong call.  
ASCII code Corresponding base  quality p (error) ASCII code 
Corresponding 
base  quality p (error) 
! 0 1 6 21 0.007943 
³ 1 0.794328 7 22 0.00631 
# 2 0.630957 8 23 0.005012 
$ 3 0.501187 9 24 0.003981 
% 4 0.398107 : 25 0.003162 
& 5 0.316228 ; 26 0.002512 
µ 6 0.251189 < 27 0.001995 
( 7 0.199526 = 28 0.001585 
) 8 0.158489 > 29 0.001259 
* 9 0.125893 ? 30 0.001 
+ 10 0.1 @ 31 0.000794 
, 11 0.079433 A 32 0.000631 
- 12 0.063096 B 33 0.000501 
. 13 0.050119 C 34 0.000398 
/ 14 0.039811 D 35 0.000316 
0 15 0.031623 E 36 0.000251 
1 16 0.025119 F 37 0.0002 
2 17 0.019953 G 38 0.000158 
3 18 0.015849 H 39 0.000126 
4 19 0.012589 I 40 0.0001 
5 20 0.01  
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Figure 4.11 Quality scores across all nucleotide bases in the control pool. The 
x and y axis represent base position in reads and base quality (PHRED scaled), 
respectively. Nucleotide bases of high (28-40), moderate (20-28) and low (0-20) 
quality are shown in green, orange and red, respectively. The central box (in yellow) 
represents the distance between the first and third quartile with the median marked 
with a red line. The upper and lower whiskers represent the 10%-90% quartiles. The 
mean base quality scores are represented by a blue curve.  
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Power calculation 
Three power calculations were performed:  
x Power to discover SNPs given the number of samples sequenced 
x Power to detect a singleton (a single alternative allele) according to the read 
depth (number of reads aligned to target regions). 
x Power to detect an association between SNP discovered and risk of LOAD 
given the effect size (i.e. odds ratios) and allele frequencies.  
Power for SNP discovery 
Power to detect a SNP given the number of DNA samples sequenced was calculated 
and is shown in Table 4.2 using Methods 2.3.7. The power to detect a SNP with 
MAF of 0.01 using 75 samples was estimated to be 78%. As a result, this study does 
not have sufficient power to detect a SNP with allele frequency less than 0.01.  
Therefore, SNPs with MAF less than 0.01 in both AD cases and controls were 
removed from further analysis as a result of the lack of power.  
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Table 4.2 Relationship between MAF, power and sample size required. Minor 
allele frequency, power to detect SNPs and sample size required are as indicated. 
Sample size required to obtain 95% power to detect a SNP with MAF between 0.001 
and 0.5 are shown on the left. Power to detect SNPs with sequencing of 75 samples 
(with MAF between 0.001 and 0.5) are shown on the right. Power to detect SNPs 
with MAF 0.01 using 75 samples is highlighted in yellow.  
Minor allele 
frequency Power 
Sample size 
required 
 
Minor allele 
frequency Power Sample size 
0.001 0.95 1497 0.001 14% 75 
0.005 0.95 299 0.005 53% 75 
0.01 0.95 149 0.01 78% 75 
0.02 0.95 74 0.02 95% 75 
0.03 0.95 49 0.03 99% 75 
0.04 0.95 37 0.04 >99% 75 
0.05 0.95 29 0.05 >99% 75 
0.1 0.95 14 0.1 ~100% 75 
0.2 0.95 7 0.2 ~100% 75 
0.3 0.95 4 0.3 ~100% 75 
0.4 0.95 3 0.4 ~100% 75 
0.5 0.95 2 0.5 ~100% 75 
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Power to detect a singleton 
6\]\J\SURYLGHVµ--SRZHU¶IXQFWLRQto estimate power to detect a singleton (a single 
alternative allele) at each nucleotide base according to the read depth  number of 
reads that mapped to the target regions.   
The majority of the base pair positions in the TRIM15 µ$¶DQGµ%¶DPSOLFRQVVKRZHGD
power value of 100, suggesting ~100% power to detect a singleton.  
Power to detect a singleton can be calculated using the method described in 
Methods 2.3.7. For example, using the average read depth of ~20,500 in the control 
pool, the power to detect a singleton can be calculated: 
۾ሾ܌܍ܜ܍܋ܜܑܗܖሿ ൌ ૚ െ ቆ૚ െ ൬ ૚૚૞૙൰ቇ૛૙૞૙૙  ൌ ૚ െ ૛Ǥ ૡ ൈ ૚૙ି૟૙ ൌ   ?૚૙૙ ? 
 
613ZLWKWKHµSRZHU¶YDOXH given by Syzygy less than 80 have been excluded from 
further analysis.  
Power to detect an association 
Power to detect an association was calculated using QUANTO v1.2.4 and the results 
are shown in Table 4.3. As indicated, the study has 80% power to detect an 
association for common variants with OR > 3 or a rare variants with OR > 4. This 
estimation, however, should be interpreted with caution as it is based on a number of 
assumptions (such as effect size and mode of inheritance), and gene-environment 
interaction (GxE) has not been taken into account.  
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Table 4.3 Sample size required to detect an association calculated using QUANTO (v 1.2.4). The required sample sizes (to have 
80% and 95% power as indicated) were calculated for common variants (0.5 > MAF > 0.05) with odds ratio between 1.1 and 4.0, and 
rare variants (0.05 > MAF > 0.01) with odds ratio between 1.5 and 12.0. The µ¶ indicates sample size was calculated based on allele 
frequencies 0.10 to 0.20 instead of 0.05 to 0.5. All sample sizes shown are the the number of case-control pairs.  
Common Variants (0.5 > MAF > 0.05) Rare Variants (0.05 > MAF > 0.01) 
OR 
Sample required to have 
80% power 
Sample required to have 
95% power 
OR 
Sample required to have 
80% power 
Sample required to have 
95% power 
4.0* 32-47 50-76 12.0 27-107 42-172 
3.0* 48-75 76-119 11.0 28-114 45-183 
2.0 88-350 141-561 10.0 30-123 48-197 
1.9 102-412 162-661 9.0 33-135 53-216 
1.8 120-498 191-797 8.0 37-150 58-241 
1.7 145-619 232-991 7.0 41-172 66-275 
1.6 183-800 293-1283 6.0 48-204 77-326 
1.5 243-1094 389-1753 5.0 60-256 95-409 
1.4 349-1618 559-2593 4.0 81-353 129-565 
1.3 569-2719 912-4357 3.0 131-589 210-943 
1.2 1171-5768 1876-9244 2.0 350-1623 561-2601 
1.1 4264-21697 6834-34778 1.5 1094-5161 1753-8273 
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High quality SNPs 
77 high quality SNPs were called using BioScope (v1.3) (Methods 2.4.1) and Syzygy 
(v1.1.0) (Methods 2.4.3).  
21 SNPs with MAF less than 0.01 in both case and control pool were excluded from 
further analysis; 56 SNPs remained for further analysis.  
Of the remaining high quality SNPs, 31 were known and 25 were novel according to 
the dbSNP database (release#132)  
Further QC, taking into account strand bias, clustering and low read depth, were 
applied to these 25 novel variants, resulting in 15 being removed. This QC did not 
apply to known SNPs.  
Known SNPs 
All 31 known SNPs show identical alternative alleles as documented in the dbSNP 
database (Table 4.4).  
Approximately half of these SNPs (15 out of the 31) were found to be documented in 
the latest version of HapMap database (release 28 - August 2010).  
With exception of a single SNP (rs1063280), which showed a significantly different 
allele frequency in comparison to the allele frequency quoted in HapMap, comparison 
of the remaining 14 SNPs showed compelling consistency with a correlation 
coefficient (R2) of 0.966 (Figure 4.12).  
$OOHOHIUHTXHQF\RIWKHµ&¶DOOHOHDOWHUQDWLYHDOOHOHRI613UVZDVHVWLPDWHG 
to be 0.21. The frequency of the same SNP is however shown to be 0.89 in HapMap 
(CEU population release 28). The discrepancy in allele frequency suggests either the 
presence of possible population heterogeneity, an error caused by read misalignment 
or more likely a mis-call due to genotyping error. 
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Table 4.4 Comparison of alternative alleles of known SNPs. Table shows all 
known SNPs with allele frequency greater than 0.01 in the case or control pools 
identified by next generation sequencing. All alternative alleles are shown in the 
forward strand. Chromosome number (CHR), SNP identifier (SNP), base pair 
positions (BP) are as indicated together with reference allele (RA), observed 
alternative allele (Observed AA) and alternative allele documented in dbSNP 
database (release 132).  
CHR SNP BP RA Observed AA 
AA found in 
dbSNP #132 
6 rs60650863 30130456 A G G 
6 rs17188113 30131123 T G G 
6 rs62407492 30131331 T C C 
6 rs9261536 30131349 T C C 
6 rs35278640 30131503 T C C 
6 rs2523733 30131515 C A A 
6 rs11961941 30131527 G T T 
6 rs17194460 30131546 A G G 
6 rs17194467 30131585 G A A 
6 rs17194474 30131711 G C C 
6 rs2074477 30132035 G A A 
6 rs41272587 30132100 G C C 
6 rs114344980 30138489 G A A 
6 rs1029238 30138645 G A A 
6 rs1029237 30138662 C T T 
6 rs41272591 30138853 C A A 
6 rs41272595 30138865 T C C 
6 rs115440118 30138895 C T T 
6 rs41272599 30139021 A T T 
6 rs929156 30139699 G A A 
6 rs1063280 30140342 T C C 
6 rs6905949 30140525 T C C 
6 rs13212414 30140540 A T T 
6 rs2844787 30140913 G T T 
6 rs9380156 30141042 A G G 
6 rs13213365 30141204 C T T 
6 rs757258 30142253 T C C 
6 rs757257 30142458 G A A 
6 rs961039 30142674 G A A 
6 rs957765 30142690 G A A 
6 rs2394737 30142999 A G G 
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Figure 4.12 Comparison of allele frequencies with HapMap data. Scatter plot 
showing correlation between allele frequencies estimated from NGS (x-axis) and 
from HapMap (CEU population - release 28) (y-axis) in the control pool. Each SNP is 
represented by a blue diamond. Black line: expected line if allele frequencies from 
both sets are identical. The dashed line highlights that the majority of the SNPs 
exhibited similar allele frequency when compared with HapMap data (CEU 
population release 28).    
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Three out of the 31 high quality SNPs with dbSNP rs numbers showed significant 
evidence of association with risk of LOAD (uncorr-p < 0.05)  rs41272591 (p = 
0.0006), rs9380156 (p = 0.0044) and rs6905949 (p = 0.034). All three SNPs are 
common (MAF > 5%) (Table 4.5). SNPs rs9380156 and rs6905949 exist in HapMap 
(CEU population release 28) with MAF 0.16 and 0.15, respectively. SNP rs41272591 
does not exist in HapMap (CEU population release 28).  
Direct genotyping of the two most significant SNPs (rs41272591 and rs9380156) 
using TaqMan® genotyping assays using the original 75 case and control samples 
showed similar allele frequency in the case pool as estimated by NGS.  
Minor allele frequency (MAF) of SNP rs41272591: 
x Case pool: 0.20 (TaqMan) and 0.19 (NGS) 
x Control pool: 0.11 (TaqMan) and 0.05 (NGS) 
Minor allele frequency (MAF) of SNP rs9380156: 
x Case pool: 0.20 (TaqMan) and 0.17 (NGS) 
x Control pool: 0.11 (TaqMan) and 0.05 (NGS) 
Calculation of LD between the two SNPs showed strong evidence of linkage (r2 = 
DQG'¶ LQWKHFRQWUROSRRODQGU2  DQG'¶ LQWKHFDVH
pool). As a result, both SNPs showed identical and significant association with LOAD 
(p = 0.036, OR = 2.09) using the same statistical test ()LVKHU¶VH[DFWWHVW-sided)).  
Genotyping using an independent sample cohort (90 LOAD cases and 91 controls) 
showed no significant difference in allele frequencies (cases compared with controls) 
(p = 0.89, OR = 1.05), although the odds ratio appears to be in the same direction as 
suggested by the NGS.  
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Table 4.5 Summary of all high quality SNPs identified in TRIM15 µ$¶DQGµ%¶DPSOLFRQVwith dbSNP rs numbers. Chromosome 
number (CHR), base pair position (BP) and SNP identifier (SNP) are indicated together with fold coverage, power to detect a singleton 
(Power), observed alleles (reference and alternative), annotation0$)FDVHDQGFRQWUROSRRODQG)LVKHU¶VH[DFWWHVW-sided) p-
values. SNPs with association p-value (p < 0.05) are highlighted in yellow.  
CHR BP SNP Fold coverage (case/control) 
Power 
(case/control) 
Allele 
(ref/alt) Annotation 
MAF in 
case pool 
MAF in 
control pool 
)LVKHU¶VH[DFWWHVW
(2-sided) p-value 
6 30138853 rs41272591 330/402 100/100 C/A INTRON.6 +67 0.1863 0.0508 0.0006 
6 30141042 rs9380156 238/404 100/100 A/G 3' DOWNSTREAM 0.163 0.0533 0.0044 
6 30140525 rs6905949 364/372 100/100 T/C  ? ?KtE^dZD 0.0803 0.1665 0.0340 
6 30138645 rs1029238 270/266 100/100 G/A INTRON.5 +251 0.033 0.0932 0.0554 
6 30131515 rs2523733 160/152 100/100 C/A EXON.1 0.3344 0.2314 0.0725 
6 30130456 rs60650863 340/276 100/100 A/G PROMOTER -536 0.0199 0.0666 0.0853 
6 30140342 rs1063280 54/32 96/74 T/C 3' UTR 0.2476 0.1662 0.1163 
6 30131546 rs17194460 178/166 100/100 A/G EXON.1 0.0333 0.0781 0.1320 
6 30139699 rs929156 186/160 100/100 G/A EXON.7 0.2355 0.3099 0.1933 
6 30138865 rs41272595 320/392 100/100 T/C INTRON.6 +79 0 0.0199 0.2475 
6 30138895 rs115440118 386/474 100/100 C/T INTRON.6 +109 0 0.0199 0.2475 
6 30140913 rs2844787 392/420 100/100 G/T 3' DOWNSTREAM 0.7586 0.6988 0.2982 
6 30131349 rs9261536 138/186 100/100 T/C 5'UTR 0.8457 0.8938 0.3030 
6 30138662 rs1029237 262/278 100/100 C/T INTRON.5 +268 0.1969 0.2449 0.4057 
6 30142253 rs757258 152/202 100/100 T/C 3' DOWNSTREAM 0.0363 0.0603 0.4127 
6 30142690 rs957765 186/234 100/100 G/A 3' DOWNSTREAM 0.2062 0.2484 0.4907 
6 30138489 rs114344980 214/160 100/100 G/A INTRON.5 +95 0 0.0134 0.4983 
6 30139021 rs41272599 302/370 100/100 A/T INTRON.6 +235 0 0.0133 0.4983 
6 30131711 rs17194474 250/290 100/100 G/C EXON.1 0.0333 0.0533 0.5724 
6 30140540 rs13212414 374/386 100/100 A/T 3' DOWNSTREAM 0.0333 0.0533 0.5724 
6 30142674 rs961039 26/30 20/28 G/A 3' DOWNSTREAM 0.2112 0.2405 0.6793 
6 30131503 rs35278640 188/194 100/100 T/C EXON.1 0.0133 0.0278 0.6843 
6 30141204 rs13213365 258/268 100/100 C/T 3' DOWNSTREAM 0.0266 0.0401 0.7497 
6 30142999 rs2394737 316/324 100/100 A/G 3' DOWNSTREAM 0.408 0.4195 0.9067 
6 30142458 rs757257 336/378 100/100 G/A 3' DOWNSTREAM 0.4202 0.4305 0.9071 
6 30131123 rs17188113 360/420 100/100 T/G 5'UTR 0.0266 0.0266 1.0000 
6 30131331 rs62407492 156/200 100/100 T/C 5'UTR 0.0421 0.0466 1.0000 
6 30131527 rs11961941 152/144 100/100 G/T EXON.1 0.0541 0.0465 1.0000 
6 30131585 rs17194467 174/182 100/100 G/A EXON.1 0.0133 0.0128 1.0000 
6 30132035 rs2074477 358/428 100/100 G/A INTRON.1 +192 0.0255 0.0333 1.0000 
6 30132100 rs41272587 352/428 100/100 G/C INTRON.1 +257 0.0266 0.0333 1.0000 
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Novel rare variants 
Ten high quality novel variants were identified in TRIM15 µ$¶DQGµ%¶DPSOLFRQV 
(Table 4.6). All of which were estimated to have an allele frequency between 0.01 
and 0.05. No novel common variants were identified. Using the tabix program (as 
described in Methods 2.4.3), four SNPs (out of the ten) have also been identified by 
the 1000 genome project; suggesting these SNPs are likely to be genuine. dbSNP rs 
numbers have yet to be assigned to these novel SNPs.  
The average fold coverage for these high quality novel rare variants was calculated 
as 230 and 242 in the case and control pools, respectively. As a result, all ten novel 
rare variants acquired maximum power to detect a singleton, which in turn provides 
confidence in them being genuine SNPs.  
None of these novel rare variants however showed significant evidence of 
association with LOAD (p < 0.05). This is perhaps unsurprising, as an association 
study requires much larger sample size than SNP discovery.  
Interestingly, one of the rare SNPs (located at chr6: 30131558) showed an allele 
frequency of 0.00 in controls and 0.0133 in cases, was found to cause a non-
synonymous change (H33Y, histidine->tyrosine at amino acid position 33) and was 
predicWHGWREHµSUREDEO\GDPDJLQJ¶ by Polyphen-2 (Methods 2.4.4).  
Furthermore, a single high quality novel SNP (chr6: 30142265) was identified as a 
deletion RIDVLQJOHµ7¶DOOHOHRXWRIHLJKW FRQVHFXWLYHµ7¶UHSHDWV7KHfrequencies of 
this deletion were estimated to be identical in both pools (Figure 4.13). 
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Table 4.6 Summary of all high quality novel rare variants identified in TRIM15 µ$¶DQGµ%¶DPSOLFRQV.  Chromosome number 
(CHR), base pair position (BP), read coverage (per chromosome) are as indicated as well as power to detect a singleton (Power), 
observed alleles (reference and alternative), annotation, MAF in case and control pools DQG)LVKHU¶VH[DFWWHVW-sided) p-values. The 
novel rare variant that causes the non-V\QRQ\PRXVFKDQJHDQGSUHGLFWHGWREHµSUREDEO\GDPDJLQJ¶E\3RO\SKHQ-2 is highlighted in 
yellow. SNPs which have been found by the 1000 genome project are highlighted in green. As no SNPs showed significant (p < 0.05) 
evidence of association, the table is presented in ascending order of base pair coordinates. 
  
CHR BP Read coverage  (case/control) 
Power 
(case/control) 
Allele  
(ref/alt) Annotation 
MAF in 
case 
pool 
MAF in 
control 
pool 
)LVKHU¶VH[DFW
test (2-sided) 
p-value 
6 30130617 152/212 100/100 G/A PROMOTER -375 0 0.0133 0.4983 
6 30131558 174/172 100/100 C/T EXON.1 0.0133 0 0.4983 
6 30131764 254/138 100/100 C/G EXON.1 0.0133 0.0263 0.6843 
6 30132314 216/298 100/100 T/A INTRON.1 +471 0.0066 0.0133 1.0000 
6 30138476 182/134 100/100 T/C INTRON.5 +82 0 0.0198 0.2475 
6 30138597 302/316 100/100 T/A INTRON.5 +203 0 0.0133 0.4983 
6 30139155 344/426 100/100 C/G INTRON.6 +369 0 0.0133 0.4983 
6 30139396 242/264 100/100 T/G INTRON.6 +610 0.0133 0.0136 1.0000 
6 30139477 264/238 100/100 G/T INTRON.6 +691 0 0.0196 0.2475 
6 30142265 162/220 100/100 T/- 3' DOWNSTREAM 0.0133 0.0133 1.0000 
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Figure 4.13 Output from IGV viewer depicting GHOHWLRQRIDµ7¶DOOHOHIURPHLJKW FRQVHFXWLYHµ7¶UHSHDWVThe deletion is as 
LQGLFDWHGPDUNHGZLWKµ---¶ case pool on the left and control pool on the right1XFOHRWLGHEDVHVµ$¶µ7¶µ&¶DQGµ*¶DUHFRORXUHG in 
green, red, blue and brown, respectively. Chromosomal locations (on the top) are shown together with reference human genome 
sequence (hg19) (at the bottom). 
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UCSC custom tracks 
All high quality SNPs (both common and rare) identified by NGS are displayed in 
UCSC custom tracks along with comprehensive UCSC annotations (Figure 4.14 and 
Figure 4.15) (Methods 2.4.5).   
Repetitive genomic regions are more likely to suffer from power issues due to 
insufficient coverage and read depth (Treangen and Salzberg, 2011). Interestingly, 
repeat masked region (using RepeatMasker) does not necessarily imply a drop of 
power. Only a few genomic regions masked by RepeatMasker demonstrated this 
loss of read depth and power, whereas the majority acquired full power of detection 
of a singleton in comparison with non-repeat masked regions.  
Furthermore, it is noteworthy that regions that have not been masked by 
RepeatMaster occasionally show similar loss of power, however, with µsharp¶ 
appearance (instead of µbroad¶ for repeat-masked regions).  
A single region of TRIM15 µ$¶DPSOLFRQVKRZHG a drop of power to detect a singleton 
(Figure 4.14). On closer inspection (using IGV viewer (Methods 2.4.5)), this region 
was found to be highly repetitive with µ7$$$¶UHSHDWV (Figure 4.16).  
Multiple repetitive regions exist for TRIM15 µ%¶DPSOLFRQA number of these regions 
showed significantly reduction of power and ability to call SNPs (Figure 4.15).  
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Figure 4.14 Summary of high quality SNPs identified in TRIM15 µ$¶DPSOLFRQ
Power to detect a singleton is shown (at the top) together with high quality SNPs 
(both known and novel) (in the middle) and association p-values (underneath SNP 
representation). SNPs are highlighted in colours according to their chromosomal 
position and their function - red (exon, non-synonymous), green (exon, synonymous), 
EOXH875DQGEODFNLQWURQV¶XSVWUHDPRITRIM15 gene). The p-value threshold 
(p = 0.05) is represented by a horizontal line.  
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Figure 4.15 Summary of high quality SNPs identified in TRIM15 µ%¶DPSOLFRQ
Power to detect a singleton is shown (at the top) together with high quality SNPs 
(both known and novel) (in the middle) and association p-values (underneath SNPs 
representation). SNPs are highlighted in colours according to their chromosomal 
positions and functions - red (exon, non-synonymous), green (exon, synonymous), 
EOXH875DQGEODFNLQWURQV¶GRZQVWUHDPRITRIM15 gene). The p-value 
threshold (p = 0.05) is represented by a horizontal line.   
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 Figure 4.16 Output from IGV viewer VKRZLQJµ7$$$¶UHSHDWVIRXQGLQWKH
TRIM15 µ$¶DPSOLFRQ1XFOHRWLGHEDVHVµ$¶µ7¶µ&¶DQGµ*¶DUHFRORXUHGLQJUHHQ
red, blue and brown, respectively. Chromosomal locations (on the top) are shown 
together with reference human genome sequence (hg19) (at the bottom). 
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Overrepresentation of reads 
A large number of overrepresented reads (50bp either side of the original amplicons) 
were observed. This overrepresentation of reads unnecessarily wasted a large 
number of reads, and thus reduced the throughput and capacity of the next 
generation sequencing.  
This overrepresentation is caused by bias where short nucleotide fragments at both 
ends of the amplicons are more likely to be presented in the library in comparison to 
nucleotide fragments located elsewhere (Figure 4.2).  
Reducing this overrepresentation of reads is thus capable of increasing the average 
read depth across the targeted interval, and provides more power to call SNPs. A 
previous stud\VXJJHVWHGWKDWXVLQJ¶-blocked primers in LR-PCR can significantly 
reduces this overrepresentation (Harismendy and Frazer, 2009).  
It should be emphasized that this overrepresentation of reads is only applicable for 
NGS data using PCR based enrichment, and enrichment using commercial kits such 
as Agilent SureSelect® are not affected in this manner.  
As only a small number of genes were inputted into this NGS project, despite the 
reads overrepresentation issue, the average read depth and fold coverage is still far 
greater than what is generally accepted as deep/high coverage; > 20x as suggested 
by Nielsen et al., 2011 and 42x as depicted by the 1000 Genome Project (The 1000 
Genomes Project Consortium, 2010). The average coverage for all TRIM15 high 
quality SNPs was ~240-fold in the case pool and ~260-fold in the control pool 
(Figure 4.17).  
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Figure 4.17 Histogram depicting read coverage in the control pool. The x and y axis represent the fold coverage and frequency of 
reads, respectively. The overrepresented regions (i.e. 50bp each side of the amplicon) and base pair positions with less than 10-fold 
coverage are not shown. As indicated, the majority of TRIM15 sequence acquired an average read coverage between 200 and 400 fold.
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4.5 Discussion 
41 high quality SNPs were identified within the TRIM15 µ$¶DQGµ%¶DPSOLFRQVIURP
analysing the next generation sequencing data generated by ABI SOLiD® 
sequencing.  
The sequencing has been successful, as reflected by a number of observations: 
x High on-target rate  ~90% of mapped reads were found to be on target (LR-
PCR enriched regions).  
x Consistent alternative alleles  100% of known SNPs identified exhibited 
identical alternative alleles as documented in the dbSNP database.  
x Consistent allele frequencies  96.6% correlation coefficient of allele 
frequency as compared with HapMap data (14 SNPs) 
x High discovery rate  all documented SNPs in HapMap and dbSNP with MAF 
greater than 0.01 were detected.  
It is noteworthy that all allele frequencies estimated in the case and control pool are 
multiples of 0.0066, which is equivalent to one minor allele out of 150 (i.e. 1/150 = 
0.0066). For example, a SNP with three minor alleles would therefore result in a 
minor allele frequency estimation of 0.0199.  
Calculation of Power 
This study was estimated to have ~78% power to detect a SNP with minor allele 
frequency (MAF) 0.01, and ~95% power to detect a SNP with MAF 0.02 (Table 4.2).  
As only a small number of genomic regions were inputted for NGS, the majority of 
sequence regions within TRIM15 µ$¶DQGµ%¶DPSOLFRQVDFTXLUHGPD[LPXPSRZHUWR
detect a singleton. The average read-depth and fold-coverage for TRIM15 µ$¶DQGµ%¶
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amplicons were estimated to be 18,382 and 245-fold in cases and 20,543 and 274-
fold in controls (Figure 4.17).  
Discovery of a SNP is dependent upon: i) SNP present in the number of samples 
chosen to be sequenced and ii) sufficient number of high quality and well mapped 
reads overlapping the SNP site (i.e. read-depth) (The 1000 Genomes Project 
Consortium, 2010). As the throughput of NGS per run is fixed, sequencing of more 
DNA samples would avoid missing variants not represented by these samples, but 
decreases the read-depth for each individual DNA sample and therefore leads to loss 
of sensitivity and accuracy.  
The power to detect an association with the risk of LOAD is dependent upon: i) effect 
size carried by the SNP (i.e. odds ratios) and the number of samples sequenced. 
With 75 matched case and control pairs, the power to detect an association was 
estimated to be ~80% for common variants with OR A? 3 and rare variants with OR A?4 
(Table 4.3). An OR > 4 for common variants or an OR > 6 for rare variants is required 
to have 95% power.  
As rare variants are more likely to have greater odds ratios in comparison with 
common variants according to studies of multiple complex disorders (Bodmer and 
Bonilla, 2008), these variants are therefore more likely to become statistically 
significant with smaller sample sizes. None of the high quality variants identified 
within TRIM15 µ$¶DQGµ%¶DPSOLFRQV exhibited an odds ratio above 6.  
Ascertainment of base quality and mapping quality thresholds 
The base quality threshold of 10 and mapping quality threshold of 50 were used in 
this study to call SNPs using Syzygy. FreeBayes was used to validate and confirm 
the Syzygy outputs (Methods 2.4.3).  
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Base quality and mapping quality thresholds are tightly correlated; a read with low 
base quality at multiple sites of a read, results in overall low mapping quality for that 
read.   
The same base quality threshold was used in this project as used by the 1000 
genome project, and a more stringent mapping quality threshold of 50 (instead of 20) 
has been used due to the high read-depth of the NGS data (The 1000 Genomes 
Project Consortium, 2010).   
High quality rare variants 
Ten novel rare variants with MAFs between 0.01 and 0.05 were identified within the 
TRIM15 µ$¶DQGµ%¶DPSOLFRQV, none of which were shown to be associated with 
LOAD with statistical significance p < 0.05 (Table 4.3).  
Nine out of the ten were found to be single nucleotide polymorphisms (SNPs); six 
SNPs were found to be located in introns, two in exon 1, and one was shown to be 
located in a predicted promoter region of the TRIM15 gene. Of the 2 exonic SNPs, 
one (located at chr6: 30131558) was identified as a non-synonymous SNP, the other 
(located at chr6: 30131764) was found to be synonymous.  
The non-synonymous SNP appears to be particularly interesting; not only is the SNP 
predicted to cause a coding change from a positive charged histidine to a neutral 
tyrosine, but is also present in cases only (with minor allele frequency 0.0133) and 
absent from the controls. Additionally, this coding change was predicted to be 
µSUREDEO\GDPDJLQJ¶ZLWKUHVSHFWWRWKHHQFRGHGSURWHLQVWUXFWXUHE\3RO\SKHQ-2 
(Methods 2.4.4).  
A deletion variant was also detected; a VLQJOHµ7¶DOOHOHRXWRIHLJKW FRQVHFXWLYHµ7¶
repeats with a frequency of 0.0133 in both case and control pools. Interestingly, a 
known deletion variant rs5875237 has been documented in dbSNP database, at a 
 Next generation sequencing of TRIM15 gene using pooled DNA samples 
189 
 
neighbouring site (chr6: 30142266) as this variant found by NGS (chr6: 30142265). It 
is likely that the novel deletion variant found in this study is the same SNP as 
documented in the database.  
Further experimental validation (using alternative genotyping methods) of these 
SNPs are required to confirm if they are genuine and worthy of further investigation.  
High quality common variants 
Three common variants (rs41272591, rs9380156 and rs6905949) exhibited 
significant evidence of associations with LOAD.  
Two of the most significant SNPs (rs41272591 and ra9380516 which were found to 
be in tight LD), have been validated by TaqMan® genotyping assays with allele 
frequencies similar to those estimated by NGS, and did not show significant evidence 
of association using an independent sample cohort (90 cases and 91 controls) (p = 
0.89, OR = 1.05). It is perhaps unsurprising as the initial p-values do not withstand 
multiple testing after Bonferroni correction. In a study of 41 independent observations, 
assuming that 5% would be expected to appear due to chance, two SNPs would be 
expected to show a significant p-value (p < 0.05) and two have been detected.  
No further efforts were made to replicate the nominal association seen with SNP 
rs9380516.  
Low quality variants 
281 low quality variants were identified using Syzygy (Methods 2.4.3). The majority 
of these low quality variants are likely to be due to errors, as discussed below, and 
therefore no further efforts were made to validate any of them.  
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Discussion over errors of NGS using pooled DNA samples 
An accurate estimation of allele frequencies using pooled DNA samples is dependent 
upon equal representation of each individual DNA sample in the library (DNA pool) 
for sequencing.  
Although gel extractions were performed to remove undesired non-specific PCR 
products and primer dimers, this however was only undertaken after the initial DNA 
pooling (Figure 4.7).  
As the exact amount of the DNA amplicon out of the 5µl (which had been pooled) 
may vary, it is likely that some of the DNA samples are more concentrated than 
others. Ideally the library is better created by gel extractions of all LR-PCR samples 
individually, this however means more cost, longer time to perform, and potential to 
introduce errors.   
Barcoding of each individual sample prior to DNA pooling and target enrichment 
(often with short non-palindromic oligos) enables downstream identification of where 
the read has originated.  
Employing individually bar-coded DNA library samples is an alternative approach to 
solve equi-molar pooling issues, where estimation of allele frequencies is less 
sensitive to differential representation of different DNA samples in the library. 
NGS using bar-coded DNA libraries results in more accuracy in calling SNPs and 
prediction of allele frequencies. An alternative allele from individually bar-coded 
samples would be represented by 50% of reads with the same barcode, whereas by 
only 0.66% in this study. As a result, differentiating errors (caused by sequencing and 
read misalignment) from a real SNP would be much easier in bar-coded NGS data.  
Furthermore, NGS with bar-codes enables identification of each individual genotype, 
which is useful in downstream analyses, e.g. imputation, studies of LD between 
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common and rare variants and meta-analysis taking into account heterogeneity 
between samples through including covariates. However, applying an individual 
barcode to each DNA sample is significantly more expensive than using a pooled 
DNA strategy (which is considered a cost effective approach). 
Furthermore, using multiple smaller DNA pools would be better in comparison with 
using a single large DNA pool. First, each alternative allele would be representing a 
higher allele frequency, making it easier to be differentiated from errors. Second, 
validation of genotype data would be easier as sequencing of a smaller number of 
DNA samples will be required (instead of sequencing all DNA samples in the pool). 
The above therefore are all considered limitations of using a DNA pooling strategy in 
next generation sequencing.  
NGS is still at its early stage. The highest capacity sequencer currently available 
requires 8-14 days to produce data, which has limited the application of this 
technology in clinical diagnosis.  
7KHPRVWDQWLFLSDWHGµUHDO-WLPHQH[WJHQHUDWLRQ¶VHTXHQFHULVLQWULDODQGXQGHU 
development. One of the examples is nanopore technology, which claims to be able 
to sequence DNA fragments while they pass through the nanopore. This technology, 
once developed, is thought to be able to sequence the entire human genome in less 
than 24 hours for $1000 (Branton et al., 2008).  
It is foreseeable that in the not too distant future, NGS technologies will be able to 
obtain sequencing data from a single cell, allowing investigation of somatic mutations 
responsible for disease, particularly in cancer genomics (Metzker, 2010).  
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4.6 Conclusion 
A next generation sequencing pipeline was described in an effort to investigate if the 
TRIM15 JHQHµ$¶DQGµ%¶DPSOLFRQVKDUERXUed multiple rare variants that may be 
associated with disease. The pipeline described can be applied to other studies that 
use the ABI SOLiD® next generation sequencing platform. 
A total of ten high quality rare variants were successfully identified. Four of which are 
likely to be genuine as they have also been found by the 1000 genome project (The 
1000 Genomes Project Consortium, 2010). The remaining six rare SNPs are novel, 
and have not been reported before. Direct genotyping using an alternative approach 
(e.g. Sanger sequencing or TaqMan® genotyping assay) will be necessary to confirm 
if these SNPs are genuine, and worthy of further investigation.  
Furthermore, none of the high quality rare variants identified were found to be 
significantly associated with LOAD (p > 0.05). This is perhaps unsurprising, as an 
association study would require much larger sample size than SNP discovery.  
Although not statistically significant, the rare SNP (located at chr6: 30131558) 
appears to be interesting; not only as it appear to cause a non-synonymous change 
in exon 1 of the TRIM15 gene, but also as it is suggestively associated with LOAD 
(found only in cases with MAF 1.33% and absent in controls), and predicted to be 
µSUREDEO\GDPDJLQJ¶by Polyphen-2. If validated, this SNP may prove to be genuinely 
associated with AD when larger samples are analysed.  
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Chapter 5:    Genetic variants influencing human ageing from 
LOAD Genome-Wide Association Studies (GWAS) 
 
5.1 Introduction 
Human ageing has long been considered a natural process of deterioration, where 
an accumulation of damage occurs to DNA molecules, cells and tissues over the life-
time. As a result, it causes frailty and malfunctions of various parts of the body, and 
eventually leads to death. It has become increasingly evident that the human ageing 
process, like all other biological processes, is subject to regulation by signalling 
pathways and transcription factors (Kenyon, 2010).  
Human ageing and longevity are closely related. There are thoughts that achieving 
longevity might mean merely adding a few years at the late stage of a life-span. 
Others thought that increasing the life-span could slow down the ageing process (i.e. 
people stay young and healthy for longer). The latter has become increasingly 
accepted. In C.elegans, long-lived mutants appear to remain young after normal 
ZRUPVµORRN¶old by assessing the rate of tissue decline (Garigan et al., 2002; 
Herndon et al., 2002). 
Human ageing is affected by both genetic and environment factors (Cutler and 
Mattson, 2006). The heritability of ageing is estimated to be 20-30% to reach mid-
eighties estimated from twin studies (Herskind et al., 1996). Furthermore, previous 
studies have shown that siblings of centenarians have an approximately 4-fold higher 
chance of survival to their early 90s compared with siblings of individuals who die at 
73 years of age (Perls et al., 1998). A larger study conducted by the same research 
group has shown an even higher fold increase (8-18 foldLQWKHµULVN¶RIORQJHYLW\IRU
siblings of centenarians compared with random controls (US 1900 birth cohort) (Perls 
et al., 1998). Evidence indicates strong familial aggregation towards human ageing.  
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Given the fact of the likely existence of ageing genes, a large number of studies have 
been undertaken using different approaches to elucidate the genetic variants 
contributing to successful ageing and longevity. As a result, various genes have been 
reported as susceptibility loci for human ageing, such as PON1, APOE, IL6, IL10, 
GSTT1, and SIRT3 (Glatt et al., 2007; Martin et al., 2007). These candidate genes 
highlight biological pathways that maybe important in human ageing, such as 
lipid/cholesterol metabolism [GO:0006629] [GO:0008203] (APOE and PON1) (de 
Chaves and Narayanaswami, 2008; Efrat and Aviram, 2010), immune system 
processes [GO:0002376] (IL6 and IL10) (Jylhava and Hurme, 2009), drug 
metabolism [KEGG:hsa00982] (GSTT1) (Glatt et al., 2007) and energy metabolism in 
mitochondria (SIRT3) (Polito et al., 2010).  
GenAge is a database of genes related to ageing (http://genomics.senescence.info/). 
To date, over 250 genes have been recorded by the GenAge database based on 
extensive literature reviews. All of these genes have shown possible association with 
human ageing (de Magalhaes et al., 2009). Most of these genes are playing critical 
parts in a variety of biological pathways, and a significant number of these genes 
(>100) are also related to severe human diseases. It is generally believed that genes 
and bio-markers implicated in age-related diseases such as cancer, coronary artery 
disease (CAD), cerebra-YDVFXODUGLVHDVH&9'DQG$O]KHLPHU¶VGLVHDVH$'KDYH
a role in successful ageing (Panza et al., 2009; Wang et al., 2009). Identification of 
genuine ageing genes ma\XQFRYHUµPDVWHUJHQHV¶WKDWLQFUHDVHRXUXQGHUVWDQGLQJ
of many age-related diseases.  
The molecular genetics underlying the human ageing process is complex and it is 
suggested that successfully ageing is likely due to numerous genes and 
environmental factors, each exerting a small effect (Lescai et al., 2009; Plomin et al., 
2009).  
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Insights into human ageing have been gained from studying model organisms. 
Extension of lifespan can be achieved by manipulating a few genes in laboratory 
animals, such as flies, worms and mice (Kenyon, 2010). The insulin/IGF-1 (insulin-
like growth factor 1) signalling pathway has a well-established role in influencing 
lifespan within model organisms with large effect (Clancy et al., 2001; Holzenberger 
et al., 2003; Kenyon et al., 1993). Genetic inactivation of the daf-2 gene (encoding 
the IGF-1 receptor homolog in C.elegans) increases the lifespan of C.elegans by 
approximately 100% (Sebastiani et al., 2009). Interestingly, there is emerging 
evidence that genes such as IGF1/IGF1R (the orthologues of which play a major part 
in ageing in animals) can play a role in human lifespan. Loss of function mutations in 
IGF1R have been found to be overrepresented in Ashkenazi Jewish centenarians 
compared with controls (Suh et al., 2008).  
Ageing genes in human may not only increase the life-span but also postpone age-
related diseases. A previous study has indicated a significantly decreased 
prevalence of age-related diseases in offspring of long-lived parents (hypertension by 
23%, diabetes mellitus by 50%, heart attacks by 60%, and no incidences of strokes) 
compared with several age-matched control groups (Atzmon et al., 2004).  
Characterising various genetic and environmental factors influencing human life-span 
is one of the ZRUOG¶Vmajor scientific challenges (Jylhava and Hurme, 2009). To date, 
GWAS are one of the most widely adopted approaches for identifying common 
genetic variations associated with human diseases. It has been suggested that with 
increasing sample size, promising signals of association between human traits and 
genetic variants can be revealed (McCarthy et al., 2008).  
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5.2 Aims 
Age is one of the biggest risk factor for many age-related diseases including 
$O]KHLPHU¶VGLVHDVH. 7KHSUHYDOHQFHRI$O]KHLPHU¶s disease rises from less than 0.6% 
in persons aged between 65 and 69 years to over 22% in persons aged 90 years and 
older (average age-at-onset: 84) (Corder et al., 1993; Lobo et al., 2000). The risk of 
developing AD approximately doubles every five years after the age of 65 (Feulner et 
al., 2009).  
The aim of this study was to i) investigate whether WKHµNQRZQ¶/2$'JHQHVplay a 
role in human ageing, and ii) search for candidate genetic risk factors associated with 
human survival and ageing, which may merit further study.  
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5.3 Strategy 
Through collaborative efforts, a combined GWAS dataset (subject-level genotype 
data) was generated from 1,385 subjects (1,047 LOAD cases and 338 controls) with 
documented age-at-death (AAD). All of these data were subject to subsequent QC 
procedures and analysis. The data analysis was performed using PLINK (Methods 
2.3.1).  
Datasets merging and QC 
The data was obtained from nine research centres, three from the USA and six from 
the UK (ARUK consortium). All studies used the Illumina 610 QuadChip, except the 
Mayo data which used the Illumina HumanHap300 chip (Carrasquillo et al., 2009). 
The Illumina 610 QuadChip includes all SNPs presented in Illumina 300 chip, which 
enabled merging of all the datasets (Table 5.1).  
,QGLYLGXDOGDWDFKDUDFWHUL]HGDVµ$87- DXWRSV\¶or having AAD information were 
extracted from the Mayo dataset (Carrasquillo et al., 2009) XVLQJWKHµ--NHHS¶DQGµ--
make-EHG¶FRPPDQG in PLINK. This was repeated for samples from ARUK GWAS 
data (Nottingham, Bristol, Manchester, Belfast, Oxford and London), National 
Institute of Mental Health (NIMH) and Washington University (WashU) where 
possible. All GWAS datasets were transformed into the same PLINK format (1 and 2 
coding in PLINK binary format). Any samples which overlapped between GWAS 
datasets were removed. Each sample was checked individually for discrepancies 
between AAD and age at sampling (AAS). Samples with AAS greater than AAD were 
removed from further analysis. Data merging was performed using (--bmerge) in 
3/,1.XQGHU³&RQVHQVXVFDOO´PRGH (shown as merged data 1 in Figure 5.1).  
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Table 5.1 Summary of sample information. GWAS data obtained from a total of 
nine centres, three from the USA (NIMH, WashU and Mayo) and six from the UK 
(Nottingham, Bristol, Manchester, Belfast, Oxford, London). Sample size, number of 
cases and controls, males and females for each cohort are as indicated together with 
details of the mean age at death in years for cases and controls and genotyping chip 
used in each study.  
Dataset Sample Size 
AD Status 
(AD/Controls) 
Gender 
(Male/Female) 
Genotyping 
Chip 
Mean AAD 
(AD/Controls) Origin 
Mayo 434 220/214 246/188 Illumina 300 73.5/71.7 USA 
NIMH  46  46/0  12/34  Illumina 610  78.1/- USA  
WashU  332  294/38  140/192  Illumina 610  84.1/86.1 USA  
Belfast  235  213/22  99/136  Illumina 610  82.2/83.1 UK  
Bristol  59  43/16  21/38  Illumina 610  82.5/81.6 UK  
London  238  194/44  83/155  Illumina 610  86.1/83.0 UK  
Manchester  1  1/0  0/1  Illumina 610  79.0/- UK  
Nottingham  39  35/4  18/21  Illumina 610  83.6/79.5 UK  
Oxford  1  1/0  0/1  Illumina 610  79.5/- UK  
Pooled 1385 1047/338 619/766 - 81.5/76.1 - 
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Figure 5.1 GWAS data QC and data merging strategy. Flow diagram summarizing 
the processes undertaken for data preparation and QC prior to subsequent analyses. 
The data was PHUJHGWRJHWKHUXQGHU3/,1.³&RQVHQVXVFDOO´mode (Merged Data 1). 
7KLVGDWDZDVVSOLWLQWRWZRJURXSV'DWDVHWµ$¶DQGµ%¶DFFRUGLQJWRJHQRW\SLQJUDWH
(SNPs which had > 95% genotyping rate for all samples (both chips) and the rest of 
the SNPs with genotyping rate > 95% for samples typed on the Illumina 610 chip). 
Both of these groups were subject to QC separately. The two datasets were then 
PHUJHG0HUJHG'DWD'DWDVHWµ$¶ZKLFKFRQWDLQHG613VFRPPRQWRERWK
platforms) was LD pruned and merged with HapMap data (CEU, CHB/JPT and YRI) 
WRIRUPµ0HUJHG'DWD¶7KLVZDVWKHQXVHGLQD3ULQFLSDO&RPSRQHQWV$QDO\VLV
ZKLFKUHYHDOHGLQGLYLGXDOVDVJHQHWLFRXWOLHUV7KHVHZHUHUHPRYHGIURPµ0HUJHG
'DWD¶*5 genotyping rate  
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QC procedures were undertaken for the merged data to account for population 
stratification and differences in Illumina chip versions. Data merging and QC 
procedures are illustrated in Figure 5.1. The merged data was separated into two 
*:$6GDWDVHWVµ$¶DQGµ%¶XVLQJWKHµ--JHQR¶FRPPDQGLQ3/,1. 
For both of the GWAS datasets, the following QC procedures were carried out in 
order.  
1) SNPs with a genotyping rate less than 0.95 (--geno 0.05) were excluded from 
further analysis.  
2) SNPs with a minor allele frequency (MAF) less than 0.01 (--maf 0.01) were 
excluded from further analysis.  
3) A list of SNPs with 0$)¶VEHWZHHQDQGZDV generated (--freq). Within 
this shortlist, SNPs with genotyping rate less than 0.99 (--geno 0.01) were excluded 
(--exclude) from further analysis.  
4) SNPs with a Hardy-Weinberg Equilibrium p-value less than 0.001 (--hwe 0.001 --
hwe-all) were excluded from further analysis, irrespective of status (AD cases or 
controls).  
5) Individuals with a genotyping rate less than 0.95 (--mind 0.05) were excluded from 
further analysis.  
6) 8VLQJWKH*:$6GDWDVHWµ$¶DLD pruned subset of 57,160 SNPs common to all 
arrays and HapMap data (--indep-pairwise) was generated using a PERL script 
ZULWWHQµLQ-KRXVH¶Appendix 8.4.1). No two SNPs within this list had a LD r2 value 
greater than 0.2 across sliding windows (window size of 1,500 SNPs and 150 SNPs 
to shift the window). The subset of SNPs was used by EIGENSTRAT (Price et al., 
2006) for following calculations:  
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x To detect genetic outliers (See Methods 2.3.9 for definition), 
x To calculate principal components (PCs),  
x To generate a population stratification plot (as described in Methods 2.3.9) 
7) Genomic control inflation factor (OZDVFDOFXODWHGXVLQJWKH*:$6GDWDVHWµ$¶
with AAD using EIGENSTRAT (Methods 2.3.9).  
8) Extraction of PCs from EIGENSTRAT results.  
Principal component analysis (PCA) using EIGENSTRAT reduces the genotype data 
to a number of dimensions, which are defined as the top eigenvectors of a 
covariance matrix between samples (Price et al., 2006). All significant PC axes (p < 
0.05) were taken into account in the analysis. The number of PC axes to be included 
as covariates was ascertained using the method as described (Methods 2.3.9).  
After the above QC, GDWDVHWµ$¶consisted of SNPs common to both Illumina 300 and 
Illumina 610 chiSVZKHUHDVGDWDVHWµ%¶FRQVLVWHG of SNPs only common to Illumina 
610 chips. The two GWAS datasets were merged using the same methods (--bmerge) 
as described (shown as merged data 2 in Figure 5.1).  
SNPs with allele frequency bias due to inter-chip and inter-cohort differences can 
cause inflation of type I error rate. A box & whisker plot was drawn using StatsDirect 
(v 2.7.8). Only two centres (Mayo and NIMH) showed significant differences in AAD 
range compared with the rest of the data. Therefore, two logistic regression tests 
were undertaken using WashU data as a control and the Mayo and NIMH data as 
cases. The test incorporated the top six PCs and AAD as covariates. For each 
comparison, a Q-Q plot of F2 of observed versus expected p-values was generated 
using GenABEL (v1.6.4) (Aulchenko et al., 2007) (Methods 2.3.9).  
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Investigation of effect of LOAD genes in ageing 
Ten known LOAD susceptibility genes (APOE, CLU, PICALM, CR1, BIN1, ABCA7, 
MS4A6A, CD33, CD2AP and EPHA1) were tested for association with ageing using 
the most significant SNPs found in the previous GWAS (Harold et al., 2009; 
Hollingworth et al., 2011; Lambert et al., 2009; Naj et al., 2011; Seshadri et al., 2010). 
The best proxy was used to inform the effect of SNPs if they were not present in the 
merged dataset (Table 5.2).  
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Table 5.2 SNP selection. The most significant SNPs found in previous LOAD GWAS 
were selected for testing their effects with human lifespan. The SNPs, associated 
genes and the GWAS study are as indicated. LD - linkage disequilibrium shown in r2. 
µ-¶LQGLFDWHVWKHRULJLQDOLQGH[613 was used rather than a proxy.  
SNP used in 
this study Gene 
SNP cited in 
literature LD (r
2) Literature 
rs2075650 APOE rs2075650 - Harold et al., 2009 
rs11136000 CLU rs11136000 - Harold et al., 2009 
rs3851179 PICALM rs3851179 - Harold et al., 2009 
rs3818361 CR1 rs3818361 - Hollingworth et al., 2011 
rs744373 BIN1 rs744373 - Hollingworth et al., 2011 
rs3764650 ABCA7 rs3764650 - Hollingworth et al., 2011 
rs610932 MS4A6A rs610932 - Hollingworth et al., 2011 
rs3865444 CD33 rs3865444 - Hollingworth et al., 2011 
rs1485780 CD2AP rs9349407 0.913 Hollingworth et al., 2011 
rs11767557 EPHA1 rs11767557 - Hollingworth et al., 2011 
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Genome-wide association studies 
Quantitative Trait (QT) analysis of all SNPs was performed using multivariable linear 
regression (--linear) adjusted for AD status, gender and the top six PCs (Methods 
2.3.1). AAD was used as a continuous trait in this analysis thus giving maximum 
statistical power. Manhattan plots were drawn using Haploview (v 4.1) to visualize 
GWAS results (Methods 2.3.5). A histogram of AAD of all individuals that passed QC 
was drawn using StatsDirect software (v 2.7.8).  
Each SNP was annotated with its gene name using the PLINK gene report function 
(Methods 2.3.1DQGD3(5/VFULSWGHYHORSHGµLQ-KRXVH¶Appendix 8.4.4).  
Genotyping of SNP rs4110518 
SNP rs4110518 was genotyped using an independent sample cohort (n = 487) using 
TaqMan® genotyping assay (Methods 2.2.7).  
Power calculation 
Power calculations were undertaken using QUANTO v1.2.4 (Methods 2.3.8). The 
required sample size was estimated using an additive model created by the software.  
MAF analysis of SNPs responsible for LOAD 
The full range of AAD (58-108 years) was separated into five age-at-death categories, 
the boundaries of which were selected to ensure each group contains an 
approximately equal number of samples. 7KLVZDVFDUULHGRXWXVLQJ³*URXSLQJ !
&DWHJRULVH´IXQFWLRQLQ6WDWV'LUHFW)RUHDFKRIWKH/2$'JHQHORFLWKHDOOHOH
frequency was calculated and stratified by AAD category.  
The separation into five age-at-death categories were used only to facilitate 
visualisation of MAF of candidate SNPs in the different age ranges, and was not 
used to generate p-values.  
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5.4 Results 
Dataset composition and QC 
The combined GWAS dataset had a sample size 1,385 before QC. After QC, four 
participants were removed for low genotyping rate (--mind 0.05) from Mayo GWAS 
(Carrasquillo et al., 2009). A single sample from Bristol was removed due to 
discrepancies between AAD and age-at-onset (AAO). An additional 16 samples were 
removed as genetic outliers by PCs analysis using EIGENSTRAT. This included 14 
samples from the Mayo data, one from NIMH and one from Belfast. The mean AAD 
in the pooled dataset (post QC) was greater than 80 years of age (Table 5.1).  
The AAD histogram follows a normal distribution (Figure 5.2), with mean AAD of 
80.2 years of age (SD = 8.9 years). The box and whisker plot depicting AAD of each 
centre was as illustrated (Figure 5.3).  
The multidimensional scaling plot (MDS) demonstrated three distinct clusters. As 
expected, each cluster represents different population ancestry - European (CEU), 
Asian (CHB and JPT), and Yoruban (YRI) (Figure 5.4). UK, USA and HapMap_CEU 
samples formed a single cluster. On closer inspection, slight deviation between UK 
and USA samples exists and this was accounted for by including PCs as covariates. 
Genomic control inflation factor (O) was calculated using EIGENSTRAT by iteratively 
including zero to ten PCs (Price et al., 2006). Including six PCs generated the lowest 
genomic control inflation factor (O = 1.003) (Table 5.3).  
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Figure 5.2 Histogram plot representing the spread of AAD of samples included 
in this study. The x and y axis represents age-at-death (AAD) in years and number 
of individuals, respectively. This graph follows a normal distribution, with mean AAD 
80.2 years (n = 1,385). 
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Figure 5.3 Box and whisker plot, showing the Age at Death (AAD) distribution 
for each centre. The central box represents the distance between the first and third 
TXDUWLOHVZLWKPHGLDQPDUNHGZLWKDGLDPRQG7KHFLUFOHVLQGLFDWHWKDWDQLQGLYLGXDO¶V
AAD is outside 2 times the interquartile range. The dashed rectangle highlights that 
the majority of the data have a similar range of AAD with the exception of the NIMH 
and Mayo data.  
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Figure 5.4 Multi-dimensional scaling (MDS) plot depicting the Principal Component Analysis of Merged Data 3. Population 
stratification was tested using HapMap data #23 as reference. UK and USA and HapMap CEU samples formed a single cluster (shown 
inside the dashed rectangle). One HapMap individual from the Asian samples appears to have dual ethnicity. The diagram inset shows 
a magnified section of UK, USA and HapMap CEU samples.  
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Table 5.3  Calculation of genomic control inflation factor (O). Table showing 
genomic control inflation factor (O) calculated before and after taking into account 
population stratification. The top six PCs were used in subsequently analyses as 
covariates (highlighted yellow).  
Number of top 
PCs adjusted O (before) O (after) 
0 1.020 1.020 
1 1.020 1.018 
2 1.020 1.018 
3 1.020 1.007 
4 1.020 1.008 
5 1.020 1.006 
6 1.020 1.003 
7 1.020 1.003 
8 1.020 1.003 
9 1.020 1.004 
10 1.020 1.005 
 
  
 Genetic variants influence human ageing from LOAD GWAS 
210 
 
It was noted that there is a difference in AAD between LOAD cases (mean AAD = 
81.63 years) and controls (mean AAD = 76.09 years), and similarly between male 
(mean AAD = 77.93 years) and female (mean AAD = 82.17 years). ANOVA tests of 
the variance of AAD between these groups were found to be significant (p < 0.001). 
This confirmed that AD status and gender were appropriate covariates.   
After stringent QC, there were 1,364 samples (1,031 LOAD cases and 333 controls, 
608 male and 756 female) and 528,430 SNPs remaining for further analysis.  
Analysis and results 
Assessment of the ten LOAD susceptibility genes yielded compelling evidence of 
association between APOE locus (rs2075650) and human ageing (uncorr-p = 5.27 x 
10-4), which withstood multiple testing after Bonferroni correction for ten independent 
tests (Table 5.4A).  
In addition to examining the association of these ten LOAD susceptibility genes with 
ageing, analyses including all SNPs on the Illumina 610 chip (post QC) were 
undertaken. The genome-wide significance threshold was calculated (p = 1.04 x 10-7) 
using Bonferroni correction for the number of independent tests (N = 483,066), which 
was estimated using Methods 2.3.3.  
No variants appear to be associated with ageing with a genome-wide level of 
significance (p < 1.04 x 10-7). There were 41 SNPs with p-value (p  5 x 10-5). These 
SNPs span the genome, representing 35 distinct signals (pairwise r2  0.8) across 13 
chromosomes. 24 of them are located within 20kb of known human genes with a 
wide range of functions. SNPs with p-value (p < 5 x 10-5) are shown in Table 5.4B. 
These signals are at best tentative but may merit study in larger sample sets.  
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Table 5.4 Summary of results. Table showing the results of the analysis of A) the 
ten documented LOAD susceptibility loci (APOE, CLU, PICALM, CR1, BIN1, ABCA7, 
MS4A6A, CD33, CD2AP and EPHA1) with human ageing. B) SNPs (rs number 
[major/minor allele]) with association p-value < 5 x 10-5. Chromosome number (CHR), 
base pair position (BP) and gene name (Gene) is shown together with p-value (P) 
DQGGLUHFWLRQRIHIIHFWµ¶LQGLFDWHVWKHPLQRUDOOHOHRIDQ\JLYHQ613 is protective, 
ZKHUHDVµ-¶PHDQVWKHPLQRUDOOHOHRIWKH613KDVD detrimental effect on ageing. In 
table B), the gene name is shown if the SNP is within 20kb of a known gene.  
A) 
SNP 
[major/minor] CHR BP Gene P 
Direction of 
Effect 
rs2075650[T/C] 19 50087459 APOE 5.27E-04 - 
rs3764650[A/C] 19 997520 ABCA7 1.35E-01 - 
rs610932[C/A] 11 59695883 MS4A6A 1.76E-01 + 
rs3851179[G/A] 11 85546288 PICALM 2.27E-01 + 
rs11767557[A/G] 7 142819261 EPHA1 2.67E-01 - 
rs3865444[C/A] 19 56419774 CD33 4.42E-01 + 
rs3818361[G/A] 1 205851591 CR1 5.63E-01 + 
rs1485780[A/C] 6 47664589 CD2AP 6.04E-01 - 
rs744373[A/G] 2 127611085 BIN1 6.89E-01 + 
rs11136000[G/A] 8 27520436 CLU 9.75E-01 - 
B) 
SNP 
[major/minor] CHR BP Gene P 
Direction of  
Effect 
rs987839[T/C] 12 21266105 SLCO1B1 3.19E-06 + 
rs17205854[G/A] 5 64458658 
 
3.74E-06 + 
rs17811551[T/C] 5 64462993 ADAMTS6 3.74E-06 + 
rs1857821[A/G] 4 77101003 NAAA 5.12E-06 + 
rs7525717[G/A] 1 56700226 
 
5.76E-06 - 
rs4673651[A/G] 2 212712848 ERBB4 6.08E-06 - 
rs17049647[G/T] 2 130093855 
 
7.12E-06 + 
rs10518142[G/T] 4 77061898 NAAA 8.89E-06 + 
rs2444861[A/G] 8 99170108 C8orf47 8.99E-06 + 
rs1418425[G/A] 1 111270409 
 
9.64E-06 - 
rs2271528[C/T] 4 77107860 SDAD1 1.02E-05 + 
rs1555453[A/C] 9 27316780 MOBKL2B 1.07E-05 + 
rs13111494[A/G] 4 77204512 ART3 1.28E-05 + 
rs12740413[C/T] 1 16388466 ARHGEF19 1.30E-05 - 
rs3210458[C/T] 3 142494320 ACPL2 1.52E-05 + 
 Genetic variants influence human ageing from LOAD GWAS 
212 
 
 
 
 
 
  
rs4859571[G/A] 4 77076333 NAAA 1.56E-05 + 
rs7803143[T/C] 7 6211011 PSCD3 1.57E-05 - 
rs7622678[T/C] 3 198798845 BDH1 1.93E-05 - 
rs4720752[G/A] 7 7735965 RPA3 1.93E-05 - 
rs6962026[C/T] 7 6213048 PSCD3 2.07E-05 - 
rs10901296[C/T] 9 132755477 ABL1 2.37E-05 + 
rs680109[C/A] 11 105255919 GRIA4 2.52E-05 + 
rs1537438[G/T] 13 26806973 
 
2.53E-05 + 
rs11206814[C/T] 1 56690636 
 
2.67E-05 - 
rs12562047[A/C] 1 164095780 UCK2 2.70E-05 + 
rs2710548[A/G] 4 126492980 FAT4 2.79E-05 - 
rs6454676[C/T] 6 88934174 
 
2.90E-05 + 
rs17047650[C/T] 3 68547103 FAM19A1 3.19E-05 + 
rs10433502[C/T] 3 68569792 FAM19A1 3.49E-05 + 
rs10485170[T/C] 6 88939371 
 
3.67E-05 + 
rs12257410[A/C] 10 13832528 FRMD4A 3.77E-05 + 
rs3125524[C/T] 10 133104931 
 
3.83E-05 + 
rs4280854[A/G] 5 105923201 
 
3.85E-05 + 
rs1037381[A/G] 2 105669675 
 
3.99E-05 - 
rs6532496[A/G] 4 95799427 PDLIM5 4.00E-05 - 
rs17618813[G/A] 4 114153483 ANK2 4.16E-05 + 
rs7103504[G/A] 11 99006474 CNTN5 4.39E-05 - 
rs10085518[C/T] 7 6252040 PSCD3 4.59E-05 - 
rs4686837[G/A] 3 188222371 ST6GAL1 4.60E-05 + 
rs6491207[T/C] 13 26828900 
 
4.63E-05 + 
rs7952321[G/T] 11 55539349 OR5AS1 4.68E-05 - 
 Genetic variants influence human ageing from LOAD GWAS 
213 
 
Without conducting logistic regression comparison, initial analysis of the association 
study suggested two genome-wide significant SNPs - rs4110518 (p = 5.96 x 10-9) 
and rs2944476 (p = 2.19 x 10-8). Comparing SNPs between NIMH and WashU data 
showed no significant difference in allele frequency, whereas five SNPs showed 
significant difference in allele frequency comparing Mayo data with WashU data after 
taking into account population stratification (i.e. PCs) and AAD. These five SNPs are 
rs4110518, rs2944476, rs10460926, rs10953303, rs7172278 (Figure 5.5 and Figure 
5.6).  
It is perhaps unsurprising that the two SNPs which showed genome-wide level of 
significance overlap with the five SNPs that showed significant bias between Mayo 
and WashU data, as the AAD of the Mayo data is significantly younger (as previously 
described). It is not possible to correct for centre, as the spread of the AAD is 
considered crucial in detecting genuine ageing associated variants. The difference in 
allele frequency due to samples with young AAD in Mayo and old AAD in WashU 
may well represent genuine associations. Including centre as a covariate would 
abolish the ability to detect this effect.  
The Manhattan plot shown in Figure 5.6 represents a scenario before removal of 
these five false positive SNPs.  
TaqMan® genotyping of SNP rs4110518 
SNP rs4110518 was genotyped using TaqMan® genotyping assay (Methods 2.2.7). 
A total of nine samples (four major homozygotes, four heterozygotes and one minor 
homozygote with GWAS data) were genotyped using the assay as positive controls. 
The positive control results showed identical genotypes as derived from the GWAS 
chips. The replication cohort consisted of 462 samples (Figure 5.7).  
As expected, SNP genotype data (rs4110518) from the replication cohort showed no 
significant evidence of association with human ageing (p = 0.5064). 
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Figure 5.5 QQ plot of F2 - F2 p-values to determine bias in SNP frequencies observed in Mayo (a), NIMH (b) versus WashU data. 
a) Logistic regression (Mayo versus WashU samples) adjusted for the top six PCs and AAD. Five SNPs (circled) showed significant bias 
in the Mayo compared with WashU data taking into account population stratification and AAD. b) Logistic regression comparing NIMH 
data versus WashU data taking into account population stratification and AAD. No bias was observed in NIMH compared with WashU. 
Solid line: expected under null hypothesis i.e. no significant difference (or no significant association); Open circles: data points. Red line: 
fitted slope of all data points. The diagram was drawn using GenABEL in R (v2.12.1).  
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Figure 5.6 Manhattan plot of GWAS in human ageing. Chromosomal position is 
shown on the x-axis versus -log10 GWAS p-value on the y-axis. The threshold for 
genome-wide significance (p = 1.04 x 10-7) and p-value threshold (p = 5 x 10-5) are 
indicated by the horizontal lines. SNPs between these thresholds show ³VXJJHVWLYH´
associations. The five SNPs (highlighted by circles) exhibit significant differences in 
allele frequencies between samples from Mayo and WashU (see Figure 5.5). Two of 
the five SNPs (rs4110518 and rs2944476) showed spurious genome-wide significant 
signals as a result of this bias.  
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Figure 5.7 TaqMan® genotyping assays for SNP rs4110518. TaqMan® results, dual scatter plots, are shown for positive control 
samples and the six 96-well plates (P1 to P6). The HEX and FAM signal thresholds are indicated by horizontal lines (green  HEX and 
blue  FAM). Individual genotypes are determined according to the signal intensities of both TaqMan® probes (HEX/FAM): depicted 
using different coloured points  EOXHLQGLYLGXDOKRPR]\JRXVIRUWKHPDMRUDOOHOHµ&¶UHGLQGLYLGXDOKRPR]\JRXVIRUWKHPLQRUDOOHOH
µ7¶JUHHn (heterozygote) and yellow (no template controls). The corresponding amplification curves are shown in Appendix 8.3.  
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Power Calculation 
Power calculations indicate that a sample size between ~3,000 and ~15,000 is 
required in order to have 80% power to detect an association with a MAF ranging 
above 0.05. Approximately ~4,000 to ~19,000 samples will be needed if 95% power 
is required.  
This estimation should be interpreted with caution as it is based on a number of 
assumptions (such as effect size and mode of inheritance), gene-environment 
interaction (GxE) has also not been taken into account.  
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5.5 Discussion 
It is known that age is one of the biggest risk factors for LOAD. The prevalence of 
LOAD was estimated ranging from 0.6% in persons aged 65 to 69 years to 22.2% in 
persons aged 90 and older (Lobo et al., 2000). Since age is one of the biggest risk 
factors for LOAD, it is important to understand whether genes involved in LOAD play 
a role in successful ageing and longevity.  
In this study, an association test of the top GWAS LOAD genes (APOE, CLU, 
PICALM, CR1, BIN1, ABCA7, MS4A6A, CD33, CD2AP and EPHA1) with human 
ageing was performed using the most significant SNPs found in previous studies. 
Apart from the well documented association between APOE and LOAD, the 
association with the other nine genes was identified recently through large GWAS, 
each with a sample size of over 10,000 (Harold et al., 2009; Hollingworth et al., 2011; 
Lambert et al., 2009; Naj et al., 2011; Seshadri et al., 2010).  
The results of this study provided compelling evidence of association between APOE 
locus (rs2075650) and human ageing (p = 5.27 x 10-4) (Table 5.4A) with risk effect 
based on the analysis of 1,364 samples using AAD as a continuous trait. The minor 
allele frequency plot (Figure 5.8) shows that the MAF of this SNP significantly 
decreases in the old AAD category (MAF = 0.21, AAD > 89 years of age, n = 228) 
compared with the other four younger AAD categories (MAF = 0.27, AAD  89, n 
=1,136),QWHUHVWLQJO\LQGLYLGXDOVKRPR]\JRXVIRUWKHPLQRUDOOHOHµ*¶VKRZHG
significantly lowered AAD (p = 0.002) compared with individuals homozygous for the 
PDMRUDOOHOHµ$¶1RHIIHFWZDVVHHQIRUWKHLQGLYLGXDOVFDUU\LQJµ$*¶JHQRW\SHp = 
0.891).  
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Figure 5.8 Minor Allele Frequency (MAF) analysis for ten LOAD genes with respect to ageing. The figure shows the relationship 
between SNP MAFs and human ageing, where AAD is separated into five categories. Each AAD category contains roughly equal 
amounts of samples to avoid bias in sample sizes. All ten documented LOAD genes are shown together with the APOE locus 
highlighted in red (all other loci in grey). The APOE locus (rs2075650) showed significant association with ageing, with MAF = 0.27, 
$$'\HDUVRIDJHQ DQG0$) $$'! 89 years of age (n = 228). None of the other gene loci were significantly 
associated with ageing. The analysis of quantitative trait was conducted on the whole dataset. The stratification of age at death into five 
age-at-death categories was only used to facilitate visualisation of the minor allele frequency of the candidate genes in the different age 
ranges, and was not used to generate p-values.  
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To date, APOE has been extensively examined with respect to human ageing due to 
its role in AD and vascular disease. A longitudinal study following subjects for 18 
years using 1,094 individuals aged 75 and older showed that the risk of mortality was 
affected by the APOE gene. Risk was increased by 22% in those carrying the APOE 
İ4 allele, decreased by 28% in those carrying the APOE İ2 allele, and individuals 
carrying the APOE İ3 allele showed no significant difference in risk (Lewis and 
Brunner, 2004; Rosvall et al., 2009). The association between APOE İ2 variant and 
ageing has been investigated in Finish centenarians, where a trend of association 
was observed  9%, 21%, and 25% in people aged 100 to 101, 102 to 103 and 104 
years and older, respectively (Frisoni et al., 2001). SNP rs2075650 is known to be in 
tight LD with the APOE İ allele (Yu et al., 2007). The direction of the effect of 
rs2075650 in this study is compatible with previous findings for the APOE İ4 allele 
(Christensen et al., 2006). APOE is a major transporter of cholesterol and has been 
implicated in multiple age-related diseases including LOAD and vascular diseases 
(Panza et al., 2007).   
No evidence of association was observed with the remaining LOAD genes implying 
that these genes are genuine LOAD genes with no detectable effects on human 
ageing. However, the possibility of these genes having weak effects on ageing that 
the dataset analysed was not sufficiently large enough to detect cannot be ruled out.  
All SNPs on the Illumina chips were subsequently analysed after stringent QC 
procedures. The mean AAD for the samples analysed was over 80 years (Table 5.1). 
This minimized the possibility of early death (prior to age 40 years) as a result of 
underlying non-genetic factors or highly penetrant genetic factors affecting the 
analysis (McGue et al., 1993).   
In an assessment of all SNPs on the chip, none were found to approach genome-
wide significance as calculated for this study (p < 1.04 x 10-7). The inability to detect 
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any novel ageing associated variants is likely the result of a lack of power. The 
calculation of power using QUANTO (v 1.2.4) has suggested a much larger sample 
size is required in order to detect an association with common variants. With rare 
exceptions, common variants are known to exert only small to moderate effects, 
according to previous studies of many complex disorders and traits (Bodmer and 
Bonilla, 2008).  
GWAS provide a method of identifying common genetic variations associated with 
disease or phenotype in an unbiased manner. However, it comes with a price of 
correction for multiple testing given that hundreds and thousands of SNPs are tested 
simultaneously. A very stringent significance threshold (p < 5 x 10-8) is often used to 
infer a genome-wide significant association and to avoid large number of false 
positives (Bertram et al., 2008).  
The analysis was conducted using AAD as a quantitative trait; this is believed to 
provide more power compared with a traditional case/control approach. The 
advantage of statistical power gained compared with the case/control analysis is 
dependent upon the design of the study. For example, dichotomizing the AAD 
distribution into cases and controls would give less power than comparing the low 
and high extremes of the quantitative trait (Plomin et al., 2009). Increasing statistical 
power by including more samples is imperative to elucidate genuine genetic 
associations in this study. Including more samples with the extreme phenotypes (e.g. 
exceptional longevity - nonagenarians and centenarians) would give more power 
than addition of samples of average AAD (Plomin et al., 2009; Tan et al., 2010). 
Domestic and international collaborations are often required to raise sufficiently large 
sample sizes in order to have adequate power to detect genuine disease 
associations. This is especially true for SNPs with a small effect size. However, such 
combined analysis can in some instances generate new problems. For instance, 
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inter-chip and inter-cohort differences could create spurious genome-wide significant 
associations. More importantly, these SNPs may pass all conventional QC filtering 
(e.g. Hardy Weinberg Equilibrium p-value, minor allele frequency, genotyping rate 
threshold) increasing the likelihood of generating false positive results, which are not 
corrected for by principal component analysis.  
As shown in Figure 5.5 and Figure 5.6, ignoring comparison of data from centres 
(Mayo and WashU) gave spurious genome-wide significant associations (rs4110518, 
p = 5.96 x 10-9 and rs2944476, p = 2.19 x 10-8). Therefore, extra caution should be 
made when performing GWAS analysis which utilises data from multiple centres.  
Including µ&entre¶ as a covariate has been widely used to solve such problems raised 
by centres and this is largely effective. However this is not always possible, 
especially in circumstances where the number of cases and controls are significantly 
different between centres. In this study, correcting for centre was not possible due to 
the AAD bias in the centres sampled. The overall spread of AAD is crucial to this 
analysis and the difference in allele frequency between individuals with relatively 
young AAD (Mayo) and relatively old (WashU) may well represent genuine 
associations.  
Furthermore, samples were included from both LOAD cases and controls in this 
study which is intended to achieve maximum power to detect novel ageing 
associated variants. Ideally this test is better performed using only control samples. 
&RQVLGHULQJWKDWµSXUHFRQWUROV¶ZKHUHLQGLYLGXDOVGLHZLWKRXWH[SHULHQFLQJDQ\DJH-
related diseases probably do not exist, it was considered valid to undertake an 
analysis using both sets. However, due to the large number of AD cases that have 
been used relative to the number of controls (about three quarter of the total), any 
association with human ageing implicated in the study may be biased and specific to 
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the AD population. Follow-up studies using only control samples will be required to 
confirm these associations.  
5.6 Conclusion 
In this chapter, a study was conducted to investigate genetic factors influencing 
human ageing using LOAD GWAS data from the GERAD1 (Genetic and 
(QYLURQPHQWDO5LVNIRU$O]KHLPHU¶V'LVHDVH and Mayo GWAS datasets that had 
documented age-at-death (Table 5.1).  
The study, which consists of both a candidate gene study and genome-wide analysis, 
were conducted using age-at-death as a quantitative trait, a method likely to provide 
more power than a traditional case/control analysis (Plomin et al., 2009).  
Testing of WKHµNQRZQ¶/2$'JHQHVIRUDssociation with human ageing may provide 
insights on whether these genes are directly associated with the disease or indirectly 
by allowing successful ageing. The APOE locus (rs2075650) showed compelling 
evidence of association with human ageing with a p-value which withstood multiple 
test correction for ten independent tests (uncorr-p = 5.27 x 10-4); the number of 
genes tested. This effect is consistent with previous reports of an association of the 
APOE locus with human ageing (Deelen et al., 2011; Panza et al., 2009).  
None of the other nine genetic loci (CLU, PICALM, CR1, BIN1, ABCA7, MS4A6A, 
CD33, CD2AP and EPHA1) showed significant evidence of association (uncorr-p > 
0.05), suggesting these genes are genuine LOAD genes with no detectable effect on 
ageing in this study.   
No SNPs were found to approach genome-wide significance in an assessment using 
all SNPs available on the genotyping chips after stringent QC. This is likely to be due 
to the lack of power. Increasing statistical power by including more samples, 
especially individuals with exceptional longevity (e.g. nonagenarians and 
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centenarians), will be imperative in identification of genuine genetic association with 
human ageing.  
Presenting data on genes that lie between 10-5 and 10-8 (Table 5.4B) may enable 
groups to identify genes for future study especially if there is overlap with other 
studies. Additionally this data could be used as part of a larger meta-analysis.   
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Chapter 6:     General discussion
$O]KHLPHU¶VGLVHDVHLVWKHPRVWSUHYDOHQWIRUPRIGHPHQWLDUHSUHVHQWLQJWKHPDMRULW\
(~60%) of dementia cases. Approximately 35 million people are affected by 
$O]KHLPHU¶s disease worldwide as of 2009, and it has been estimated that this figure 
will increase to ~65 million and ~115 million by 2030 and 2050, respectively (Ferri et 
al., 2009).  
In Mendelian disorders, presence or absence of a disease is often caused by 
mutations in a single gene. These mutations are found to be 100% penetrant (i.e. all 
individuals would get the disease if they carry the mutation). As opposed to 
Mendelian type of disorders, the penetrances of genetic factors found responsible for 
LOAD are low. As a result, it is intractable to map these genes through linkage 
analysis using family pedigrees with the exception of APOE İ(Brookfield, 2010).  
GWAS is a powerful approach in identifying susceptibility genes responsible for 
common diseases. In comparison with candidate gene studies, GWAS is known to 
have several major advantages: 
x not limited to pre-defined set of candidate genes, 
x the ability to adjust and account for complex population substructures (e.g. 
principal component analysis using EIGENSTRAT), 
x fine mapping via imputation analysis,  
x serve as a replication dataset for proposed associations without having to 
perform additional genotyping experiments (Bertram, 2011).  
Since 2009, nine novel genetic loci (in addition to APOE İhave been unequivocally 
identified and confirmed by several large GWAS as associated with the risk of LOAD 
though large consortium efforts (Harold et al., 2009; Hollingworth et al., 2011; 
Lambert et al., 2009; Naj et al., 2011; Seshadri et al., 2010).  
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These genes highlighted biological pathways: immune system function, cholesterol 
metabolism, synaptic cell membrane processes and endocytosis, which provide 
novel insights into the development of effective therapeutic treatments and more 
accurate diagnosis (Morgan, 2011). 
Despite recent success in identification of common variants associated with risk of 
LOAD, there is increasing evidence that a substantial fraction of the genetic variation 
contributing to AD risk remained unexplained (See Introduction 1.9).  
Insufficient power has meant a large number of early GWAS failed to generate any 
convincing results. From 2007 to 2009, there were ten published GWAS of AD 
performed by individual research teams reporting on nine distinct datasets. Although 
nearly all these studies confirmed the association with the APOE locus, collectively 
very few novel AD risk genes were identified, and nearly all these findings were not 
confirmed in independent samples (Sherva and Farrer, 2011).  
A cross-platform meta-analysis of four GWAS was performed in an effort to search 
for novel genetic associations (Chapter 3), as combining individually underpowered 
GWAS would increase power thus allowing identification of novel genetic risk factors 
associated with LOAD. A single SNP rs929156 located in exon 7 of TRIM15 gene 
showed a significant evidence of association with risk of LOAD (uncorr-p = 8.77x10-8), 
and the random effect meta-analysis of odds ratios was also found significant (p = 
0.03). The minor allele of this SNP was found to be risky with odds ratio 1.11 (95% CI 
1.01-1.22). 
 An approach was described in this study which may prove to be useful when larger 
datasets are utilized. In addition, a PERL script was written to automate the cross-
platform GWAS meta-analysis using FishHU¶VFRPELQHGSUobability test (Chapter 3).  
Given the hypothesis that GWAS signals may be attributable to multiple rare variants 
nearby (Dickson et al., 2010), it is imperative to determine whether the region 
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surrounding the GWAS SNPs harbours multiple rare variants which are associated 
with the disease.  
A next generation sequencing pipeline was described which can be applied to other 
studies which use the ABI SOLiD® next generation sequencing platform.  
Evolutionary conserved regions encompassing the SNP (rs929156) were enriched by 
LR-PCR and sequenced using ABI SOLiD® next generation sequencing (Chapter 4). 
A pooled DNA strategy using 150 samples (75 LOAD cases and controls) was 
employed, where each pool was estimated to provide ~80% power to detect a SNP 
with an allele frequency of ~1%, and >95% power to detect a SNP with allele 
frequency above 2%. 
SNP rs929156, which was found significantly associated with LOAD from the cross-
platform meta-analysis, did not however show significant evidence of association by 
analysing the NGS data (uncorr-p = 0.193). This is perhaps unsurprising as the 
number of samples sequenced by NGS is likely to be underpowered for a 
case/control study.  
With respect to SNP discovery, all 31 SNPs with documented allele frequency 
greater than 1% in the latest SNP databases (dbSNP#132 and HapMap#28 CEU 
population) were identified. All of which exhibited identical alternative alleles as 
documented in the database. With the exception of a single SNP, the remaining 14 
SNPs showed a compelling correlation coefficient (96.6%) of allele frequency in 
comparison to the allele frequency quoted in the HapMap database (CEU population, 
release 28).  
Ten high quality novel rare variants were identified after in-depth quality control 
measures. Four of which have also been discovered by the 1000 genome project, 
suggesting these SNPs are likely to be genuine (The 1000 Genomes Project 
Consortium, 2010).    
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Genotyping of the remaining novel rare variants using alternative genotyping 
methods (e.g. TaqMan® genotyping assay, Sanger sequencing) are required to 
confirm if they are genuine SNPs, and worthy of further investigations.  
Three common SNPs (rs41272591, rs9380156 and rs6905949) with MAF greater 
than 5% showed significant (p < 0.05) evidence of association with LOAD. The top 
two SNPs were validated using TaqMan® genotyping assays with allele frequency 
similar to those estimated by NGS. Genotyping of an independent sample cohort (90 
LOAD cases and 91 controls) however failed to achieve significance (p = 0.89).  
As a pilot study, the NGS study has only a limited power to detect an association: ~ 
80% power to detect common variants if OR > 3 and rare variants if OR > 4 
estimated using QUANTO (v 1.2.4).  
None of the rare variants were found to be significantly associated with LOAD, which 
is likely the result of lack of power. The odds ratios for these high quality rare variants 
were found to be less than 4, consistent with the power calculation.   
Interestingly, a coding change (H33Y) (located at chr6: 30131558) was found only in 
cases (with MAF = 1.33%) and absent in controls, and SUHGLFWHGWREHµSUREDEO\
GDPDJLQJ¶E\3RO\SKHQ-2. Provided with sufficient power, this association may prove 
to be genuine.  
In Chapter 5, bioinformatic analyses were undertaken to investigate genetic variants 
influencing human life-span using late-RQVHW$O]KHLPHU¶VGLVHDVH*:$6GDWDZLWK
documented AAD.  
$VDJHLVRQHRIWKHELJJHVWULVNIDFWRULQ$O]KHLPHU¶VGLVHDVHLWLVimportant to 
understand whether LOAD genes are directly associated with the disease or 
indirectly by allowing successful ageing.   
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The ten most promising LOAD genes (APOE, CLU, PICALM, CR1, BIN1, ABCA7, 
MS4A6A, CD33, CD2AP and EPHA1) identified through recent large GWAS (Harold 
et al., 2009; Hollingworth et al., 2011; Lambert et al., 2009; Naj et al., 2011; Seshadri 
et al., 2010) were tested for association with human ageing in a merged dataset 
(from ARUK and GERAD consortia) using the most significant SNPs found in 
previous studies.  
The results of the analysis provided compelling evidence of association between the 
APOE locus (rs2075650) and human ageing (p = 5.27 x 10-4) as expected. The minor 
allele of this SNP was found to be overrepresented in individuals with a young AAD 
(MAF = 0.27; A? 89 years of age) in comparison to individuals with an old AAD (MAF = 
0.21; > 89 years of age). None of the other LOAD gene loci showed significant 
evidence of association (p < 0.05) with ageing, suggesting that these genes are likely 
to be genuine LOAD genes with no detectable effect on human ageing.   
A genome wide analysis was performed in an effort to search for novel genetic risk 
factors associated with human lifespan. No SNPs were found to be associated with 
human ageing with genome-wide level of significance after assessing all SNPs on 
the chip. Increasing statistical power by including more samples is paramount to 
enable detection of novel genetic associations with human ageing. Tan et al., 2010 
have shown that increasing sample age from nonagenarians to centenarians further 
increases the power to discover variants associated with human ageing. 
Furthermore, the chapter highlighted the importance of quality control procedures 
taking into account inter-chip and inter-cohort differences in an analysis; these 
differences may lead to spurious genome wide significant associations, which may 
pass all conventional QC filters (e.g. Hardy Weinberg Equilibrium p-value, minor 
allele frequency, genotyping rate threshold) and not be corrected for by principal 
component analysis.  
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Future perspective 
Late-RQVHW$O]KHLPHU¶VGLVHDVHLVDPXOWLIDFWRULDODQGFRPSOH[GLVHDVHDIIHFWHGE\
both environmental and genetic factors, where genetic factors are estimated to 
contribute as much as 76% of LOAD cases (Harold et al., 2009; van Es and van den 
Berg, 2009).   
The APOE gene found almost 20 years ago remains the single most outstanding risk 
factor (Corder et al., 1993; Hardy and Higgins, 1992), which has been estimated to 
account for ~25% of the risk of LOAD. The newly found LOAD genes (CLU, PICALM, 
CR1, BIN1, ABCA7, MS4A6A, CD33, CD2AP and EPHA1) were estimated to 
contribute to another ~30% of the population risk for the disease (Naj et al., 2011). 
However, these estimations are likely to be inflated, and the true proportions of the 
genetic predisposition accounted for by these genes are likely to be much lower 
(Sherva and Farrer, 2011). Additional genetic risk factors are likely to be found and 
replicated in the near future, where it has become increasingly evident that less 
frequent and rare variants are also playing a role (Manolio et al., 2009).  
TRIM15 acts as a potential LOAD candidate gene, and the association with LOAD 
remains to be confirmed through larger studies. TRIM15 encodes for a protein likely 
to be involved in the innate immune system, one of the pathways known to be 
involved in LOAD pathogenesis (Jones et al., 2010; McNab et al., 2010; Morgan, 
2011).  
Furthermore, genetic loci identified by GWAS are unlikely to be functional, and 
merely act as proxies in LD with functional variants. The advent of next generation 
sequencing technology, for the first time in human genetic research, enables 
identification and testing of novel functional variants at base-pair resolution with 
affordable costs (Bertram, 2011). With the improved understanding of pathways 
uncovered by genetic research in LOAD, it is hoped that in the not too distant future, 
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earlier diagnosis and better therapy targeting the root cause of the devastating 
disease will become available.  
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8. Appendices 
8.1 DNA samples sequenced by next generation sequencing.  
TRIM15 gene was sequenced in 150 samples (75 AD cases and controls) by ABI 
SOLiD® next generation sequencing. The study is described in Chapter 4.  
 
 
AD203 M390 L1 L67 AD203 M41 L11 L69
AD206 M392 L12 L68 AD208 M411 L12 L7
AD207 M393 L13 L69 AD209 M419 L13 L71
AD208 M394 L14 L7 AD210 M424 L15 L72
AD209 M395 L16 L71 AD211 M426 L16 L73
AD210 M396 L17 L72 AD212 M429 L17 L74
AD212 M397 L18 L74 AD213 M438 L18 L75
AD215 M398 L19 L75 AD216 M447 L19 L76
AD216 M400 L2 L77 AD218 M455 L2 L77
AD217 M401 L20 L80 AD219 M46 L21 L79
AD218 M41 L21 L83 AD221 M503 L22 L8
AD223 M410 L23 L85 AD222 M504 L23 L80
AD224 M411 L24 L86 AD223 M505 L25 L81
AD226 M419 L29 L87 AD224 M506 L28 L82
AD227 M424 L3 L88 AD225 M507 L29 L83
AD229 M426 L31 L9 AD226 M508 L3 L84
AD232 M429 L32 L91 AD232 M509 L31 L85
AD233 M438 L34 L92 AD233 M510 L32 L86
AD235 M441 L35 L95 M032 M511 L33 L87
AD236 M447 L38 L96 M050 M512 L35 L88
M004 M455 L4 N135 M111 M513 L38 L89
M005 M503 L41 N138 M123 M514 L4 L91
M021 M504 L46 N139 M125 M515 L41 L92
M022 M505 L47 N140 M325 M517 L44 L93
M026 M506 L49 N141 M38 M518 L47 L95
M050 M507 L50 N142 M385 M519 L49 L96
M053 M508 L51 N143 M388 M520 L50 N133
M070 M509 L53 N145 M389 M521 L51 N134
M102 M512 L54 N146 M390 M59 L53 N138
M106 M513 L55 N148 M392 M616 L54 N139
M111 M515 L56 N149 M393 M618 L56 N141
M125 M517 L59 N150 M394 M619 L6 N142
M32 M519 L6 N151 M395 M620 L62 N143
M325 M520 L60 N152 M396 M624 L63 N145
M38 M521 L61 N153 M397 M626 L64 N148
M385 M619 L62 N155 M398 M632 L65 N154
M388 M633 L64 N156 M400 M77 L67 N156
M389 L65 M401 L68
TRIM15 B
AD cases controlAD cases control
TRIM15 A
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8.2 Variant Classifier Input File 
High Quality SNPs identified in TRIM15 µ$µ DQGµ%¶DPSOLFRQVusing next generation 
sequencing were annotated using Variant Classifier (Chapter 4). The input file for the 
bioinformatic tool is shown below. 
----------------------   VC_input.txt ------------------------- 
91 92 1 G 
252 253 1 A 
758 759 1 G 
966 967 1 C 
984 985 1 C 
1138 1139 1 C 
1150 1151 1 A 
1162 1163 1 T 
1181 1182 1 G 
1193 1194 1 T 
1220 1221 1 A 
1346 1347 1 C 
1399 1400 1 G 
1670 1671 1 A 
1735 1736 1 C 
1949 1950 1 A 
8111 8112 1 C 
8124 8125 1 A 
8232 8233 1 A 
8280 8281 1 A 
8297 8298 1 T 
8488 8489 1 A 
8500 8501 1 C 
8530 8531 1 T 
8656 8657 1 T 
8790 8791 1 G 
9031 9032 1 G 
9112 9113 1 T 
9334 9335 1 A 
9977 9978 1 C 
10175 10176 1 T 
10548 10549 1 T 
10677 10678 1 G 
10839 10840 1 T 
11888 11889 1 C 
11900 11901 1 - 
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12093 12094 1 A 
12309 12310 1 A 
12325 12326 1 A 
12634 12635 1 G 
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8.3 Amplification curve for TaqMan® genotyping of SNP rs4110518 
 
The diagram depicts fluorescence intensities for TaqMan® genotyping of SNP rs4110518. Each amplification curve corresponds to a 
dual scatter plot as shown in Figure 5.7 in Chapter 5. 
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8.4 PERL programs 
Respective specific utilities of each PERL script listed are described in Methods 
2.3.2. 
8.4.1 Determination of common SNPs between different chip platforms 
------------------ perl.pl ------------------- 
use strict; 
use warnings; 
use modules; 
 
my $filename1 = 'mydata.bim'; # input SNP file in PLINK format 
my $filename2 = 'SNPs.txt';   # a list of SNP from GWAS 
my $str = modules::readData($filename1, $filename2); 
 
------------------ modules.pm ----------------- 
package modules; 
 
use strict; 
use warnings; 
 
# readData subroutine 
sub readData { 
my $filename1 = $_[0]; 
my $filename2 = $_[1]; 
my @array; 
my %hash; 
my %hashtwo; 
open (OUT, ">results.txt") or die "Unable to open results.txt: $!\n"; 
open (FILE, "<$filename2") or die "Unable to open $filename2: $!\n"; 
my $count=0; 
while (<FILE>){ chomp; 
if (/^(\w+)/) {$hash{$1} ="unmatched";$hashtwo{$count}=$1;$count++;} } 
open (MYFILE, "<$filename1") or die "Unable to open $filename1: $!\n"; 
while (<MYFILE>) { chomp; 
@array = split(' ',$_); 
my $SNP = $array[1]; # it specifies the column where the SNP is 
located 
if ($hash{$SNP}) { 
# QT indexed SNPs looking for same SNPs in CC results 
$hash{$SNP} = "$_";  
foreach my $keys (sort {$a <=> $b} keys %hashtwo) { 
print "$hashtwo{$keys}\t$hash{$hashtwo{$keys}}\n"; 
print OUT "$hashtwo{$keys}\t$hash{$hashtwo{$keys}}\n";} 
close MYFILE; 
close FILE; 
close OUT;} 
 
1; 
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8.4.2 Calculation of number of independent tests 
------------------ number_independent_test.pl -------------- 
use strict; 
use warnings; 
use modules; 
 
my $filename1 = 'mydata.ld'; # .ld file from PLINK analysis 
my $str = modules::readData($filename1); 
 
------------------ modules.pm ------------------------------------------ 
package modules; 
use strict; 
use warnings; 
 
# readData subroutine 
sub readData { 
my $input1 = $_[0]; my @array; my $col1; my $col2; my %hash; 
open (MYFILE, "<$input1") or die "Unable to open $input1: $!\n"; 
my $count=0; my $count2=1; 
while (<MYFILE>) { chomp; @array = split("\t",$_); 
$col1=$array[0];$col2=$array[1]; 
if ($count==0) {$hash{$col1} = 1; $hash{$col2} = 1; 
} else { 
if (exists $hash{$col1} && exists $hash{$col2}){ 
if ($hash{$col1} == $hash{$col2}) { next; 
} else { 
if ($hash{$col1} > $hash{$col2}) { my $stringTemp = $hash{$col1}; 
foreach my $keys (keys %hash) { 
if ($hash{$keys}==$stringTemp) { 
$hash{$keys} = $hash{$col2}; 
}}} else { my $stringTemp = $hash{$col2}; 
foreach my $keys (keys %hash) { 
if ($hash{$keys}==$stringTemp) { $hash{$keys} = $hash{$col1}; 
}}} $count2 = $count2-1;}}  
elsif (exists $hash{$col1} || exists $hash{$col2}){ 
if (exists $hash{$col1}) { 
$hash{$col2} = $hash{$col1};} 
if (exists $hash{$col2}) { 
$hash{$col1} = $hash{$col2};}} else { 
$hash{$col1} = $count2+1; $hash{$col2} = $count2+1; $count2++;}} 
$count++;} 
close MYFILE; 
open (OUT, ">results.txt") or die "Unable to open results.txt: $!\n"; 
my %hashtwo; my $count3=0; 
foreach my $keys (sort {$hash{$b} <=> $hash{$a}} keys %hash) { 
$count3++; 
print OUT "$keys => $hash{$keys} => $count3\n"; 
$hashtwo{$hash{$keys}}=0; } 
# $hashtwo counts the number unique values from using $hashone  
my $counttwo=0; 
foreach my $keystwo (keys %hashtwo) { $counttwo++;} 
print "The number of LD clusters is: $counttwo\n"; 
print "Check [ results.txt ] for details of LD clusters"; 
close OUT;} 
 
1; 
  
 Appendices 
259 
 
8.4.3 GWAS meta-analysis 
------------------ meta_analysis.pl --------------- 
use strict; 
use warnings; 
use modules; 
use Time::Local; 
 
# type in file name 
my $filename1 = 'test.txt'; 
 
# type in 'CC' for Case/Control analysis or 'QT' or Quantitative 
Trait analysis, the default is for Case/Control  
# analysis. NB: This parameter is for checking SNP 'flippers', 
failure to adjust the parameter for correct type of  
# analysis will result in incorrect output in the results file.  
my $analysis = 'CC'; 
 
# Do NOT edit after this line 
my $time = localtime; 
print "Analysis started: $time\n"; 
my $arrayRef = modules::readData($filename1); 
modules::printHeader($$arrayRef[1]); 
print "Writting results to file [results.txt]\n"; 
my $SNP = modules::analyzeData($$arrayRef[0],$$arrayRef[1],$analysis); 
$time = localtime; 
print "Analysis finished: $time\n"; 
 
------------------ modules.pm ----------------------------- 
package modules; 
use strict; 
use warnings; 
 
# readData subroutine 
sub readData { 
my $filename1 = $_[0]; my @arrayOne; my %hash; my $string; 
open (OUT, ">results.txt") or die "Unable to open results.txt: $!\n"; 
open (FILE, "<$filename1") or die "Unable to open $filename1: $!\n"; 
my $countAll=0; my $count=0; my $countProxy=0; my $totalProxy; 
my $fileTag; my $SNPID; my $string1; my $string2; my $string3; 
my $fileNo=0; 
while (<FILE>){ 
chomp; 
if (/^(\s+)(\S+)/) { 
if ($count==1) { $countAll++; @arrayOne = split(" ", $_); 
$SNPID = $arrayOne[2]; 
$totalProxy=$arrayOne[5];#TOTAL proxy 
$fileTag = $arrayOne[1]; 
$hash{$SNPID}The 1000 Genomes Project Consortium, 
=$countAll;#sequence 
$hash{$SNPID}{2}=$arrayOne[1];#file number 
$hash{$SNPID}{3}=$arrayOne[0];#chromosome number 
$hash{$SNPID}{4}=$arrayOne[3];#bp number 
$hash{$SNPID}{5}=$arrayOne[4];#p-value 
if ($arrayOne[1] > $fileNo) { 
$fileNo = $arrayOne[1]; }} 
if ($count==3 && $totalProxy ==0) {print "[Error1]\n";die;} #check 
file integrity 1 
if ($count==3) { 
@arrayOne = split(" ", $_); 
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if ($arrayOne[1] eq $SNPID) {} else {print "[Error2]\n";die;} #check 
file integrity 2 
$hash{$SNPID}{6}=$arrayOne[7];#odds ratio 
} if ($count>3) { 
my $proxyID=0; 
@arrayOne = split(" ", $_); 
if (scalar(@arrayOne)==7) { 
my $checkFile = checkFile($fileTag,$arrayOne[4]); 
$string1 = $arrayOne[0]; 
$string2 = $arrayOne[1]; 
$string3 = $arrayOne[2]; 
if ($checkFile==1) { 
$countProxy++; 
$proxyID = $arrayOne[0]; 
my $fileID = $arrayOne[4]; 
$hash{$SNPID}{7}{$fileID}{$proxyID}The 1000 Genomes Project 
Consortium, =$countProxy; #proxy count 
$hash{$SNPID}{7}{$fileID}{$proxyID}{2}=$arrayOne[1]; #proxy kb 
$hash{$SNPID}{7}{$fileID}{$proxyID}{3}=$arrayOne[2]; #proxy RSQ 
$hash{$SNPID}{7}{$fileID}{$proxyID}{4}=$arrayOne[5]; #proxy P-value 
$hash{$SNPID}{7}{$fileID}{$proxyID}{5}=$arrayOne[6]; #proxy OR 
$hash{$SNPID}{8}=1; #total proxy 
if ($fileID > $fileNo) { 
$fileNo = $fileID;}}}  
if (scalar(@arrayOne)==3) { 
@arrayOne = split(" ", $_); 
my $checkFile = checkFile($fileTag,$arrayOne[0]); 
if ($checkFile==1) { 
$countProxy++; 
$proxyID =$string1; #proxy ID 
my $fileID = $arrayOne[0]; 
$hash{$SNPID}{7}{$fileID}{$proxyID}The 1000 Genomes Project 
Consortium,  = $countProxy; #proxy count 
$hash{$SNPID}{7}{$fileID}{$proxyID}{2} = $string2; #proxy KB 
$hash{$SNPID}{7}{$fileID}{$proxyID}{3} = $string3; #proxy RSQ 
$hash{$SNPID}{7}{$fileID}{$proxyID}{4} = $arrayOne[1]; #proxy P-value 
$hash{$SNPID}{7}{$fileID}{$proxyID}{5} = $arrayOne[2]; #proxy OR 
$hash{$SNPID}{8}=1; #total proxy 
if ($fileID > $fileNo) { 
$fileNo = $fileID; 
}}}} $count++; } 
if (/^(\-)/) { $count=0; $totalProxy=0; $countProxy=0;}} 
my @array = (\%hash,\$fileNo); 
return \@array; close FILE; close OUT;} 
 
# checkFile subroutine 
sub checkFile { 
my $input1 = $_[0]; 
my $input2 = $_[1]; 
if ($input1==$input2) { 
return 0; 
} else { return 1; }} 
 
# analyzeData subroutine 
sub analyzeData { 
open (OUT, ">>results.txt") or die "Unable to open results.txt: $!\n"; 
my $hash = $_[0]; my $input = $_[1]; my $test = $_[2]; 
my $count1=1; my $maxFile = $$input-1; 
foreach my $key (sort {${$hash}{$a}The 1000 Genomes Project 
Consortium,  <=> ${$hash}{$b}The 1000 Genomes Project Consortium, } 
keys %{$hash}) { #key is the indexID 
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my $totalProxy = ${$hash}{$key}{8}; 
if (defined $totalProxy) { 
my $fileNo = ${$hash}{$key}{2}; 
my $indexPvalue = ${$hash}{$key}{5}; 
my $indexOR = ${$hash}{$key}{6}; 
my $indexCHR = ${$hash}{$key}{3}; 
my $proxyNo = ${$hash}{$key}The 1000 Genomes Project Consortium, ; 
print OUT "$count1\t$key\t$fileNo\t$indexCHR\t"; 
my %hash2; my %hash3; my $count=0; 
$hash3{$fileNo}=$indexPvalue; 
foreach my $fileID (keys %{${$hash}{$key}{7}}) { 
$count++; 
my $arrayRef = bestSNP(\%{${$hash}{$key}{7}{$fileID}});  
my $proxyID = $$arrayRef[0]; 
my $proxyKB = ${$hash}{$key}{7}{$fileID}{$proxyID}{2}; 
my $proxyRSQ = ${$hash}{$key}{7}{$fileID}{$proxyID}{3}; 
my $proxyPvalue = ${$hash}{$key}{7}{$fileID}{$proxyID}{4}; 
my $proxyOR = ${$hash}{$key}{7}{$fileID}{$proxyID}{5}; 
$hash2{$fileID}The 1000 Genomes Project Consortium,  = $count; 
$hash2{$fileID}{2} = $proxyPvalue; 
$hash2{$fileID}{3} = $proxyOR; 
$hash2{$fileID}{4} = $proxyID; 
$hash2{$fileID}{5} = $fileID; 
$hash2{$fileID}{6} = $proxyKB; 
$hash2{$fileID}{7} = $proxyRSQ; 
$hash3{$fileID}=$proxyPvalue; } 
my $fisherPvalue = getFisher(\%hash2,$indexPvalue); 
my $proxyCount = $$fisherPvalue[1]; 
foreach my $key2 (sort {$hash2{$a}The 1000 Genomes Project Consortium,  
<=> $hash2{$b}The 1000 Genomes Project Consortium, } keys %hash2) 
{ print OUT 
"$hash2{$key2}{4}\t$hash2{$key2}{5}\t$hash2{$key2}{6}\t$hash2{$key2}{
7}\t"; 
printSpace($maxFile,$proxyCount,1); # space 1 
} 
my $flipper = getFlipper(\%hash2,$indexOR,$test); # $test = "C/C" or 
"QT"  
$fisherPvalue = sprintf "%.2e" ,$$fisherPvalue[0]; 
print OUT "$fisherPvalue\t"; 
if ($flipper==0) {print OUT "YES\t"; } elsif ($flipper==1) { print 
OUT "NO\t";} else { print OUT "NA\t";} 
foreach my $key2 (sort keys %hash3) { 
for (my $emptySpace=1;$emptySpace<=$$input;$emptySpace++) { 
if (defined $hash3{$emptySpace}) { 
} else { 
$hash3{$emptySpace}="-";}}} 
foreach my $key3 (sort keys %hash3) { 
print OUT "$hash3{$key3}\t";# all proxy pvalue 
} print OUT "\n"; $count1++;}} close OUT;} 
 
# printSpace subroutine 
sub printSpace { 
my $input1 = $_[0]; 
my $input2 = $_[1]; 
my $input3 = $_[2]; 
if ($input1 != $input2) { 
my $DETA = $input1 - $input2; 
if ($input3 ==1) { 
for (my $count=0;$count<$DETA;$count++) { 
print OUT "-\t-\t-\t-\t";} 
} elsif ($input3 ==2) { 
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for (my $count=0;$count<$DETA;$count++) { 
print OUT "-\t";}}}} 
 
# printHeader subroutine 
sub printHeader { 
my $input1= $_[0]; 
open (OUT, ">results.txt") or die "Unable to open results.txt: $!\n"; 
print OUT "ClumpNo\tSNP\tF1\tCHR\t"; 
my $fileNo = $$input1; 
for (my $count=1;$count<$fileNo;$count++) { 
my $count2 = $count+1; 
print OUT "PROXY$count\tF$count2\tKB$count\tRSQ$count\t"; } 
print OUT "FISHER\tFLIPPER\t"; 
for (my $count=1;$count<=$fileNo;$count++) { 
print OUT "Pvalue$count\t"; } 
print OUT "\n"; close OUT;} 
 
# bestSNP subroutine 
sub bestSNP { 
my $hash =$_[0]; my $count =0; my $count2=0; my $Num; 
my $firstNum; my %hash2; 
foreach my $key (keys %{$hash}) {  
$count2++; $hash2{${$hash}{$key}{2}}=$key; } 
foreach my $key (sort {${$hash}{$a}The 1000 Genomes Project 
Consortium,  <=> ${$hash}{$b}The 1000 Genomes Project Consortium, } 
keys %{$hash}) { 
if ($count==0) { $firstNum = ${$hash}{$key}{2}; } 
if ($count>0) {  
$Num = ${$hash}{$key}{2}; $firstNum = compareKB($firstNum,$Num); } 
$count++; 
if ($count2 == $count) { 
my @array = ($hash2{$firstNum},$count); return \@array; } 
}} 
 
#getFisher subroutine 
sub getFisher { 
my $hash = $_[0]; my $indexPvalue = $_[1]; 
my $firstNum; my $Num; my $count=0; my $count2=0; 
foreach my $key (keys %{$hash}) { $count2++;} 
foreach my $key (sort {${$hash}{$a}The 1000 Genomes Project 
Consortium,  <=> ${$hash}{$b}The 1000 Genomes Project Consortium, } 
keys %{$hash}) { 
if ($count==0) { $firstNum = ${$hash}{$key}{2}; } 
if ($count>0) { 
$Num=${$hash}{$key}{2}; $firstNum = combineP($firstNum,$Num); } 
$count++; 
if ($count2 ==$count){ 
$firstNum = combineP($firstNum,$indexPvalue); 
my @array = ($firstNum,$count); return \@array; } 
}} 
 
# getFlipper subroutine 
sub getFlipper { 
my $hash = $_[0]; my $indexOR = $_[1]; my $test = $_[2]; my $Num; 
my $firstNum; my $count=0; my $count2=0; my $NAcheck=0; 
my $testCheck=0; 
foreach my $key (keys %{$hash}) { $count2++; } 
if ($indexOR == -9) { $NAcheck=1; } 
foreach my $key (keys %{$hash}) { 
if (${$hash}{$key}{3} == -9) { $NAcheck=1; }} 
if ($test eq 'CC') { # analysis check "CC" or "QT" 
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$testCheck=1; 
} elsif ($test eq 'QT') { 
$testCheck=2; 
} else { 
print "Unrecoginized analysis!";die;} 
foreach my $key (sort {${$hash}{$a}The 1000 Genomes Project 
Consortium,  <=> ${$hash}{$b}The 1000 Genomes Project Consortium, } 
keys %{$hash}) { 
if ($count==0) { $firstNum = ${$hash}{$key}{3}; } 
if ($count>0) { $Num=${$hash}{$key}{3}; 
if ($firstNum==-9 && $Num != -9) { $firstNum=$Num; 
} elsif ($firstNum == -9 && $Num == -9) { $firstNum = -9; 
} elsif ($firstNum != -9 && $Num == -9) { $firstNum = $firstNum; 
} else { if ($testCheck ==1) { $firstNum = compareOR($firstNum,$Num); 
} elsif ($testCheck ==2) { $firstNum = compareBETA($firstNum,$Num); } 
if ($firstNum ==0) { # '0' represent flipping effect 
return 0; }}} $count++; 
if ($count2 ==$count){ 
if ($firstNum==-9 || $indexOR == -9) { return 2; 
} else { if ($testCheck ==1) { 
$firstNum = compareOR($firstNum,$indexOR); 
} elsif ($testCheck ==2) { 
$firstNum = compareBETA($firstNum,$indexOR); } 
if ($firstNum ==0) { return 0; 
} elsif ($NAcheck ==0) { return 1; 
} else { return 2; 
}}}}} 
 
# compareBETA subroutine 
sub compareBETA { 
my $input1 = $_[0]; my $input2 = $_[1]; 
if ($input1 > 0 && $input2 >0) { return $input1; 
} elsif ($input1 <0 && $input2 <0) { return $input1; 
} else { return 0; }} 
 
# compareOR subroutine 
sub compareOR { 
my $input1 = $_[0]; my $input2 = $_[1]; 
if ($input1 > 1 && $input2 >1) { return $input1; 
} elsif ($input1 <1 && $input2 <1) { return $input1; 
} else { return 0;}} 
 
# combineP subroutine 
sub combineP { 
my $input1 = $_[0]; my $input2 = $_[1]; my $sum; my $result; 
$input1 = log(1/$input1); $input2 = log(1/$input2); 
$sum = $input1 + $input2; $result = 1/exp($sum); return $result;} 
 
# compareKB subroutine 
sub compareKB { 
my $input1 = $_[0]; my $input2 = $_[1]; 
my $a = abs($input1); my $b = abs($input2); 
if ($a > $b) { return $input2; 
} else { return $input1; }} 
 
1; 
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8.4.4 Plug-LQIRU3/,1.µJHQHUHSRUW¶IXQFWLRQ 
------------------ gene_report_plugin.pl -------------- 
use strict; 
use warnings; 
use modules; 
 
my $filename1 = 'myfile.range.report'; # input PLINK gene report file 
µUDQJHUHSRUW¶LVHQWHUHGKHUH 
my $str = modules::readData($filename1); 
------------------ modules.pm -------------------------- 
package modules; 
use strict; 
use warnings; 
 
sub readData { 
my $input1 = $_[0]; my @array; my $col1; 
my $col2; my %hash; 
open (MYFILE, "<$input1") or die "Unable to open $input1: $!\n"; 
open (OUT, ">results.txt") or die "Unable to open results.txt: $!\n"; 
print OUT "SNP\tCHR\tBP\tP\tBETA\tGENE\tLENGTH\tDIST\n"; 
while (<MYFILE>) { 
chomp; 
if (/^\s+.+rs/) { 
@array = split(' ',$_); 
$hash{3} = $array[2]; 
$hash{4} = $array[0]; 
$hash{5} = $array[12]; 
$hash{6} = $array[7]; 
$hash{7} = $array[3]; 
$hash{8} = $array[1]; 
print OUT "$hash{3}\t$hash{8}\t$hash{7}\t$hash{5}\t$hash{6}\t$hashThe 
1000 Genomes Project Consortium, \t$hash{2}\t$hash{4}\n"; } 
if (/^(\w+)/) { 
@array = split(' ',$_); 
$hash{1} = $array[0]; $hash{2} = modules::math($array[4]); 
}} 
close MYFILE; close OUT; } 
 
sub math { 
my $input1 = $_[0]; my $first_number; my $full_number; 
if ($input1 =~ m/^(\d+)(\.\d+)\w+/) { 
$first_number = $1-40; $full_number = $first_number.$2."kb"; 
} elsif ($input1 =~ m/^(\d+)\w+$/) { 
$first_number = $1-40; $full_number = $first_number."kb"; 
} else { die "Error in the length of the gene!"; 
} return $full_number;} 
 
1;  
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8.5 UCSC custom tracks input files 
Custom tracks input file for the TRIM15 µ$¶DPSOLFRQ (used in Chapter 4): 
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Custom tracks input file for the TRIM15 µ%¶DPSOLFRQXVHGLQChapter 4): 
 
